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Ad35   adenovirus type 35  
ADAM  a Disintegrin and metalloproteinase domain-containing protein 
aHUS   atypical haemolytic uremic syndrome  
APC   allophycocyanin  
APC   antigen presenting cell 
APP   amyloid precursor protein   
BBB   blood brain barrier 
BSA   bovine serum albumin 
CFSE   carboxyfluorescein diacetate succinimidyl ester   
CHO   Chinese hamster ovary   
CNS   central nervous system   
CTF   cytoplasmic transmembrane fragment   
CTF1   cytoplasmic transmembrane fragment-Cyt1 
CTF2   cytoplasmic transmembrane fragment-Cyt2  
CTL   cytotoxic lymphocyte  
CTLA4  cytotoxic T-lymphocyte antigen 4 
CVO   control vector only  
DAPT   N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycinet-Butyl 
  Ester 
EAE   experimental autoimmune encephalomyelitis   
EBV   Epstein–Barr virus  
ELISA  enzyme-linked immunosorbent assay   
ER   endoplasmic reticulum   
FITC   fluorescein isothiocyanate  
FoxP3   factor forkhead box P3   
GVHD  graft-versus-host disease  
GWAS  genome wide association studies  
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HHV-6  human herpes virus 6  
HRP   horseradish peroxidase 
HUS  hemolytic uremic syndrome 
ICD   intracellular domain  
IFN   interferon 
IP   immunoprecipitation 
iTreg   inducible T regulatory cell 
MBP   myelin basic protein  
MHC   major histocompatability complex   
MMP   metalloproteinase  
MOG   myelin oligodendrocyte glycoprotein  
MS   multiple sclerosis  
MV   measles virus  
MVB   multivesicular bodies  
Mw   molecular weight  
NMFI   normalised mean fluorescence intensity 
nTreg   natural T regulatory cell  
p-LAT  phosphorylated linker activation  
PAMPS  patterns associated with microbial pathogens  
PBMC  peripheral blood mononuclear cells    
PE   phycoerythrin  
PGE-2  prostaglandin E2  
PRR   pathogen recognition receptors  
PγS   presenilin-γ-secretase   
RA   rheumatoid arthritis   
RIPA   radio immunoprecipitation assay buffer   
RRMS  relapsing-remitting multiple sclerosis   
sCD46  soluble CD46   
!
! xvi!
SCID   severe combined immunodeficiency  
SCR   short consensus repeat   
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gel electrophoresis   
SLE   systemic lupus erythematosus  
STAT   signal transducer and activators of transcription  
STP   serine, theronine and proline  
T-bet   T-box expressed in T cells   
TCL   total cell lysate  
TCR   T cell receptor  
Th   helper T cell 
TMB   tetramethylbenzidine   
Tr1   type I regulatory T cells   
Tregs   T regulatory cells  
UNCL.F1  uncleavable cytoplasmic transmembrane fragment-Cyt1 
UNCL.F2  uncleavable cytoplasmic transmembrane fragment-Cyt2  




CD46 is a ubiquitously expressed transmembrane molecule and has an important 
role in the innate and adaptive immune system. CD46 was originally identified as 
a complement receptor that protects cells from autologous attack. However, 
CD46’s immunological profile is ever expanding and more recently it was 
identified as a T cell costimulatory molecule. Notably, in the presence of IL-2, 
CD46 can induce a Tr1-like phenotype that is characterized by the secretion of 
large amounts of the potent anti-inflammatory cytokine, IL-10. Defects in CD46-
induced IL-10 secretion have been identified in multiple sclerosis, asthma and 
rheumatoid arthritis.  Despite CD46’s promiscuous nature in immune responses 
there is little known about its underlying processing and signalling pathways.  
 
Herein, I report that CD46 expression and processing are important for regulating 
T cell anti-inflammatory responses and activation. Cyt1 but not Cyt2 promotes an 
increased ratio IL-10+ cells compared to cells that secrete both Il-10 and IFNγ. 
Upon CD46 costimulation, proteolytic cleavage of CD46 occurs at the surface 
and intracellularly with the subsequent release of a functional intracellular 
domain (ICD). As a result of alternative splicing, there are two main cytoplasmic 
isoforms of CD46, both of which release ICDs, Cyt1 and Cyt2. It is shown that 
the smaller Cyt1 ICD fragment facilitates T cell activation, whereas, Cyt2 
promotes T cell activation when expressed in an uncleaved form. 
 
As the expression and cleavage of CD46 is important for regulating T cell 
function, I went on to identify factors that can regulate CD46 cleavage. Herein, it 
is demonstrated that T cell activation by the T cell receptor (TCR) acts as a major 
regulator of CD46 cleavage and expression, emphasizing the inherent role of 
CD46 in T cell activation. TCR stimulation also modulates CD46 glycosylation, 
which may effect CD46 expression and T cell phenotype. Importantly, I have 
identified a dysregulated expression of CD46 in a preliminary cohort of RRMS 
!
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patients. It will be interesting to examine if aberrant CD46 glycosylation or 






CD46 is a ‘pathogen magnet’ and not without reason: understanding how CD46 
stands on the cross roads of innate and adaptive immunology will open the door 
to a more integrated view of the immune system during health and disease.!
!
1.1 The!inflammatory!response!
A healthy immune system regulates pathogen infection while maintaining 
tolerance to self (Sakaguchi et al., 2008, Bluestone, 2011). In vertebrates, the 
immune system consists of two elements, the innate and the adaptive immune 
response. The innate system is responsible for the initial detection of pathogens 
through the expression of germ-line encoded pathogen recognition receptors 
(PRR), which detect conserved patterns associated with microbial pathogens 
(PAMPS) (Medzhitov and Janeway, 1998, Janeway and Medzhitov, 2002). 
PAMPS are only expressed on microorganisms and therefore host antigens do not 
activate PRRs. Innate immune cells include macrophages, dendritic cells and 
neutrophils. Once innate immune cells have encountered PAMPS they become 
activated and their effector mechanisms are initiated. These mechanisms include 
phagocytosis of pathogens, cytokine secretion and the activation of the adaptive 
immune response (Medzhitov and Janeway, 1998, Abbas and Janeway, 2000, 
Janeway and Medzhitov, 2002). The adaptive immune response is acquired 
through one’s lifetime and retains memory of previous pathogens encountered 
(Abbas and Janeway, 2000, Sprent and Surh, 2002). The cells of the adaptive 
immune response are the T and B cells. T cells are activated by antigen 
presenting cells (APCs), which include the dendritic cells and macrophages of the 
innate immune system (Medzhitov and Janeway, 1998, Abbas and Janeway, 
2000). In order to recognise pathogens, T cells utilize receptors (TCRs) that are 
created by a somatic process of random gene rearrangement to recognise 
pathogenic antigens. Each TCR generated by gene rearrangement is believed to 
be cross-reactive with up to 1 million peptides. As a result, TCRs are capable of 
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detecting a massive range of potential pathogens (Mason, 1998, Sewell, 2012). 
There are two subgroups of T cells: the CD8+ cytotoxic lymphocytes (CTLs) and 
the CD4+ helper T cells (Th). CTLs directly target infected cells that are 
presenting their cognate antigen and induce cell death, whereas the Th cells as the 
name suggests, help to guide other leukocytes during the immune response. Th 
cells have two main functions, to induce B cell activation and to secrete 
cytokines, which is fundamental to the regulation of the immune response. Once 
B cells are activated they produce high quantities of antibodies specific to the 
pathogen. These antibodies spread throughout the body, inhibiting pathogen 
function or labelling them for phagocytosis by the innate cells.  Therefore, the 
innate and adaptive immune systems work together to provide a highly efficient 
defence against pathogens (Medzhitov and Janeway, 1998, Abbas and Janeway, 
2000). Indeed, the immune system is a complex system and important regulatory 
mechanisms must be in place to control its function. 
 
When the immune system is not correctly regulated it can give rise to both 
autoimmunity and allergy. To prevent this from happening there are a series of 
checkpoints in lymphocyte development – these occur in the thymus (central 
tolerance) and in the periphery (peripheral tolerance) (Bluestone, 2011). Within 
the thymus, the population of T cells is enriched with T cells that are only 
reactive to antigen that is presented in the context of the host’s major 
histocompatability complex (MHC) receptors. MHC receptors help the host’s 
immune system differentiate between self and pathogen. T cells that cannot bind 
to the host’s MHC cannot interact with APCs and are therefore eliminated in a 
process known as positive selection (Medzhitov and Janeway, 1998, Abbas and 
Janeway, 2000). The T cells that are positively selected are reactive to both 
pathogens and self. In order to prevent the self-reactive T cells from being 
activated in the periphery and causing unwanted inflammatory reactions, the 
majority of these highly self-reactive cells undergo cell death in a process called 
negative selection (Medzhitov and Janeway, 1998, Abbas and Janeway, 2000, 
Mueller, 2010, Bluestone, 2011). However, this process does not eliminate all 
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self-reactive T cells and these cells escape into the periphery as mature T cells. 
Within the periphery there are further processes in place, which not only prevent 
the activation of self-reactive T cells but also control inflammatory responses to 
pathogens (Mueller, 2010, Goverman, 2011, Bluestone, 2011).  
!
The first basic mechanism of control in the periphery is the requirement of the T 
cell to receive two activating signals from the APC. First, for a T cell to become 
activated it needs to encounter its cognate antigen in context of the appropriate 
MHC this is called “signal 1”. However, a T cell must also receive a 
costimulatory signal from the APC called “signal 2” (figure 1.1) (Janeway, 1989). 
The most well studied costimulatory pathway involves the T cell costimulatory 
receptor CD28 and its ligands CD80 (B7-1) and CD86 (B7-2) that are expressed 
on professional APCs (Sperling and Bluestone, 1996). The costimulatory 
stimulus is required for full activation of a T cell and if signal 2 is not received 
the T cell becomes functionally inactive or anergic (Sperling and Bluestone, 
1996, Medzhitov and Janeway, 1998, Abbas and Janeway, 2000, Mueller, 2010). 
Of note, other costimulatory receptors are also important for T cell activation 
including; ICOS, OX40, 4-1BB and CD2 (Leitner et al., 2010). The focus of this 
project is on the more recently discovered T cell costimulatory receptor CD46 
(Astier et al., 2000) (figure 1.1) 
   
Figure 1.1: The two-signal model of T cell activation. Signal 1 involves the 
interaction between the TCR and its cognate peptide:MHC complexes. Signal 2 
is received by a costimulatory stimulus; the costimulatory molecules CD28 and 




Once T cells are activated they act to co-ordinate an inflammatory response 
against invading pathogens. In order to prevent the activation of self-reactive T 
cells or excessive immune responses, a second important mechanism of 
peripheral tolerance is required: T regulatory cells (Tregs) (Sakaguchi et al., 
1995). Tregs are a subset of T cells that can prevent excessive immune responses 
to pathogens or the activation of self-reactive T cells. Specifically, Tregs suppress 
the effector function of several immune cells, including CD4+ T cells, CD8+ T 
cells, NKT cells, B cells, macrophages and dendritic cells (Sakaguchi et al., 2008, 
Sakaguchi et al., 2010). The function of Tregs is known to be dysfunctional in 
several inflammatory diseases, including multiple sclerosis (MS) and the 
mechanisms of their functions are under intensive investigation (Sakaguchi, 
2004, Wraith et al., 2004, Roncarolo et al., 2006, Costantino et al., 2008b, 
Sakaguchi et al., 2010).   
 
1.2 CD4+!T!cell!Subsets!
CD4+ T cells are a fundamental part of the adaptive immune response as they can 
orchestrate the role of other adaptive and innate immune cells.  There are several 
subsets of CD4+ T cells, which have been characterised based on their specific 
function in vivo (Mosmann et al., 1986, Sakaguchi et al., 1995, Groux et al., 
1997, Harrington et al., 2006). Generally, prior to encountering its cognate 
antigen a T cell is referred to as a naïve T cell and does not yet have a specific 
role. However, upon antigen recognition, a naïve T cell receives a range of cues 
from the antigen interaction itself, cytokines, and costimulatory and adhesion 
molecules. The combination of these signals results in the activation of sets of 
transcription factors that regulate gene expression to shape T cell differentiation 
and function. Mossman et al first described the first two recognised subsets: Th1 
and Th2 (Mosmann et al., 1986).  However, the number of subsets later expanded 
to include Tregs (Sakaguchi, 2004, Groux et al., 1997) and Th17 cells (Langrish 
et al., 2005, Harrington et al., 2006) (figure 1.2). Both Th1 and Th17 cells are 
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thought to play an important role in the pathogenesis of MS, while Tregs play a 
protective role (Costantino et al., 2008a, Petermann and Korn, 2011, Nylander 
and Hafler, 2012). These T cell subsets are described below.  
 
Figure 1.2: A schematic representing the relevant and well-described CD4+ 
T cell subsets.  
 
1.2.1 Th1!
The Th1 T cell subset is characterised by their secretion of interferon-γ (IFNγ) 
and their specific function of targeting intracellular pathogens such as 
Mycobacterium tuberculosis (Mosmann et al., 1986, Mosmann and Coffman, 
1989). Naïve T cells are driven into the Th1 lineage in the presence of IL-12 and 
IFNγ. These cytokines result in the activation of signal transducer and activators 
of transcription (STAT) 1 and STAT4 leading to the upregulation of the 
transcription factor, T-box expressed in T cells (T-bet) (Hsieh et al., 1993, 
Nishikomori et al., 2002, Hibbert et al., 2003). T-bet is described as the Th1 
‘master regulator’, a key marker for Th1 differentiation. T-bet inhibits both Th2 
and Th17 responses, and promotes IFNγ production providing a positive 
feedback loop for Th1 commitment (Kanno et al., 2012). In addition to 
autoregulation, IFNγ also activates macrophages, cytotoxic T cells and natural 
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killer T cells and antibody IgG2a production by B cells (Petermann and Korn, 
2011). This subset also produces IL-2, TNF-α, GM-CSF, lymphotoxin, IL-10 but 
no IL-4, the trademark cytokine of Th2 differentiated cells (Mosmann et al., 
1986, O'Garra and Vieira, 2007). Of note, dysregulated Th1 responses have 
traditionally been associated with chronic inflammation and tissue destruction 
(Petermann and Korn, 2011).  
 
1.2.2 Th17!
The Th17 T cell subset is a more recently identified lineage of effector T cells 
(Langrish et al., 2005, Harrington et al., 2006). This subset is characterised by IL-
17 production and is crucial to the control of extracellular fungi, bacterial 
infections and microbes that are not targeted by Th1 or Th2 effector T cells 
(Harrington et al., 2006).The Th17 phenotype is promoted in the presence of 
TGFβ, IL-1β, IL-6 and IL-21 or IL-23 (Manel et al., 2008). The ‘master 
regulator’ of Th17 differentiation is the transcription factor, RORγt, which works 
in concert with RORα to drive Th17 lineage commitment and IL-17 secretion 
(Yang et al., 2008).  IL-17 can induce the release of inflammatory cytokines and 
chemokines from a wide variety of cells and plays an important role in the 
recruitment of neutrophils (Petermann and Korn, 2011). Of note, both Th1 and 
Th2 trademark cytokines, IFNγ and IL-4 strongly suppress Th17 differentiation 
(Harrington et al., 2006). However Th17 subsets are not as stable as Th1 and Th2 
subsets and this has raised questions about their existence as a distinct lineage 
(Petermann and Korn, 2011). Nonetheless, due to the pro-inflammatory nature of 
Th17 cytokines, they have become an important target in the understanding and 
treatment of autoimmune diseases. For example, Th17 related cytokines, IL-23 
and IL-17, have been shown to play a pivotal role in some experimental 
autoimmune encephalomyelitis (EAE) models and collagen-induced arthritis 





As previously mentioned, whilst inflammatory responses are key to keeping 
pathogens under control, there are also mechanisms in place to prevent excessive 
inflammatory responses and attacks against self. One such mechanism utilizes a 
subset of CD4+ T cells called Tregs (Sakaguchi et al., 1995). Tregs suppress 
immune responses against self, altered self (tumours) and non-self antigens. 
Tregs can be broadly divided into two categories, natural Tregs or inducible 




Natural Tregs (nTregs) are thymus derived and the transcription factor forkhead 
box P3 (FoxP3) is critical for their development and function (Fontenot et al., 
2003), with mutations of the FoxP3 gene resulting in patients with immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) 
(Bennett et al., 2001 ) and systematic autoimmunity in the scurfy mouse 
(Fontenot et al., 2003). FoxP3 upregulates the expression of the IL-2 receptor 
alpha (CD25) and the cytotoxic T cell antigen 4 (CTLA-4) and suppresses the 
secretion of the cytokines IL-2, IL-4 and IFNγ (Sakaguchi et al., 2008). 
Paradoxically, IL-2, associated with effector cell proliferation, is an absolute 
requirement for nTreg development, survival and function and is believed to 
provide a fundamental negative feedback loop in immune regulation (Sakaguchi 
et al., 2008).  In the mouse, CD4+CD25+ T cells identify an enriched group of 
nTregs. However, in humans only those cells with very ‘high’ CD25 expression 
contain an enriched group of nTregs (Baecher-Allan et al., 2001). It has become 
apparent that human Tregs are a more heterogeneous group than mouse Tregs and 
definitive markers for human nTregs still remain to be identified (Lowther and 
Hafler, 2012). Nonetheless, low expression of the IL-7 receptor CD127 also 
correlates with an enriched expression of FoxP3. CD62L (L-selectin) can be used 
as a marker to distinguish recently activated effector T cells from regulatory T 
cells, as it is downregulated after activation. Thus, an enriched population of 
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human nTregs can be isolated based on CD25highCD65L+CD127low expression 
(reviewed in (Sakaguchi et al., 2010, Lowther and Hafler, 2012)).  
 
Although the exact mechanism of Treg suppression remains to be fully 
elucidated, four basic modes have been proposed.  These are (1) IL-10 and TGFβ 
anti-inflammatory cytokine secretion, (2) effector cell cytolysis though granzyme 
or perforin dependent pathways, (3) metabolic disruption of effector cells, 
including cytokine deprivation and adenosine secretion, and (4) attenuation of 
APC maturation and function, including the downregulation of the costimulatory 
molecules CD80/CD86 (reviewed in (Sakaguchi et al., 2008, Vignali et al., 
2008)).  The absence of nTregs or their dysfunction is associated with a number 
of autoimmune diseases, such as MS (Wraith et al., 2004, Costantino et al., 
2008a, Sakaguchi et al., 2010), and will be discussed in section 1.4.3.  
 
1.2.3.2 Inducible!Tregs!!
In addition to nTregs that are thymic derived and matured upon exit from the 
thymus, naïve T cells can also be induced to become Tregs in the periphery. 
These Tregs are called adaptive or inducible Tregs (iTregs). Interestingly, the 
presence of iTregs is common at the environmental interface and their induction 
is promoted by factors in these regions such as Vitamin D in the skin and 
retinoic-acid in the gut (reviewed in (Sakaguchi et al., 2008, Vignali et al., 2008, 
Sakaguchi et al., 2010, Cope et al., 2011)). Three proposed subsets of iTregs have 
been described, FoxP3+ iTregs, type I regulatory T cells (Tr1) and Th3 cells. 
FoxP3+ regulatory iTregs can be induced upon antigen stimulation in the presence 
of TGFβ, IL-2 and retinoic acid (Sakaguchi et al., 2008). As FoxP3 is expressed 
in activated effector T cells in humans it is hypothesised that this transcription 
factor may play a role in facilitating a negative feedback loop in activated T cells 
(Sakaguchi et al., 2008, Sakaguchi et al., 2010). The latter group, Th3 cells are 
characterised by their large secretion of TGFβ and were first described to 
suppress EAE after oral administration of antigen (Chen et al., 1994). However, it 
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has been suggested that at least some of the Th3 subset may actually represent 
FoxP3+ iTregs (Carrier et al., 2007).  As CD46 can induce a Tr1-like phenotype 
and is the focus of this thesis, this subgroup is further discussed below. 
 
1.2.3.2.1 IL-10 and Tr1 T cells 
Tr1 cells are regulatory T cells characterised by the secretion of IL-10, a cytokine 
with potent anti-inflammatory capacity. CD46 costimulated T cells were initially 
described to induce a Tr1 phenotype (Kemper et al., 2003). However, this 
function was later shown to be defective in patients with MS (Astier et al., 2006, 




IL-10 is a cytokine that has diverse anti-inflammatory effects on a wide range of 
immune cells, including T cells (reviewed in (Moore et al., 2001)). In brief, IL-10 
can directly inhibit inflammatory cytokine secretion from T cells, including IL-2, 
TNF and IL-5. However, IL-10 primarily suppresses effector T cells through its 
indirect effects on professional APCs. For example, IL-10 downregulates APC’s 
secretion of IL-1, TNF, GM-CSF and IL-12 and prevents the upregulation of 
costimulatory and MHC class II molecules (Moore et al., 2001). By limiting the 
ability of APCs to efficiently activate T cells their responses are also curtailed. In 
respect of this, IL-10 plays a pivotal role in preventing immunopathology 
(O'Garra et al., 2004, Gregori et al., 2012). For example, IL-10 knockout mice 
succumb to colitis and are more susceptible to EAE (Kuhn et al., 1993, Bettelli et 
al., 1998) and Tregs from IL-10-deficient mice were unable to suppress active 
EAE (Zhang et al., 2004). Moreover, suppression of EAE after treatment with a 
soluble myelin basic protein (MBP) or myelin oligodendrocyte glycoprotein 
(MOG) peptide demonstrated a key role for IL-10 in inducing tolerance (Burkhart 




IL-10 is secreted by a variety of cells including several CD4+ T cell subsets, B 
cells, dendritic cells, monocytes, macrophages, eosinophils and mast cells. Within 
the T cell subsets, Th2 cells were originally believed to be the primary source of 
IL-10 (Moore et al., 2001). However, it soon became apparent that Th1 cells 
could also secrete similar levels of IL-10 as Th2 cells (O'Garra and Vieira, 2007, 
Moore et al., 2001). It has also become evident that IL-10 secretion by Th1 cells 
prevents host damage by limiting excessive immune responses (Gazzinelli et al., 
1996, O'Garra and Vieira, 2007, Gabrysova et al., 2009). For example, IL-10 
knockout mice, infected with Toxoplasma gondii induced lethal effects associated 
with increased IFNγ, IL-12 and TNFα (Gazzinelli et al., 1996).  Conversely, Th1 
cells that produced elevated levels of IL-10 prevented the clearance of Leshmania 
major resulting in chronic infection (Anderson et al., 2007). Therefore the 
relative secretion of IL-10 and IFNγ is key to both the clearance of pathogens and 
preventing damage to the host.  This is of particular importance to CD46 
costimulated T cells as the ratio of IL-10 and IFNγ is an important factor in 
determining whether CD46 activated cells are regulatory or inflammatory 
(Cardone et al., 2010) and will be addressed in detail below. 
 
Tr1&
Activation of T cells in the presence of large amounts of IL-10 can induce a 
subset of T cells that secrete large amounts of IL-10 and can suppress bystander 
effector cells (Groux et al., 1997). The first evidence of the Tr1 subset was 
documented in 1994 by Bacchetta et al who described long-term tolerance to 
stem cell allografts in patients with severe combined immunodeficiency (SCID). 
Despite the presence of host specific CD4+ and CD8+ T cells of donor origin 
there was no graft-versus-host disease (GVHD). This tolerance was believed to 
be the result of high levels of IL-10 and low levels of IL-2 identified in PBMCs 
from the patient compared to healthy controls. Indeed, host reactive CD4+ T cell 
clones isolated from the SCID patient also expressed high levels of IL-10 and low 
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levels of IL-2 upon antigen stimulation in vitro (Bacchetta et al., 1994). Groux et 
al further investigated these suppressive IL-10 secreting T cells and determined 
that antigen specific CD4+ T cells that undergo chronic stimulation in the 
presence of IL-10 proliferate poorly, produce high amounts of IL-10 and IL-5, 
secrete moderate levels of IFNγ and TGFβ, low levels of IL-2 and no IL-4. These 
antigen specific T cells could suppress autologous effector T cells partially 
through the effects of IL-10 and TGFβ secretion in vitro and in vivo in an antigen 
dependent manner (Groux et al., 1997). Moreover, IL-10 acts as a positive 
autocrine factor in the induction of IL-10 secreting cells, which is in contrast to 
its effects on both Th1 and Th2 development (Barrat et al., 2002). Importantly, 
co-transfer of these antigen specific T cells with pathogenic CD4+CD45RBhigh T 
cells could suppress colitis induced in SCID mice (Groux et al., 1997). More 
recently, islet specific IL-10 secreting Tregs have also been isolated from non-
diabetic individuals (Tree et al., 2010). Interestingly, pathogen specific Tr1 cells 
were also found in the respiratory tract of mice infected with Bordetella pertussis. 
It is believed that these Tr1 cells are induced by the bacteria to avoid clearance by 
Th1 immune responses. This highlights how bacteria have evolved to manipulate 
Tr1 cells in order to evade host immune system detection (McGuirk et al., 2002).   
 
Although the secretion of IL-10 is the main mechanism of Tr1 function, Tr1 cells 
also employ contact dependent suppression mechanisms, which are reviewed in 
(Gregori et al., 2012). In brief, the inhibitory co-receptors CTLA-4 and PD-1 play 
a key role in the suppression of allergen specific T cells. Similar to FoxP3+ Tregs, 
Tr1 cells also induce metabolic disruption in effector T cells through the 
production of adenosine (Mandapathil et al., 2010) (Gregori et al., 2012). 
Furthermore, Tr1 cells can kill target cells through the expression of granzyme B 
(Grossman et al., 2004). Tr1 cells are similar to nTregs in their low proliferative 
capacity, minimal IL-2 secretion, cell-cell contact suppression (Sakaguchi et al., 
2008). Importantly however, Tr1 cells do not express high levels of FoxP3, the 
transcription factor that defines nTregs and FoxP3+ iTreg (Vieira et al., 2004) 




Groux et al originally demonstrated that antigen specific T cells activated by 
APCs in the presence of IL-10 induced a Tr1 phenotype (Groux et al., 1997). 
However, IL-10 was not sufficient to induce Tr1 cells in the absence of 
professional APCs suggesting that other soluble factors or costimulatory 
molecules were involved in their induction. In this regard, it was noted that the 
addition of IFNα alongside IL-10 markedly increased differentiation of naïve T 
cells into Tr1 cells (Levings et al., 2001). Further investigations also reported that 
the immunosuppressive drug, Rapamycin, also enhanced IL-10 induction of Tr1 
T cells and induced a state of long term tolerance in diabetic mice after pancreatic 
islet transplantation (Battaglia et al., 2006). Of note, treatment of naïve T cells 
with a combination of dexamethasone, vitamin D and neutralising antibodies 
against IL-4, IFNγ and IL-12 produced a more homogenous population of IL-10 
producing cells that did not express IL-4, IL-5 or IFNγ. In accordance with their 
cytokine secretion profile, the expression of T-bet and GATA-3 traditionally 
associated with Th1 and Th2 subsets, was also downregulated (Barrat et al., 
2002). IL-27, a member of the IL-12 cytokine family can also induce a Tr1 
regulatory cell phenotype while concomitantly inhibiting Th17 differentiation 
(reviewed in (Pot et al., 2011a)). In this regard, IL-27 was shown to play a 
protective role in EAE models (Fitzgerald et al., 2007) and is also upregulated in 
patients with MS that positively respond to interferon-β (IFNβ) treatment 
(Sweeney et al., 2011). In addition to soluble factors in the milieu, Tr1 cells can 
also be induced by APCs. For example, repeated exposure of naïve T cells with 
both immature and IL-10 induced tolerogenic dendritic cells can induce Tr1 cells 
with suppressive capacity (Levings et al., 2005, Gregori et al., 2010). Moreover, 
tolerogenic dendritic cells can induce Tr1 cells after only one round of 
stimulation (Gregori et al., 2010) suggesting that chronic stimulation may not be 
an absolute requirement of Tr1 induction. The fact that in the absence of APCs, 
IL-10 alone is not sufficient to induce Tr1s suggests that costimulatory molecules 
could play an important role. Indeed, in an airway hyper reactivity (AHR) model, 
dendritic cells induced Tr1 cells in an ICOS-ICOS ligand dependent fashion. 
After adoptive transfer these Tr1 cells inhibited AHR in sensitised mice (Akbari 
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et al., 2002). Interestingly, IL-27 induced Tr1 cells also upregulated the ICOS 
receptor which acted to boost Tr1 differentiation (Pot et al., 2009). This suggests 
that the ICOS pathway may play an important role in Tr1 development. Other 
costimulatory molecules can also induce Tr1 cells including CD2 and CD46 
(Wakkach et al., 2001, Kemper et al., 2003).  Indeed, CD2 costimulated naive T 
cells also required only one stimulation to induce a suppressive Tr1 phenotype 
(Wakkach et al., 2001). The role of CD46 induced Tr1s is central to this thesis 
and is discussed in section 1.3. 
 
Importantly, it remains to be determined if Tr1 cells are generated from naïve 
cells or are simply a terminal differentiation state of other T cell subsets, such as 
Th1 or Th2 subsets (Cope et al., 2011, Pot et al., 2011b). In light of this, the 
existence of Tr1 T cells as a distinct subtype of T cells remains controversial. 
Nonetheless, the uniting characteristic of all Tr1 cells or IL-10 producing Tregs is 
that they produce high amounts of IL-10 and can suppress bystander T cell 
responses (O'Garra et al., 2004, Gregori et al., 2012). Identification of Tr1 
specific markers will help resolve the identity or Tr1s as unique T cell subset or 
terminal differentiation state of other T helper subsets (Pot et al., 2011b).  
 
CD46 costimulated T cells can induce either a Tr1-like or Th1-like phenotype 
(Kemper et al., 2003, Sanchez et al., 2004, Cardone et al., 2010). In MS patients, 
CD46 induced IL-10 secretion was defective (Astier et al., 2006, Martinez-Forero 
et al., 2008). Given the importance of IL-10 and Tregs in suppressing 
inflammation, the role of CD46 in regulating T cell activation was investigated. 
The structure and known functions of CD46 are described below. Both the 
structure of CD46 and its previously described functions give useful insights into 
how CD46 might regulate T cells’ phenotype. 






CD46 is a type I transmembrane protein that is expressed in all nucleated cells 
except erythrocytes (figure 1.3) (Seya et al., 1986). CD46 is not expressed in the 
mouse, except in the testis (Tsujimura et al., 1998). CD46 has the ability to 
regulate T cell (Astier et al., 2000, Kemper et al., 2003, Oliaro et al., 2006, Ni 
Choileain and Astier, 2011), B cell (Fuchs et al., 2009), monocyte (Karp et al., 
1996), macrophage (Hirano et al., 1999, Kurita-Taniguchi et al., 2000, Katayama 
et al., 2000, Kurita-Taniguchi et al., 2002), dendritic (Barchet et al., 2006, 
Vaknin-Dembinsky et al., 2008), astrocytes (Ghali and Schneider-Schaulies, 
1998) and epithelial cell (Kallstrom et al., 1998, Lee et al., 2002, Ludford-
Menting et al., 2002, Cardone et al., 2011) responses during inflammation. CD46 
influences various cell functions including cytokine secretion (Karp et al., 1996, 
Ghali and Schneider-Schaulies, 1998, Kemper et al., 2003), cell activation (Astier 
et al., 2000), apoptosis/necrosis (Elward et al., 2005, Cole et al., 2006, Grumelli 
et al., 2011), polarity (Ludford-Menting et al., 2002, Oliaro et al., 2006, Ludford-
Menting et al., 2011), morphology (Zaffran et al., 2001), migration (Alford et al., 
2008, Tsai et al., 2012), autophagy (Joubert et al., 2009), antigen presentation 
(Rivailler et al., 1998), toll-like receptor activation (Iacobelli-Martinez and 
Nemerow, 2007), wound repair (Cardone et al., 2011) and has more recently been 
shown to have an anti-microbial function (Basmarke-Wehelie et al., 2011). 
Moreover, dysregulation of CD46 responses have been reported in several 
immunopathologies including MS (Astier et al., 2006, Martinez-Forero et al., 
2008, Ma et al., 2009), systematic lupus erythematosus (SLE) (Le Buanec et al., 
2011), asthma (Xu et al., 2010, Tsai et al., 2012), rheumatoid arthritis (RA) 
(Cardone et al., 2010), atypical haemolytic uremic syndrome (HUS) (Richards et 
al., 2003) and human C3 deficiency (Ghannam et al., 2008). Despite its role in 
such a wide range of immune responses much of CD46 intracellular signalling 





The basic structure of CD46 consists of an extracellular domain of four short 
consensus repeats (SCR1-4), three exons rich in serine, theronine and proline 
(STP A, B and C), a region of unknown significance, a transmembrane segment, 
and a short intracellular tail (figure 1.3) (Liszewski et al., 1991).  
 
Figure 1.3: Schematic of Cyt1 and Cyt2 isoforms with STP splicing. 
Schematic of six different CD46 isoforms as a result of splicing of the STP and 
cytoplasmic regions – ABC1, ABC2, BC1, BC2, C1, and C2. Antibody binding 




At the DNA level, CD46 consists of 14 exons and multiple isoforms of CD46 are 
produced as a result of alternative mRNA splicing (Russell et al., 1992). Splicing 
of exon 13 gives rise to two distinct cytoplasmic tails: Cyt1 and Cyt2 (figure 1.4) 
(Liszewski et al., 1991, Russell et al., 1992). Cyt1 and Cyt2 isoforms are co-
expressed in all cell types. However, there is preferential expression for Cyt2 in 
the brain and kidney (Johnstone et al., 1993). In addition, the STP region can also 
be alternatively spliced resulting in the isoforms BC-Cyt1 (BC1), BC-Cyt2 
(BC2), C-Cyt1 (C1) or C-Cyt2 (C2) (figure 1.3) (Seya et al., 1999). Individuals 
express both the BC and C isoforms of CD46, however, the exact ratio of BC:C 
expression varies. Dominant expression of the BC isoform is most common 
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(65%), and dominant expression of the C isoform is the least common (6%), the 
remainder of the population have equal expression of both isoforms (Ballard et 
al., 1987). Tissue specific expression of the STP-ABC, BC and C isoforms also 
exists (Seya et al., 1999). For example, the ABC isoform is primarily expressed 
in the intestine, salivary gland and cancer cells (Xing et al., 1994). The BC 
isoforms are preferentially expressed in the kidney and foetal heart, while the C 
isoform is preferentially expressed in the brain (Johnstone et al., 1993). This 
suggests that there is a biologically significant role for distinct CD46 proteins. 
Importantly for this project, in a transgenic mouse model expressing Cyt1- or 
Cyt2-CD46, these isoforms had contrasting roles in regulating a contact 
hypersensitivity reaction (discussed below) (Marie et al., 2002). Prior to 
beginning this investigation, their function or expression during human T cell 
activation had not been reported. 
 
Figure 1.4: Schematic of CD46 exons, cytoplasmic tail splicing and amino 
acid sequences. (A) CD46 Exons: (Exon 1) 5’ untranslated region (UT), (Exon 
2-6) SCRs, (Exon 7-9) STP domain, (Exon 10) Unknown, (Exon 11-12) TM – 
transmembrane domain. (Exon 13) Cyt1 and also a stop codon (indicated by 
arrow). (Exon 14) Cyt2. If exon 13 is translated (blue) exon 14 is converted into 
the 3’ untranslated region (UT). If exon 13 is absent then exon 14 (purple) 
encodes the cyt2 tail and the 3’ UT region. (B) Amino acid sequence of Cyt1 and 
Cyt2: This schematic is adapted from “Weyand NJ, Lee SW, Higashi DL et al 
Monoclonal antibody detection of cd46 clustering beneath Neisseria 






Glycosylation of proteins is a post-translational modification and, similarly to 
phosphorylation, it is an important regulator of receptor cell signalling (Ohtsubo 
and Marth, 2006). Due to its complexity, however, it is often overlooked. In 
contrast to the nucleic acids of amino acids monosaccharides are not limited to a 
linear assembly and can form much more complex 3D structures (Varki, 2009, 
Clark and Baum, 2012b). Thus, glycans give a huge diversity to a limited number 
of amino acids and support the huge complexities associated with biological 
systems such as the immune system. Throughout T cell development in the 
thymus and in the periphery, global cell surface changes in glycosylation occur 
(Piller et al., 1988, Galvan et al., 1998, Comelli et al., 2006, Clark and Baum, 
2012a), which can alter T cell activation (Demetriou et al., 2001, Lau et al., 2007, 
Chen et al., 2007, Chen et al., 2009), migration (Sperandio et al., 2009) and 
apoptosis (Galvan et al., 2000, Nguyen et al., 2001, Hernandez et al., 2006). Such 
changes in glycosylation are largely the result of alterations of golgi transferase 
expression levels, which are highly sensitive to differentiation state, extracellular 
cytokine milieu (Wagers et al., 1998, Grabie et al., 2002, Toscano et al., 2007) 
and genetic variations (Mkhikian et al., 2011). Glycan alterations can initiate 
subtle or large immunological responses by regulating protein stability (Tifft et 
al., 1992, Pulido and Sanchez-Madrid, 1992), localisation (Brewer et al., 2002, 
Chen et al., 2007), ligand affinity (Demetriou et al., 2001, Lau et al., 2007) and 
subsequent cell signalling (Demetriou et al., 2001, Lau et al., 2007, Chen et al., 
2009). Indeed, modulations of transferases are associated with regulatory and 
inflammatory T cell phenotypes (Wagers et al., 1998, Jenner et al., 2006, Toscano 
et al., 2007), autoimmunity (Demetriou et al., 2001, Mkhikian et al., 2011) and 
cancer (Partridge et al., 2004).  There are two commonly studied types of 
glycans, N-glycans and O-glycans, both of which have attachment sites on CD46. 
To date, there have been no studies addressing the role of CD46’s N- or O- 
glycans during T cell activation. However, in Chapter 5 the role of these glycans 
in regulating CD46 costimulation will be described. Although no studies have 
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investigated the structure of CD46’s glycans in depth, the general structure of N- 
and O- glycans is described below. 
 
1.3.4.2 NLglycans!
N-glycosylation of CD46 occurs on SCR1, SCR3 and SCR4 (figure 1.3)(Lublin 
et al., 1988). N-glycosylation refers to the covalent binding of a sugar to the 
nitrogen of asparagine with an Asn-X-Ser/Thr amino acid sequence, where X is 
any amino acid except proline. N-glycosylation occurs as the nascent protein 
passes through the endoplasmic reticulum (ER) and Golgi (Ohtsubo and Marth, 
2006, Varki, 2009, Clark and Baum, 2012b). The majority of N-glycans have the 
same core structure (Man9GlcNAc2) and three subtypes exist which are classified 
by the sugars that are attached to the core; high mannose, hybrid and complex. 
High mannose glycans are the initial glycans attached to proteins but their sugars 
can be trimmed by glycosidases, giving access to glycotransferases to add non 
mannose sugars thereby creating hybrid or complex glycans (figure 1.5) (Ohtsubo 
and Marth, 2006, Varki, 2009, Clark and Baum, 2012b). Complex N-glycans 
contain lactosamine repeats that are important for lectin binding, cellular 
interactions and migration. This core group can then be modified by the addition 
of more sugars like sialic acid, fructose or acetyl groups. This is termed 
‘branching’ or ‘decorating’. All three N-glycan subtypes are present on T cells 
(Ohtsubo and Marth, 2006, Clark and Baum, 2012b).  With respect to CD46’s 
function, N-glycans were shown to support measles virus (MV) and Neisseria 
infection (Maisner et al., 1994, Maisner et al., 1996, Hsu et al., 1997, Kallstrom 
et al., 2001) and also complement inactivation (Liszewski et al., 1998). The 
glycans are believed to play a role in regulating the correct conformation of 
CD46 for ligand binding (Persson et al., 2010). Glycosylation changes in CD46 
could therefore affect ligand binding and conformation changes during T cell 




Figure 1.5: Schematic of N-glycans subsets. High mannose, hybrid and 
complex. This schematic is adapted from “Clark MC, Baum LG. T cells modulate 
glycans on CD43 and CD45 during development and activation, signal 
regulation, and survival. Ann N Y Acad Sci. 2012”. 
 
1.3.4.3 OLglycans!
O-glycosylation of CD46 occurs in the STP region (figure 1.3). STP splicing 
regulates the potential number of O-glycan sites. The STP-A contains five 
potential O-glycosylation binding sites, the STP-B contains ten (Xing et al., 
1994) and the STP-C region contains 2 sites 
(http://www.uniprot.org/uniprot/P15529, accessed 09/02/12). O-glycosylation 
refers to the binding of a glycan to the hydroxyl group of serine and theronine 
and generally occurs in the Golgi apparatus. O-glycosylation occurs serially, 
where the first sugar added to serine or theronine proteins is N-
acetylgalactosamine (GalNAc). Extension of the first sugar results in the 
formation of different core O-glycan groups. Addition of the first sugar, GalNAc 
results in the formation of the Core 1 structure (asialo core 1). If sialic acid is 
added to the core structure it is known as sialo core 1. Extension of this sugar 
with N-acetylgalactosamine (GlcNAc) forms the Core 2 structure (figure 1.6) 
(Ohtsubo and Marth, 2006, Clark and Baum, 2012a). Similar to N-glycans, Core 
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2 structures can be further extended to form lactosamine repeats. Core 1 and Core 
2 structures are commonly expressed on T cells and are altered during T cell 
activation (Varki, 2009, Clark and Baum, 2012b). Although research into the 
glycosylation of CD46 is limited, earlier studies have identified that both the 
mature forms contain sialic acid, complex N-glycans and O-glycans (Yu et al., 
1986, Ballard et al., 1988). Interestingly, the more heavily glycosylation BC 
isoform has an increased ability to bind and deactivate C4b providing enhanced 
protection to the classical complement pathway (Liszewski and Atkinson, 1996). 
This suggests that glycosylation may be important for regulating CD46 function. 
The effects of CD46 glycosylation during T cell activation were investigated 
during this project and are described in Chapter 5. 
 
 
Figure 1.6: Schematic of O-glycan subsets. Asialo core 1, Sialo core 1 and 
core 2 o-glycans. The line and asterix represents a polylactosamine repeat. This 
schematic is adapted from “Clark MC, Baum LG. T cells modulate glycans on 
CD43 and CD45 during development and activation, signal regulation, and 





The role of CD46 during T cell activation is the basis of this project. Initial 
studies of CD46 function in the literature are focused on the role of CD46 as a 
complement regulator and as a pathogen receptor. For descriptive purposes, 
CD46’s functions are therefore categorised into three groups: complement 
regulator, T cell costimulatory molecule and a pathogen receptor (figure 1.7). 
However, these functions are not mutually exclusive and CD46’s function in T 
cell activation is intrinsically linked to its other roles (Ni Choileain and Astier, 
2011, Ni Choileain and Astier, 2012).  Understanding the functions of CD46 in 
other capacities gives important clues as to how CD46 can regulate T cell 
phenotypes. Each function is described below. In the case of complement 
regulation and the pathogen receptor functions, their relationship with CD46’s 
role as a costimulatory molecule is also discussed. 
 
   
Figure 1.7: A schematic of the functions of CD46 in immunology. 
 
1.3.5.1 T!cell!activation!!
Over a decade ago CD46 was identified as a T cell co-stimulatory molecule that 
linked the innate and adaptive immune systems. Astier et al demonstrated that 
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CD46 costimulation in CD4+ T cells induced marked actin relocalisation, 
morphological changes, strong proliferation and involved the activation of the T 
cell signalling molecules p120CBL, LAT, Vav, Rac, Erk and MAPK (Astier et al., 
2000, Zaffran et al., 2001). Following on from these reports, CD46 costimulation 
in the presence IL-2 was shown to induce the secretion of large amounts of IL-10 
with little or no IL-2, IL-4 or IL-5 (Kemper et al., 2003, Price et al., 2005). Due 
to the cytokine profile of these T cells and their ability to suppress effector T 
cells, CD46 activated T cells were termed Tr1 T cells (Kemper et al., 2003, Price 
et al., 2005). Several reports expanded on the role of CD46 activated T cells as 
regulatory T cells. For example, CD46-activated Tr1 cells express granzyme B 
and can kill target cells in a perforin dependent manner (Grossman et al., 2004). 
Moreover, non-identified soluble factors released by CD46-activated T cells were 
also shown to play a role inhibiting Mycobacterium bovis BCG specific CD4+, 
CD8+ and γδ T cell responses. Of note IL-10 played no role in the suppression of 
γδT cells highlighting the ability of CD46 to suppress inflammation through other 
mechanisms (Cardone et al., 2010). Thus, CD46 activated T cells can induce 
different regulatory functions in an inflammatory environment. Of note, factors 
that promote the IL-10-induced differentiation of Tr1 cells also support the 
differentiation of CD46-Tr1 cells. For example, IFNα also been shown to skew 
nTreg differentiation towards Tr1 differentiation in the presence of CD46 
ligation. Moreover, active lupus is related to increased levels of complement 
stimulation of CD46 and high levels of IFNα that inhibit nTreg contact dependent 
suppression (Le Buanec et al., 2011). Furthermore STAT3 which is fundamental 
to Tr1’s role in inducing IL-10 secretion (Gregori et al., 2012) binds to the CD46 
promoter and induces its upregulation (Buettner et al., 2007). Indeed, CD46 
costimulation resulted in increased levels of phosphorylated STAT3 (pSTAT3), 
suggesting a positive feedback loop. In correlation with these findings, CD46 
costimulation of T cells in the presence of the immunomodulator prostaglandin 
E2 (PGE-2), induced decreased levels of pSTAT3, that correlated with a reduced 
Tr1 phenotype (Kickler et al., 2012). Moreover, although CD46-Tr1 cells have 
been reported to have a strong proliferative capacity, further studies have noted 
that with suboptimal TCR stimulation, CD46-Tr1 cells display a reduced 
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proliferative capacity, reminiscent of other Tregs, that was the result of a 
defective Akt/Survivin pathway (Meiffren et al., 2006). This study reflected the 
observations made by Adams et al that adenovirus infection or CD46 crosslinking 
in the presence of low CD3 stimulation induced reduced T cell proliferation 
(Adams et al., 2012).  
 
Despite these findings questions remain over the exact phenotype of CD46 
induced T cells. Sanchez et al demonstrated that CD46 costimulation in the 
presence of PMA or CD28 stimulation increased IFNγ and IL-2 secretion, 
characteristic of a Th1 phenotype (Sanchez et al., 2004). Later it was proposed 
that CD46 Tregs originate from a Th1 subset. The concentration of IL-2 was 
deemed crucial for switching CD46 activated T cells from a Th1 to an IL-10 
producing Treg phenotype. During early activation CD46 induces IFNγ secretion, 
however as the concentration of IL-2 increases CD46 activated cells begin to 
switch to IL-10 secreting cells (Cardone et al., 2010). Notably, CD46 regulatory 
cells are now termed Tr1-like cells to reflect their potential Th1 origins, cytokine 
profile and their suppressive function. Regardless of the origins of CD46 Tregs, 
their cytokine profile remains distinct to that of classic CD28 costimulated T cells 
as they display increased ratio of IL-10:IFNγ and have low levels of IL-2 
secretion (Kemper et al., 2003, Kickler et al., 2012). Importantly, CD46 induced 
IL-10 secretion was defective in MS patients and CD28 induced IL-10 secretion 
was not (Astier et al., 2006). In summary, CD46 activation can alter the 
phenotype of T cells by promoting a suppressive phenotype. Further 
investigations are required, however, to determine the exact phenotype of CD46 
costimulated T cells. Of note, however, the plasticity of CD46 responses may be 
explained by the diversity of its cytoplasmic tails. As mentioned, a key study by 
Marie et al using a contact hypersensitivity model in a transgenic mouse model 
expressing either Cyt1- or Cyt2-CD46 demonstrated that Cyt1 suppressed 
inflammation and Cyt2 promoted inflammation (Marie! et! al.,! 2002). Prior to 
commencing this project, the role of Cyt1 and Cyt2 in human T cell activation 
had not been addressed. Therefore, the expression levels and functions of Cyt1 
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and Cyt2 during human T cell activation were hypothesised to play a role in 
regulating CD46 function and were investigated in Chapter 3 and Chapter 4.  
 
1.3.5.2 Complement!regulator!
Over two decades ago, CD46 was identified as a member of the regulators of 
complement activation (RCA) family gene cluster, located on chromosome 1, 1 
q32 (Lublin et al., 1988). CD46 protects autologous cells from complement attack 
by acting as a cofactor for the factor-1 mediated cleavage of C3b and C4b (Seya 
et al., 1986, Seya et al., 1999, Liszewski et al., 1991). Binding of complement 
requires the SCR2-4 domains (Adams et al., 1991, Seya et al., 1998). Atypical 
HUS is a pathology characterised by massive complement activation on renal 
endothelial cells, thrombocytopenia, microangiopathic haemolytic anaemia and 
acute renal failure (Kavanagh et al., 2006). Several mutations in CD46 that affect 
complement binding or cleavage predispose individuals to atypical HUS 
(Richards et al., 2003). Furthermore, expression of CD46 in the female 
reproductive tract fluid is also believed to protect the foetus from complement 
attack (McLaughlin et al., 1996). Moreover, certain tumor cells upregulate CD46 
expression and release soluble CD46 to evade complement attack and enhance 
metastasis (Gorter and Meri, 1999, Hakulinen et al., 2004, Tuve et al., 2006),  
therefore, CD46 expression regulates susceptibility to complement attack. 
Moreover, C3b ligation of CD46 in the presence of TCR stimulation induces a 
Tr1-like phenotype in T cells (Kemper et al., 2003).  The expression levels of cell 
surface CD46 during T cell activation could therefore regulate complement 
induced cell death and CD46 induced T cell responses. Prior to this study, surface 
expression of CD46 during T cell activation had not been examined and is 
detailed in Chapter 3. 
 
1.3.5.3 Pathogen!Receptor!
CD46 was labelled a ‘pathogen magnet’ due to the large number of bacteria and 
viruses that it binds (Cattaneo, 2004). CD46’s function as a pathogen receptor 
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was established when it was found to bind to the Edmonton strain of MV and was 
named gp57/67 due to its molecular weight (Dorig et al., 1993, Naniche et al., 
1993a).  Today, CD46 has been identified as the receptor for several group B 
adenoviruses (Segerman et al., 2003, Gaggar et al., 2003), herpes virus 6 (HHV-
6) (Santoro et al., 1999), streptococcus (Okada et al., 1995)  and pathogenic 
Neisseria (Kallstrom et al., 1997). Pathogen ligation of CD46 can induce cellular 
responses that can aid both host defense and pathogen survival. In defense of the 
host, CD46 pathogen binding can induce inflammatory cytokine production 
(Ghali and Schneider-Schaulies, 1998), antibody class switching (Imani et al., 
1999), autophagy (Joubert et al., 2009) and increased sensitivity to complement 
attack (Schnorr et al., 1995). Conversely, CD46 can also facilitate a pathogen’s 
adhesion and entry into cells and activate signalling pathways that regulate 
cytokine production (Karp et al., 1996, Price et al., 2005) and function (Oliaro et 
al., 2006) in their favour. Indeed, the popularity of CD46 with pathogens 
emphasizes the importance of CD46 signalling in regulating the immune 
response. How a cell’s function is regulated by pathogen ligation of CD46 is 
described below.!
 
1.3.5.3.1 Measles Virus 
Measles virus (MV) is a negative strand RNA virus that infects the respiratory 
tract (Gerlier et al., 1994a). Immune suppression follows MV infection and is 
associated with a high mortality rate and a marked decrease in IL-12 production 
by monocytes (Karp et al., 1996). MV binds to CD46 SCR1-2 domains, which 
facilitates cell entry and replication of the virus (Dorig et al., 1993, Naniche et al., 
1993a, Manchester et al., 1995, Iwata et al., 1995, Greenstone et al., 2002). In 
vitro CD46 activation in monocytes by MV or C3b induces a decrease in IL-12 
production (Karp!et!al.,!1996). Therefore, CD46 signalling was thought to play a 
key role in MV-induced immunosuppression and introduced evidence that 
pathogens could manipulate CD46 signalling pathways to regulate cytokine 
production. However, MV ligation of CD46 in macrophages supports host 
defence by increasing IL-12, IFN-α/β and nitric oxide production thereby 
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promoting macrophage activation and reducing viral replication (Hirano! et! al.,!
1999,!KuritaJTaniguchi!et!al.,!2000,!Katayama!et!al.,!2000). Differences in the 
maturation state of monocytes are believed to regulate CD46’s role in regulating 
IL-12 secretion. Notably, however, CD46’s regulation of IFN-α/β and nitric 
oxide required its cytoplasmic tail (Hirano et al., 1999, Katayama et al., 2000) 
and indicated that active signalling was involved in altering cell function. To 
date, expression levels of Cyt1 and Cyt2 in monocytes and macrophages have not 
been analysed. However, as Cyt1 and Cyt2 have contrasting roles in regulating 
inflammation (Marie et al., 2002), differences in their expression could explain its 
apparently contrasting responses during MV infection.  
 
MV activation of CD46 in astrocytes and B cells also affected their function 
(Ghali!and!SchneiderJSchaulies,!1998,!Imani!et!al.,!1999). Specifically, CD46 
crosslinking on astrocytes or treatment with MV proteins can induce IL-6 
production (Ghali!and!SchneiderJSchaulies,!1998)!and!MV infection or CD46 
crosslinking prior to IL-4 treatment of B cells induced IgE class switching (Imani 
et al., 1999).  Of note, IL-6 secreting B cells were recently shown to play a role in 
promoting disease in the EAE model (Barr et al., 2012). Whether CD46 
crosslinking in B cells can also induce increased IL-6 secretion may be an 
interesting avenue of research. These data indicate that CD46 can induce 
signalling in a variety of cell types that influence the immune response. 
Understanding the expression and regulation of CD46 in T cells will be important 
starting point to an overall understanding of CD46’s role in the immune response. 
 
1.3.5.3.2 Human Herpes Virus 
HHV-6 is a double stranded DNA virus that is present in the majority of the 
humans without major complications and preferentially infects CD4+ T cells (De 
Bolle et al., 2005). HHV-6 is normally latent but under periods of immune 
weakness its reactivation has been associated with direct immunosuppression and 
serious opportunistic infections (De Bolle et al., 2005). Interestingly, due to its 
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latency, periodic reactivation and neurotropism, HHV-6 has also been linked to 
MS, albeit controversially (Clark, 2004). MS relapses and EDSS score have been 
linked to viral replication and increased levels of HHV-6 in cerebral plaques and 
serum (Berti et al., 2002, Cermelli et al., 2003, Alvarez-Lafuente et al., 2006), 
supporting the hypothesis that HHV-6 reactivation is linked to MS. Cross-
reactive epitopes have also been identified on HHV-6 and myelin basic protein 
(MBP) and therefore T cells could potentially become activated by HHV-6 in the 
periphery and trigger an autoimmune response to myelin in the central nervous 
system (CNS) via a process known as ‘molecular mimicry’ (Tejada-Simon et al., 
2003, Cheng et al., 2012). HHV-6 adherence to CD46 was dependent on the 
SCR2 and SCR3 domains (Greenstone et al., 2002). Upon binding to CD46 
HHV-6 causes the relocation of CD46 to lipid rafts allowing the entry of HHV-6 
into the cell via pH dependent cell fusion (Tang et al., 2008). Ludford-Menting et 
al have shown that the localisation of CD46 into lipid rafts plays a role in 
regulating CD46 function in T cells (discussed in Chapter 4) (Ludford-Menting 
et al., 2011) and suggests that HHV-6 could induce CD46 relocation to lipid rafts 
as a mechanism to induce specific signalling. Furthermore, CD46 expression on 
astrocytes and oligodendrocytes is believed to support cell to cell fusion with 
infected CD4+ T cells aiding the transmission of the virus into the CNS (Tang!et!
al.,!2008).  Therefore, CD46 could facilitate the spread of pathogens with myelin 
cross-reactive epitopes into the CNS. Moreover, the presence of HHV-6 in the 
CNS may provide additional local signalling ligands for CD46. These findings 
underline the importance of understanding CD46 signalling pathways, which 




Human adenoviruses are double stranded DNA viruses that are classified into 
different subgroups (A-F) (Wang et al., 2007). Several viruses in the subgroup B 
utilize CD46 as their receptor including Adenovirus type 35 (Ad35). Ad35 binds 
to CD46 via SCR1 and SCR2 and is mainly associated with urinary tract and 
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kidney infection (Tuve et al., 2006, Wang et al., 2007). Recent studies highlight 
the ability of adenoviruses to manipulate the adaptive immune system. 
Specifically, adenovirus infection of dendritic cells induces high levels of IFNα 
and cell maturation that is CD46 dependent (Lore et al., 2007) suggesting that 
CD46 signalling acts to protect the host upon adenovirus infections. However, 
IFNα has also been shown to promote CD46 Treg function (Le Buanec et al., 
2011) and therefore may also act as negative feedback loop that regulates the 
inflammatory response. Moreover, Ad35 can inhibit CD4+ T cell IL-2 secretion 
predominantly through its knob protein actions with CD46 (Adams et al., 2011, 
Adams et al., 2012). Direct treatment of CD4+ T cells with Ad35 or antibody 
cross-linking of CD46 also decreased naïve CD4+ T cell proliferation and 
inhibited NFkB activation in CD28 costimulated cells (Adams et al., 2011). 
Decreased T cell proliferation upon Ad35 ligation of CD46 reflects observations 
by Meiffren et al who identified abortive proliferation in CD46 activated T cells 
when low doses of TCR stimulation were used (Meiffren et al., 2006). 
Reduced/low proliferation of T cells upon CD46 costimulation is in contrast to 
previous reports that have shown that CD46 ligation induced increased T cell 
proliferation (Astier et al., 2000, Ni Choileain et al., 2011). The differences in 
these reports likely reflect lower levels of TCR stimulation and raise questions 
that the strength of TCR ligation may regulate CD46’s function. In Chapter 5, the 
role of the TCR in regulating CD46 expression and structure is elucidated. To 
conclude, the varying roles of CD46 in regulating immune cell responses upon 
pathogen ligation suggest that CD46 regulation is complex and that different 
mechanisms are in place, including TCR stimulation, to regulate CD46’s 
function.    
 
1.3.5.3.4 Neisseria 
Neisseria is a gram-negative bacterium that utilizes the surface organelle type IV 
to bind CD46 and adhere to cells. The pili of both Neisseria gonorrhoeae and 
Neisseria meningitides bind to CD46 (Kallstrom et al., 1997). Kallstrom et al 
demonstrated that the SCR3, STP region that the cytoplasmic tails also plays an 
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active role in bacterial adherence (Kallstrom et al., 2001). Moreover, upon 
ligation, Cyt2 becomes tyrosine phosphorylated and this involves the Src kinase 
c-Yes (Lee! et! al.,! 2002). Antibody ligation of CD46 in Jurkat T cells also 
induces the tyrosine phosphorylation of Cyt2 by Lck, an Src kinase (Wang!et!al.,!
2000). Therefore, bacterial binding to CD46 initiates active signalling that 
supports the bacterial infection. Again, Neisseria ligation of CD46 emphasizes 
the ability of pathogens to manipulate CD46 signalling, for their advantage.   
 
1.3.5.3.5 Streptococcus pyogenes 
Streptococcus pyogenes is a gram-positive bacterium that causes group A 
streptococcal infection that ranges from minor skin infections to deeper infection 
in the fascia causing life threatening necrotizing fasciitis. The streptococcus M 
protein binds to CD46 facilitating attachment to the cell and evasion of 
oponization by the alternative complement pathway (Okada et al., 1995, 
Rezcallah et al., 2005). CD46 transgenic mice become highly susceptible to 
necrotizing fasciitis upon infection leading to death (Matsui et al., 2009). 
Bacterium adherence requires the SCR3 and SCR4 domains and the cytoplasmic 
tails were shown to play a role in the bacterium’s entry into epithelial cells 
(Giannakis et al., 2002, Rezcallah et al., 2005). Moreover, upon CD46 ligation 
the streptococcal M protein can manipulate the adaptive immune system by 
inducing T cells to secrete large amounts of IL-10 and granzyme B production 
(Price et al., 2005). This reflects the finding of Mcguirk et al who demonstrate 
that antigen specific Tr1s were induced by Bordetella pertussis in an attempt to 
avoid Th1 responses (McGuirk et al., 2002). Streptococcus also induced shedding 
of cell surface CD46 from epithelial cells (Lovkvist et al., 2008). Interestingly, 
pathogen manipulation of CD46’s signalling capacities are often associated with 
its downregulation: shedding or internalisation. In fact, all of the pathogens 
described above induce CD46 downregulation (Naniche et al., 1993b, Gill et al., 
2003, Sakurai et al., 2007, Lovkvist et al., 2008).  Considering the role of these 
pathogens in regulating CD46 signalling, it raises the question of whether CD46 
downregulation or shedding is important for CD46 costimulation. Prior to this 
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report, the downregulation of CD46 cell surface expression in human primary T 
cells had not been investigated. Previous reports have described CD46 
downregulation in other cell types and these are described below. 
 
1.3.6 CD46!expression!and!downregulation!
It is known that CD46 can be downregulated from the cell surface as a result of 
internalisation and/or surface shedding (Naniche et al., 1993b, Van Den Berg et 
al., 2002, Gill et al., 2003, Crimeen-Irwin et al., 2003, Hakulinen et al., 2004, 
Elward et al., 2005, Sakurai et al., 2007, Lovkvist et al., 2008, Weyand et al., 
Hakulinen and Keski-Oja, 2006), however its downregulation in primary human 
T cells had not been specifically investigated. In order to determine if 
downregulation is important for CD46 signalling, its method of downregulation 
needs to be addressed during T cell activation and is described in Chapter 3. 
Crimeen-Irwin et al elucidated the mechanism of CD46 internalisation in 
lymphoid and non-lymphoid cells using either monovalent or multivalent 
antibody ligation. Upon monovalent ligation of CD46 in non-lymphoid cells, 
including monocyte and dendritic cells, CD46 was constitutively internalised 
after 30 min via clathrin coated pits to multivesicular bodies, in the vicinity of the 
Golgi and recycled to the cell membrane. Internalisation of CD46 into clathrin-
coated pits was dependent on the interaction of its YRYL amino acid sequence 
and the clathrin adaptor protein AP-2. Constitutive internalisation was not 
observed in lymphoid cells at this timepoint and was therefore believed to act as a 
sensor for APCs and support antigen presentation (Crimeen-Irwin et al., 2003).  
Indeed, expression and downregulation of CD46 facilitates highly efficient 
antigen presentation of MV particles by the MHC Class II molecule in murine B 
cells (Gerlier et al., 1994b). Upon CD46 multivalent crosslinking in both 
lymphoid and non-lymphoid cells, CD46 is degraded following downregulation 
through macropinocytosis. Of note, the cellular pool of CD46 is thought to be in 
dynamic equilibrium with the cell surface and multivesicular bodies (MVB). 
Therefore any CD46 in MVB is rapidly sent to the surface where it can be 
internalised and degraded. It is hypothesised that CD46 may be prevented from 
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recycling in lymphoid cells by the binding of p56lck as is the case for CD4 
(Sleckman et al., 1992). 
 
Shedding of CD46 from the surface membrane can be the result of the release of 
the full intact form or a soluble form that does not contain the cytoplasmic tail. 
The full length CD46 is shed from various apoptotic cancer cell lines including 
the Jurkat T cell line (Hakulinen et al., 2004, Elward et al., 2005). Increased 
shedding of CD46 was associated with increased deposition of C3b on apoptotic 
cells indicating how CD46 can regulate “don’t eat me” signals (Elward et al., 
2005). Chemically induced apoptosis enhanced sCD46 levels which were due to 
cleavage of CD46 by metalloproteinases (MMP)(Hakulinen et al., 2004). 
Furthermore, the venom from Loxoceles and Neisseria infection induces cleavage 
of CD46 from epithelial cells (Van Den Berg et al., 2002, Weyand et al.). Further 
studies have identified specific MMPs involved in CD46 proteolysis. CD46 is 
cleaved by ADAM10 during apoptosis of epithelial cells (Hakulinen and Keski-
Oja, 2006) and MMP3, -8, -9 during neuronal cell apoptosis (Cole et al., 2006). 
Of note both the vesicular CD46 and the sCD46 retain their ability to mediate 
cleavage of C3b by factor I (Hakulinen et al., 2004). The release of functionally 
competent CD46 into the milieu may act to taper complement activation in the 
surrounding area and act as a negative feedback loop under inflammatory 
conditions.   
 
In summary, CD46 downregulation occurs by different routes and so far has been 
identified in the involvement of pathogen entry, complement regulation, 
apoptosis and antigen presentation. Prior to this study it remained to be 
determined how CD46 was specifically downregulated in primary human T cells 
and if downregulation occurred, what was its purpose? Understanding how CD46 
expression is regulated and how this affects its functions in T cells will advance 
our understanding of the possible mechanisms of CD46 dysfunction in MS, RA 
and asthma. Defective IL-10 secretion upon CD46 costimulation was first 
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described in patients with MS (Astier et al., 2006, Astier and Hafler, 2007). It 
was these findings that initiated the investigation of CD46 expression and 
function in this project. 
 
1.4 Multiple!Sclerosis!
MS is a chronic inflammatory disease of the CNS characterised by multifocal 
demyelination and progressive neurodegeneration (Sospedra and Martin, 2005, 
Zozulya and Wiendl, 2008, Petermann and Korn, 2011, Nylander and Hafler, 
2012). Clinical symptoms vary depending on the location of the lesions but 
commonly include chronic and relapsing paralysis, sensory dysfunction and 
cognitive impairment. Although MS is believed to be a heterogeneous disease, 
disease types are commonly classified into three subtypes. The most common 
form of MS is relapsing-remitting MS (RRMS) (85-90%) and involves periodic 
subacute clinical events followed by complete or almost complete recovery. 
However, over time the majority of patients with RRMS will eventually develop 
irreversible progressive neurological damage termed secondary progressive MS 
(SPMS). The third subtype is called primary progressive MS (PPMS), which is a 
more aggressive form of the disease. PPMS occurs in about 10-15% of cases and 
follows a progressive disease course in the absence of the relapsing –remitting 
phase of the disease (Sospedra and Martin, 2005, Zozulya and Wiendl, 2008, 
Petermann and Korn, 2011, Nylander and Hafler, 2012).   
!
1.4.1 Causes!
MS is an autoimmune disease that is believed to occur due to a combination of 
genetic and environmental factors (Sospedra and Martin, 2005, Goverman, 2011, 
Nylander and Hafler, 2012).  The role of genetics in contributing to disease was 
established early on and demonstrated that the probability of developing the 
disease was 20-50 fold higher in first-degree family members than unrelated 
individuals. Furthermore, in monozygotic twins, the probability of a second twin 
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having MS is roughly 25% (Sospedra and Martin, 2005). To date, variations in 
the MHC class II genes is associated with strongest independent risk factor in 
MS. Moreover, with the onset of the genome wide association studies (GWAS) 
over the last five years, large strides in the identification of specific risk factor 
genes have taken place. The GWAS studies analysed the whole genome with the 
aim of identifying genetic variations associated with disease. Of note there is 
strong enrichment of identified genes associated with lymphocytes and 
particularly T cell function and proliferation. For example, susceptibility to 
disease has been linked with the cytokine pathway (IL2R, IL7R, IL7, IL12), 
signal transduction (STAT3, STAT4, T-bet) and costimulatory molecules (CD58, 
CD80, CD86, CD40) (Sawcer et al., 2011b).   However, genetics do not account 
for the entirety of MS susceptibility and in the last few years there has been 
intense research into the role of sunlight exposure and Vitamin D levels in MS 
(Cantorna et al., 1996, Correale et al., 2009, Ascherio et al., 2010, Sawcer et al., 
2011b). There is a strong correlation with latitude and the incidence of MS, 
whereby countries further north with less sunshine have increased incidence of 
MS. In line with this, evidence indicates that Vitamin D deficiency is associated 
with an increased incidence of disease (Ascherio et al., 2010). Moreover active 
vitamin D has been shown to have immunomodulatory properties including Treg 
induction and the attenuation of EAE severity (Correale et al., 2009, Cantorna et 
al., 1996). Importantly, genetic risk factors associated with Vitamin D 
metabolism have also been identified (Sawcer et al., 2011b) highlighting how 
environmental and genetic factors could combine to increase disease 
susceptibility. Other environmental factors include Epstein–Barr virus (EBV) 
infection and this is evidenced by the fact that 100% of MS patients have EBV 
compared to 90% of healthy people (Ascherio and Munger, 2007). It has been 
demonstrated that EBV specific T cells cross react with myelin antigens and raise 
the possibility that EBV could enhance risk susceptibility as a result of 




It is clear from our current understanding that the immune system plays a key role 
in the etiology of MS. In accordance with this and extensive research in EAE 
(Sospedra and Martin, 2005, O'Connor and Anderton, 2008, Wraith and 
Nicholson, 2012, Nylander and Hafler, 2012), a model was developed to explain 
the initiation of the inflammatory cascade in MS that leads to the neurological 
damage. It is hypothesised that autoreactive T cells to myelin become activated in 
the periphery and migrate across the blood brain barrier (BBB). Once within the 
CNS, these T cell become reactivated by local APCs and initiate a cascade of 
events that lead to myelin destruction (Goverman, 2011)  (figure 1.8).  Curiously, 
autoreactive T cells to myelin components are present within both healthy 
individuals and patients with MS (Sun et al., 1991, Zhang et al., 1994, Raddassi 
et al., 2011). Therefore, determining why these myelin reactive T cells in patients 
become activated and not in healthy controls has been intensively investigated 
(Costantino et al., 2008a, Goverman, 2011, Nylander and Hafler, 2012). Two 
main concepts are thought to be involved: (1) there is a break in tolerance that 
allows these reactive cells to become activated; and (2) infectious agents such as 
EBV activate myelin specific T cells as a result of molecular mimicry 
(Goverman, 2011). As Tregs play a pivotal role in maintaining immunological 
homeostasis, examining their development and function in MS patients for 
potential discrepancies became a key focus of MS research. The role of Tregs in 
MS is discussed below.  
 
Figure 1.8: Model of T cell induced multiple sclerosis. Myelin autoreactive 
T cells are activated in the periphery. Following activation they migrate across 
the blood brain barrier (BBB) into the central nervous system (CNS) where they 
become reactivated. Reactivation of T cells initiates the inflammatory cascade 




CD4+ T cells can cause direct damage to neurons through the secretion of pro-
inflammatory cytokines or through orchestrating other immune cells such as B 
cells, macrophages and NK cells to cause direct damage to neurons via 
autoantibody secretion, phagocytosis and cytolysis respectively (Venken et al., 
2010). Indeed, animal models of MS, such as EAE, highlighted a central role for 
the involvement of CD4+ T cells. In genetically susceptible mice, immunization 
with myelin proteins in the presence of adjuvant or myelin reactive CD4+ T cells 
was sufficient to induce disease with a pathology similar to that observed in MS 
(O'Connor and Anderton, 2008, Sospedra and Martin, 2005). Moreover, an 
increased frequency in MOG reactive T cells were found in MS patients 
compared to healthy controls (Zhang et al., 1994, Raddassi et al., 2011). As 
mentioned previously, genetic studies have identified the MHC class II DRB1 
gene as the strongest association to MS susceptibility (Sawcer et al., 2011a), 
these data strongly associated CD4+ T cells with the pathogenesis of MS. With 
respect to patient treatments, Alemtuzumab, an anti-CD52 monoclonal antibody, 
that reduces T cell numbers, significantly improves RRMS disability after 6 
months treatment (Coles et al., 2006). Thus evidence from the EAE model, 
genetic studies and MS treatment support the proposal that T cells are key players 
in driving disease (Nylander and Hafler, 2012).  The subtype of T helper cells 
responsible for driving EAE was originally believed to be the Th1 subset and was 
evidenced by the protective effect of T-bet knockdown and IL-12 neutralisation 
in mice with EAE (Leonard et al., 1995, Bettelli et al., 2004). Furthermore 
treatment of MS patients with IFNγ, the trademark Th1 cytokine, was shown to 
exacerbate disease (Panitch et al., 1987). However, knockout of key Th1 
differentiation molecules, IFNγ-/-, IFNγR-/- and IL-12p35-/- (a subunit of the IL-
12p35/p40 heterodimer), in mice failed to protect them from EAE and increased 
disease susceptibility (Ferber et al., 1996, Willenborg et al., 1996, Becher et al., 
2002). It was then discovered that the IL-12 subunit p40 was not only shared with 
p35 but also p19 to form IL-23, which we know now to be involved in Th17 cell 
differentiation and EAE susceptibility (Oppmann et al., 2000, Cua et al., 2003).  
Indeed, both subtypes are now accepted to play an important role in EAE 
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induction (Petermann and Korn, 2011). The balance of Th1 and Th17 that are 
involved in inducing disease likely varies within patients and could be an 
important variable in treatment of the disease (Wraith and Nicholson, 2012). 
More research is required to determine the exact role of Th1 and Th17 subsets in 
MS. 
 
Although, there is no doubt that CD4+ T cells play a role in MS pathology there is 
increasing evidence that other immune cells such as CD8+ T cells and B cells are 
also involved. For example, the predominant T cell presence in lesions is that of 
CD8+ T cells. Furthermore, clonal expansion of CD8+ T cells has been identified 
in lesions and axonal damage is closely linked to their activity (Neumann et al., 
2002).  B cells also appear to play an important role as demonstrated by the 
consistent presence of increased immunoglobulin levels and clonally expanded B 
cells in the CSF of MS patients’ (Franciotta et al., 2008). As mentioned, depletion 
of B cells also ameliorates disease in the EAE model (Barr et al., 2012). 
Moreover, Rituximab an anti-CD20 monoclonal antibody that is used to treat MS 
selectively depletes B cells, thereby reducing lesions and relapses in patients 
(Nylander and Hafler, 2012). Taken together, these findings indicate that MS is 
an autoimmune disease, in which myelin reactive CD4+ T cells, in addition to 
other adaptive immune cells, play a fundamental role.   
 
1.4.3 Tregs!
As describer earlier, Tregs are crucial in regulating inflammatory responses and 
their function is defective in MS (Viglietta et al., 2004, Wraith et al., 2004, Astier 
and Hafler, 2007, Costantino et al., 2008a, Venken et al., 2010). The role of 
nTregs in EAE has been extensively studied and their ability to regulate disease 
susceptibility and severity has been investigated in depletion and co-transfer 
models (reviewed in (O'Connor and Anderton, 2008)). Importantly, McGeachy et 
al demonstrated that the depletion of nTregs inhibited the natural resolution of 
EAE (McGeachy et al., 2005) and emphasised the importance of nTregs in 
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disease recovery.  Moreover, FoxP3+ iTregs could also block EAE in an IL-10 
dependent manner (Selvaraj and Geiger, 2008), thereby underscoring the potency 
of both Treg subsets and IL-10 in regulating disease susceptibility. Initial studies 
of CD4+CD25high Tregs from MS patients demonstrated that patients have similar 
levels of CD4+CD25high Tregs as healthy controls (Viglietta et al., 2004). 
However, CD4+CD25high Tregs in RRMS were shown to be functionally 
defective in the suppression of CD4+CD25- effector cells (Haas et al., 2005, 
Viglietta et al., 2004). The defect of MS Tregs could be attributed to a lower 
frequency of FoxP3 that is reduced in the CD4+CD25high Treg population and at 
the single cell level (Venken et al., 2008). Further examination of the Treg subset 
by Michel et al demonstrated that it was the CD127high subset of CD4+CD25high 
cells that were defective in MS. CD4+CD25highCD127high cells were 
hyperproliferative and produced increased levels of pro-inflammatory cytokines 
IFNγ, TNFα and IL-2 in MS patients compared to healthy controls (Michel et al., 
2008). Recently, the extent of Treg plasticity has come to the forefront and it is 
recognised that Tregs are also capable of secreting inflammatory cytokines (Zhou 
et al., 2009). Dominguez-Villar et al have identified an increased frequency of 
Th1-like FoxP3+ Treg (CD4+CD25highCD127low/-) in RRMS patients compared to 
healthy controls. This population was characterised by IFNγ secretion, T-bet 
expression and reduced suppressive capacity. Moreover, this population is 
sensitive to IFNβ therapy which restores their frequency to that of healthy 
controls (Dominguez-Villar et al., 2011).  Treg deficiency is not only evident in 
the periperphy but also appears to occur during their development in the thymus. 
For example, studies investigating recent thymic emigrating Tregs (RTE-Tregs) 
showed a decreased frequency of these cells in the periphery of RRMS patients 
compared to healthy controls (Haas et al., 2007) (Venken et al., 2008). These 
developments indicate that MS patients have defective Treg development in the 





As discussed earlier, CD46 is a T cell co-stimulatory molecule (Astier et al., 
2000) that induces a Tr1-like phenotype characterised by the secretion of large 
amounts of IL-10 (Kemper et al., 2003).  However, in MS patients CD46 
stimulated T cells produced little or no IL-10 in comparison to healthy controls. 
This defect was specific to CD46 stimulated T cells and was not observed upon 
CD28 costimulation (Astier et al., 2006). Of note, higher stimulation of CD3 or 
increased concentrations of IL-2 did not restore IL-10 secretion (Astier et al., 
2006, Martinez-Forero et al., 2008). This study was reproduced by two 
independent reports, one using an in vivo MS monkey model (Martinez-Forero et 
al., 2008, Ma et al., 2009). Furthermore defects in CD46 induced IL-10 secretion 
have also been documented in asthma (Xu et al., 2010, Tsai et al., 2012) and RA 
(Cardone et al., 2010). The mechanism for this defect remains to be elucidated. 
Using a transgenic mouse model expressing either the Cyt1 or Cyt2 isoform of 
CD46. Marie et al demonstrated that Cyt1 attenuated and Cyt2 promotes 
inflammation in a contact hypersensitivity model (Marie et al., 2002). 
Interestingly, Astier et al also reported increased expression of Cyt2 mRNA in 
MS patients suggesting that differences in CD46 isoform expression may 
contribute to the inflammatory response in MS (Astier et al., 2006).  CD46 
costimulated T cells from asthma patients also expressed increased levels of Cyt2 
and decreased levels of Cyt1 at the RNA level (Tsai et al., 2012).  Therefore there 
is evidence to suggest that the expression levels of the Cyt1 and Cyt2 isoforms 
may play a role in determining CD46 induced IL-10 production.  
 
In summary, CD46 has wide-ranging signalling capacities in a variety of cell 
types that intertwine both the innate and adaptive immune responses. These 
functions are utilised by pathogens to alter the inflammatory response in their 
favour. CD46’s ubiquitous expression and the breadth of its functional duties 
suggest that CD46 signalling pathways are complex. Expression of different 
CD46 isoforms, namely Cyt1 and Cyt2, and the glycosylation of CD46 likely 
facilitates specific responses in different environments and inflammatory 
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conditions. Specifically of interest to this project is the role of CD46 in inducing 
regulatory T cells, which is characterised by the secretion of IL-10. This function 
is defective in MS patients and was the reason for initiating this project. In order 
to understand why IL-10 secretion was defective in MS patients, the expression, 
regulation and function of CD46 was investigated in healthy controls (Chapters 
3-5).  In Chapter 6, the findings from healthy controls were compared to those 
from patients with MS. Indeed, defects in CD46 expression and regulation were 
noted in MS patients and provide an important platform for understanding 
defective IL-10 production in T cells from these patients. Furthermore, given the 
wider context of CD46 function in the immune system, understanding the 
regulation of CD46 in T cells will no doubt have implications for other cell types 





1. CD46 expression is regulated by T cell activation. 
2. The cytoplasmic tails, Cyt1 and Cyt2, have different functions. 
3. Altered expression of CD46 is responsible for the defect of CD46 upon 
activation in MS.  
 
1.6 Aims!
1. To determine the expression levels of surface CD46, intracellular Cyt1 
and Cyt2 upon T cell activation in healthy controls. 
2. To determine the function of the Cyt1 and Cyt2 isoforms during T cell 
activation.  
3. To determine the mechanism(s) of the regulation of expression of CD46 
in T cells. 
4. To identify defects in CD46 expression/regulation that may account for a 







All chemical reagents were sourced from Sigma-Aldrich unless otherwise stated. 
 
2.2 Blood!donors!
To assess CD46 expression and function in healthy controls and patients with 
MS, CD4+ T cells were isolated from peripheral blood. Blood samples were taken 
by venupuncture into heparin vacutainers (Sarstedt, Germany). The 
characteristics of the healthy and patient donors are described in table 2.1. Blood 
donations were taken after informed consent was given. Ethical approval was 
obtained from the Lothian Board Ethics Committee prior to obtaining blood 
donations from patients. 
 
Table 2.1: Characteristics of the donors used in this study.  
 Healthy Controls Patients with MS 
Sex (Female:Male) 1:1 3.6:1 
Age (year, mean ± SD) 35.1±7.9 42.5±9.5 
Age range 25-55 26-58 
EDSS (mean ± SD) - 2.9±1.6 







In order to isolate CD4+ T cells, peripheral blood mononuclear cells  (PBMC) 
were first isolated from whole blood using density gradient centrifugation 
(Hettich Rotina 420). Heparinised whole human blood was diluted 1:2 in RPMI 
1640 medium (PAA, GE Healthcare, UK) at room temperature under sterile 
conditions. The diluted blood sample was gently layered above the Ficoll-paque 
plus (GE Healthcare, UK) in 50 ml Falcon tubes (15 ml Ficoll and 35 ml diluted 
blood) to produce two separated phases. The tubes were then centrifuged for 25 
min at 990 x g without brakes. This resulted in the formation of a cloudy 
mononuclear cell layer, which was removed from the interphase carefully with a 
Pasteur pipette and transferred into a new 50 ml Falcon tube. The cells were then 
washed four times with Phosphate buffered saline (PBS) (PAA, GE Healthcare, 
UK) at 460 x g for 10 mins. Finally an aliquot of the purified cells was diluted 
with trypan blue and counted using a counting chamber.  
 
2.3.2 CD4+!T!cell!Isolation!
CD4+ T cells were negatively isolated from PBMCs using magnetic beads (CD4+ 
Isolation Kit II; Miltenyi Biotec, Auburn, USA). PBMCs and reagents were kept 
on ice at all times in sterile culture conditions. The PBMCs were resuspended in 
40 µl MACS buffer (PBS, 0.5% BSA, 2 mM EDTA) per 107 total cells. The 
biotin-antibody cocktail was added at 10 µl per 107 total cells. Then the cells were 
mixed well and incubated on ice for 10 mins. Following the incubation, 30 µl of 
MACS buffer and 20 µl of anti-biotin microbeads per 107 total cells was added 
and mixed well. Cells were incubated on ice for 15 mins, and then washed with 
15 mls of MACS buffer at 370 x g for 5 mins. After centrifugation, cells were 
resuspended in 500 µl of MACS buffer and the CD4+ cells were isolated by 
magnetic separation using a large size (LS) column (Miltenyi Biotec, Auburn, 
USA) and a midiMACS™ separator (Miltenyi Biotec, Auburn, USA). The LS 
column was placed in the magnetic field of the separator and was rinsed with 3 
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mls of MACS buffer. The cell suspension was gently placed at the bottom of the 
column and allowed to pass through into a 50 ml Falcon tube. The column was 
then washed three times with MACS buffer. The entire effluent was collected in 
the same 50 ml Falcon tube. This tube now contained the enriched population of 
unlabelled CD4+ T cells. CD4+ T cell purity was assessed by flow cytometry 
using a mouse αCD4-fluorescein isothiocyanate (FITC) monoclonal antibody 
(clone OKT4, eBioscience, San Diego, USA) and the CD4+ T cell isolations with 
a purity of >90% were used for further experiments. 
 
2.4 T!cell!activation!
In order to activate CD4+ T cells, tissue culture plates (Nunc, Rochester, NY) 
were pre-coated with αCD3 (clone OKT3, 5 µg/ml), αCD28 (5 µg/ml) or αCD46 
(clone MC120.6, 10 µg/ml), kindly provided by Dr. Chantal Rabourdin-Combe 
from Lyon in France. CD4+ T cells were stimulated with αCD3 alone, 
αCD3/CD28, αCD3/CD46 or αCD3/CD28/CD46. When T cells were transfected 
with the CD19-fusion proteins, cells were also activated with the mouse αCD19 
monoclonal antibody at a concentration of 10 µg/ml (clone MCA19; AbD 
Serotec, UK). In one experiment the natural ligand of CD28, recombinant B7-1 
(R&D Systems, USA) was used to stimulate the T cells at a concentration of 2.5 
µg/ml. Recombinant human IL-2 (10 U/ml, Roche, Switzerland) was added to 
αCD3/CD46 stimulated cells to induce a regulatory phenotype as previously 
described (Kemper et al., 2003, Astier et al., 2006). The concentration of 
activating antibodies were as indicated, unless otherwise stated, and were diluted 
in PBS.  The cell culture plates were coated with the antibody dilutions for 2 hrs 
at room temperature then washed once with PBS. CD4+ T cells were seeded onto 
to the plates at the required density, suspended in 10% RPMI 1640 (10% v/v 
foetal calf serum (FCS)(Bio Sera, East Sussex, UK), 1% minimum essential 
medium non essential amino acids (MEM NEAA) 100X (PAA, GE Healthcare, 
UK), 1% v/v sodium pyruvate (PAA, GE Healthcare, UK), 1% v/v HEPES 1M 
(PAA, GE Healthcare, UK), 1% v/v penicillin streptomycin 100x (PAA, GE 
Healthcare, UK), 1% v/v L-glutamine 200 mM 100x (PAA, GE Healthcare, 
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UK)). Cells were activated for a period of up to 5 days. In two experiments 
phorbol myristate acetate (PMA) (5 ng/ml) and ionomycin (50 ng/ml) were used 
to activate T cells. In these experiments, T cells were plated in uncoated 48 well 
culture plates in 10 % RPMI 1640 and PMA/Ionomycin was added to the 
medium. The cells were cultured overnight and then harvested for flow cytometry 




In some experiments the protease inhibitors of MMP/ADAM or PγS were added 
to CD4+ T cell cultures at the time of activation. The MMP/ADAM inhibitor was 
GM6001 (Merck Chemicals, Germany) and was added to T cell cultures at a 
concentration of 10 µM. The PγS inhibitor used was DAPT (N-[N-(3,5-
Difluorophenacetyl-L-alanyl)] -S-phenylglycinet-Butyl Ester) and was added at a 
final concentration of 10 µM.  
 
2.5.2 Protein!Degradation!
In order to inhibit the endosomal/lysosomal pathway CD4+ T cells were pre-
incubated overnight at 37 oC with chloroquine (at 10 µg/ml unless otherwise 
stated). Likewise, inhibition of proteosome degradation was achieved by pre-
incubating CD4+ T cells overnight at 37 oC with MG132 (Boston Biochem, 
Cambridge USA) at the indicated concentrations. Following incubation with the 
inhibitors, T cells were activated as previously described. 
 
2.5.3 Glycosylation!!
In some experiments, inhibitors of N- and O- glycosylation were used. In order to 
inhibit N-glycosylation CD4+ T cells were pre-incubated overnight with 
tunicamycin (15 µg/ml). To inhibit O-glycosylation, CD4+ T cells were pre-
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incubated overnight with Benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside 





The cytoplasmic transmembrane fragment (CTF) constructs were kindly provided 
by our collaborators Dr. Nathan Weyand and Prof. Maggie So (University of 
Arizona, Tucson, USA). The wild-type Cyt1 and Cyt2 CTFs (CTF1 and CTF2) 
and their mutant counterparts (UNCLF.1 and UNCLF.2), that could not be 
cleaved by PγS were created as previously described (Ni Choileain et al., 2011) 
and cloned into the pIRESneo vectors (GenBank Accession no. U89673). In 
order to construct the uncleavable UNCLF.1 and UNCLF.2, the predicted PγS 
cleavage site in the transmembrane domain of the wild-type CTF (CTF wt) was 
mutated (CTF VV_GG) as shown in figure 2.1A. The cleavage site was predicted 
based on the known PγS cleavage site for Notch (figure 2.1A). The mutation 
successfully inhibited the cleavage of the CTF by PγS in CHO cells and is 







Figure 2.1: Mutation of the CTF constructs. (A) (Top diagram) Schematic of 
the Cyt1 cytoplasmic transmembrane fragment (CTF) (CTF1) construct and the 
predicted PγS cleavage site is indicated with a downward arrow. SP = 
heterologous signal peptide, TM= transmembrane domain, Cyt1 = Cyt1 
cytoplasmic tail (the Cyt2 cytoplasmic tail was used for the CTF2 constructs). 
(Bottom diagram) The amino acid sequences of the wild-type (CTF wt) and the 
mutated (CTF VV_GG) CTF proteins. The PγS cleavage site is indicated with the 
downward arrow and the mutated amino acids are boxed. As a comparison, the 
cleavage site of Notch1 is shown with an upward arrow.  (B) Expression of the 
wt and mutant CTFs in CHO cells. The arrow indicates the ~6 kda peptide 
released upon PγS cleavage. GAPDH was used as a loading control. 
 
2.6.2 Fusion!proteins!
The CD19 fusion proteins were constructed by fusing the extracellular domain of 
CD19 to either the Cyt1 or Cyt2 CTFs (CTF1 and CTF2) of CD46. These fusion 
proteins were called CD19-Cyt1 and CD19-Cyt2 and were kindly provided by 
Joelle Thomas, Université Lyon, France. The protein fragments were obtained 
from HeLa and Raji cell lines, fused and cloned into the pcDNA3 vector 
(Invitrogen) as previously described (Ni Choileain et al., 2011). Sequencing was 
used to verify the correct construction of all chimeric proteins. 
 
2.6.3 Amaxa!cell!transfection!
Amaxa nucleofection (Lonza, Switzerland) was carried out according the 
manufacturers guidelines. Briefly, prior to transfecting T cells, culture medium 
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(10% RPMI 1640) was pre-warmed at 37 oC in a 48 well plate. Freshly isolated T 
cells (~5 x 106 per transfection condition) were transferred into a 1.5 ml 
eppendorf and washed once with PBS. The PBS was removed and the cell pellet 
was gently resuspended by flicking the tube. Then 1 µg of the required plasmid 
was added to the cell suspension, followed by 100 µl of the nucleofactor reagent. 
After mixing gently, the cell suspension was transferred to a cuvette, avoiding 
bubble formation and placed in the AMAXA nucleofection device, which was set 
to the program U-14. Following transfection, using a Pasteur pipette, a little of 
the pre-warmed culture medium from the 48 well plate was added to the cuvette 
and the transfected cells were transferred to the 48 well plate. The T cells were 
allowed to rest overnight at 37 oC. The following day, the transfected T cells were 
activated as normal. 
 
2.6.4 Fugene!cell!transfection!
For the experiments using the CD19 fusion proteins, HEK-293 cells were 
transfected with the FuGENE HD transfection Reagent Kit (Roche, Switzerland). 
HEK-293 were cultured overnight at 37 oC in a 6 well plate at 2.5 x 105/ml (per 
transfection condition) in 10% RPMI 1640.  The FuGENE HD transfection 
reagent was preincubated with 1 µg of the required plasmid for 15 mins at room 
temperature and then added to the required well.  The cells were cultured 
overnight and the following day they were assessed for CD19, Cyt1 and Cyt2 




The cell surface expression of CD46, CD69, CD25, CTLA-4, CXCR3 and 
CXCR4 were determined using fluorescent-labelled antibodies specific for these 
receptors. After the required T cell activation period, ~1 x 105 T cells were 
harvested from each activating condition. Of note, for cell surface staining, CD4+ 
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T cells and reagents were kept on ice at all times.  The T cells were span down at 
13000 RPM for 20 sec and washed twice with fluorescence-activated cell sorting 
(FACS) buffer (2% v/v FCS in PBS). After washing, the cells were incubated on 
ice for 20 mins, in the dark, with the required fluorescent-labelled antibodies 
diluted in FACS buffer. The antibodies for flow cytometry were purchased from 
BD Pharmingen (San Jose, USA) unless otherwise stated and were as follows: 
anti-CD46-FITC (clone MEM-258, Biolegend, San Diego, CA, USA), anti-
CD69-PE (clone FN50), anti-CD25-Allophycocyanin (APC) (clone M-A251), 
and anti-CTLA-4-phycoerythrin (PE) (clone BNI3), anti-CD19-PE (clone 
HIB19), anti-CXCR3-FITC (R&D Systems, Minneapolis, USA), anti-CXCR4-PE 
(R&D Systems, Minneapolis, USA). In addition, T cells from each activated 
condition were also incubated with their corresponding isotype controls in order 
to determine the level of background fluorescence. The isotypes used were 
purchased from BD Pharmingen. After incubation, the cells were washed 3 times 
with FACS buffer and resuspended in 200 µl FACS buffer. The cells were then 
analysed for their cell surface expression of CD46, CD69, CD25, CTLA-4, 
CXCR3 and/or CXCR4 using the BD Biosciences FACSCalibur flow cytometer 
equipped with Cell Quest software. CD4+ cells were gated based on the forward 
and side scatter to exclude debris and dead cells. The data was exported and then 
analysed using FlowJo 8.8.4 software (TreeStar USA).  
 
2.7.2 Intracellular!staining!
In order to determine the expression levels of Cyt1 and Cyt2 upon T cell 
activation, cytoplasmic tail-specific monoclonal antibodies were used, these were 
designed by our collaborators Dr. Nathan Weyand and Prof. Maggie So 
(University of Arizona, Tucson, USA) (Weyand et al., 2006). After the indicated 
T cell activation period, ~2 x 105 T cells were harvested from each activating 
condition. The T cells were span down at 11000 x g for 20 sec and washed twice 
with FACS buffer (2% v/v FCS in PBS). After washing, the cells were incubated 
at room temperature for 20 mins with either the anti-Cyt1 or anti-Cyt2 antibody 
diluted in a permeabilisation buffer (0.1% w/v saponin in PBS). T cells from each 
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condition were also incubated with a mouse IgG1 (Invitrogen. Carlsbad, CA, 
USA) antibody to measure background fluorescence. After incubation, the cells 
were washed 3 times with FACS buffer and incubated for 20 mins, in the dark, 
with the fluorescent rat anti-mouse IgG-FITC secondary (BD Bioscience, USA). 
Finally, cells were washed 3 times with FACS buffer and resuspended in 200 µl 
FACS buffer. T cells were then analysed for their cell intracellular expression of 
Cyt1 and Cyt2 with the BD Biosciences FACScan flow cytometer using Cell 
Quest software. CD4+ cells were gated based on the forward and side scatter to 
exclude debris. The data was exported and then analysed using FlowJo 8.8.4 
software (TreeStar USA). 
 
2.7.3 Detection!of!phosphorylated!LAT!
In order to determine the expression of phosphorylated linker of activated T cells 
(p-LAT), T cells were activated with either αCD3 (50 µg/ml)/CD28 (50 µg/ml) in 
the presence or absence of αCD19 (50 µg/ml) in addition to an anti-mouse IgG 
crosslinker (Jackson Immunoresearch, USA) for 5 mins. The cells were 
immediately fixed (Cytofix buffer, BD Bioscience, USA) and permeabilised 
(Phosflow Perm III Buffer, BD Bioscience, USA).  The cells were stained for p-
LAT-PE (BD Bioscience, USA) for 20 mins in the dark and washed twice with 
FACS buffer. Finally, the cells were resuspended in 200 µl FACS buffer. T cells 
were then analysed for their cell expression of p-LAT with the BD Biosciences 
FACalibur flow cytometer. CD4+ cells were gated based on the forward and side 
scatter to exclude debris. The data was exported and then analysed using FlowJo 








IL-10 and IFNγ secretion was determined by either enzyme-linked 




ELISA was used to determine IL-10 and IFNγ secretion from the supernatants of 
T cells that had been activated for 5 days (section 2.4). T cells suspensions were 
collected from the tissue culture plate and centrifuged at 6000 x g for 20 seconds. 
The supernatant was carefully removed from the eppendorf and transferred to a 
new tube, without disturbing the cell pellet. These supernatants were frozen at -20 
oC or used immediately for ELISA. IL-10 and IFNγ secretion was determined 
using an ELISA specific for human IL-10 (BD Pharmingen, San Jose, USA) and 
IFNγ (Pierce Biotechnology, Rockford, USA). Each well of high binding 96 well 
plates (Nunc, Rochester, NY) was coated with either 50 µl of IL-10 (1 in 500) or 
IFNγ (1 in 1000) diluted in a plate coating solution (0.1M NaHCO3 in ddH2O) 
and incubated for 2 hrs at room temperature. Each plate was washed 3 times with 
TBST (PBS with 0.05% v/v Tween 20 (Bio-Rad, Hercules, USA)). Then, each 
well was blocked for 2 hrs at room temperature with 200 µl of 1% w/v bovine 
serum albumin (BSA)(Roche Diagnostics Ltd, UK) in PBS. The blocking 
solution was discarded and the supernatants were loaded onto the plate. Samples 
were added in duplicate with the appropriate serial dilutions. Recombinant human 
IL-10 (BD Pharmingen, San Jose, USA) and human IFNγ (Pierce Biotechnology, 
Rockford, IL) were used as standards. After adding the samples and standards to 
the plates, they were incubated for 2 hrs at room temperature and then washed 
three times with TBST. Each plate was coated with 50 µl/well of either a 
biotinylated anti-human IL-10 (1 in 2000 in 1% w/v BSA-PBS) or biotinylated 
anti-human IFNγ (1 in 1000 in 1 % w/v BSA-PBS) and incubated for 1 hr at 
room temperature. Each plate was washed three times with TBST and coated 
with 50 µl per well of a streptavidin-horseradish peroxidase (HRP) (R&D 
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Systems, Minneapolis, USA) conjugate dilution (1 in 10,000 in 1 % w/v BSA-
PBS). The plates were incubated for 1 hr at room temperature and washed three 
times with TBST.  After the final wash, 50 µl per well of a tetramethylbenzidine 
(TMB) substrate kit (Invitrogen, Carlsbad, Ca, USA) was used as a substrate for 
HRP. The reaction was stopped with 50 µl per well of stop solution (1M H3PO4 in 
ddH2O). Each plate was read at 450 nm using a BioTek microplate reader 
(Winooski, VT, USA). Results were exported to Microsoft Excel for analysis and 
Graphpad software was used for figure preparation. 
 
2.8.2 Secretion!assays!
In order to assess the percentage of cells secreting IL-10 or IFNγ an IL-10-PE and 
IFNγ-APC secretion assay (Miltenyi Biotec, Auburn, CA, USA) were used. T 
cells were activated as described in section 2.4. After three days activation ~ 2 x 
105 T cells from each activation condition were collected in a 1.5 ml eppendorf 
and centrifuged for 5 min at 900 x g. The supernatants were discarded and the 
cells were washed with 1 ml of cold wash buffer (0.5 % w/v BSA and 2 mM 
EDTA in PBS). The cells were resuspended in 80 µl of cold 10 % RPMI 1640 
culture medium (see section 2.4) and 3 µl of the αIL-10 and αIFNγ catch reagents 
(IL-10 or IFNγ specific monoclonal antibodies conjugated to a CD45 specific 
monoclonal antibody) were added to each tube. The eppendorfs were then 
incubated for 5 mins on ice before adding 1 ml of pre-warmed (37 oC) 10% 
RPMI 1640 culture medium to each tube. To allow cytokine secretion to occur, 
the samples were incubated at 37 oC under slow continuous rotation for 45 mins.  
Then, the cells were washed with 0.5 ml of cold buffer and resuspended in 160 µl 
of cold wash buffer.  Half of the cell suspension was transferred to a fresh tube 
labeled ‘negative control’. To the remaining half of the cell sample 3 µl of the IL-
10 (PE) and IFNγ (APC) detection antibody was added, mixed well and 
incubated on ice for 10 mins. Following this incubation period, each cell sample 
was washed once with 1 ml of cold buffer, resuspended in 160 µl of FACS buffer 
(see section 2.7.1) and IL-10 and IFNγ secretion was analysed on the BD 
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Biosciences FACSCalibur flow cytometer using Cell Quest software. The data 




Freshly isolated T cells were plated at a concentration 5 x 104 in a 96 well culture 
plate, pre-coated with the stimulating antibodies. Each activating condition was 
carried out in duplicate. T cells were activated for 72 hrs, before adding 1 µCi  of 
[3H]thymidine (Amersham) diluted in 20 µl of 10% RPMI 1640. After 24 hrs, 
proliferation was determined using a Liquid Scintillation Counter (Wallac, 
Boston, USA).  
 
2.9.2 CFSE!incorporation!
To assess proliferation using carboxyfluorescein diacetate succinimidyl ester 
(CFSE) (eBioscience, San Diego, USA), freshly isolated CD4+ T cell (2 x 106) 
were span down in a 1.5 ml eppendorf and washed 3 times with 500 µl of ice cold 
PBS. Cells were incubated with CFSE at 37 oC for 10 mins on a rotator in the 
absence of light. Ice cold 10% RPMI was added to cells and the samples were left 
for 4 mins on ice. Finally the cells were washed 3 times with cold medium and 
stimulated as previously described. After 4 days activation, the CFSE-labelled 
cells were harvested and proliferation levels were assessed by flow cytometry 
using the BD Biosciences FACSCalibur flow cytometer. The data was exported 
and then analysed using FlowJo 8.8.4 software (TreeStar USA). 
 
2.10 Immunoprecipitation!
In order to immunoprecipitate CD46 from supernatants or cell lysates, all 
reagents were kept on ice at all times and incubation steps were preformed at 4 
oC.  When CD46 was immunoprecipitated from cell samples, 300 µl of radio 
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immunoprecipitation assay buffer (RIPA) lysis buffer (NP40 1% v/v, NaCL 150 
mM, Tris Ph 7.6 50 mM, EDTA 5 mM, PMSF 1 mM, NaF 10 mM, NagVO4 25 
mM, protease inhibitor cocktail 1 % v/v, SDS 0.08% w/v, DOC 0.5% w/v) was 
added to each sample. Then each sample was vortexed and incubated with the 
RIPA buffer for 10 mins. The lysates were centrifuged for 10 mins at 9200 x g 
and the supernatants were transferred to fresh tubes for immunoprecipitation.  
 
Both cell supernatants and cell lysate samples underwent a pre-clear step using 
the protein G covalently bound to sepharose beads (GE Healthcare, UK). Protein 
G (20 µl diluted 1:1 with lysis buffer) was added to each sample and left to 
incubate for 45 mins on an orbital rotator. The samples were then centrifuged for 
1 min at 4000 x g. The supernatants were carefully removed from the eppendorfs, 
taking care not to touch the protein G beads at the bottom of the tube, and 
transferred to fresh eppendorfs. Mouse αCD46 (1 µg in 50 µl RIPA buffer per 
sample, clone MCI20.6) was added to each tube and incubated for 2 hrs on an 
orbital rotator. Following incubation, 20 µl of protein G beads was added to each 
sample and incubated on the shaker for 1 hr.  The samples were centrifuged at 
4000 x g for 1 min and the supernatant was carefully removed, again taking care 
not to disturb the protein G beads, which were now bound to the CD46 
antibodies. The protein G beads were washed twice with lysis buffer. After the 
final wash the supernatant was removed and 10 µl of 3x reducing sample buffer 
(glycerol 10% v/v, Tris pH 6.8 0.1M, bromophenol blue 0.02% w/v, 15% v/v β-
mercaptoethanol) was added to each eppendorf. The samples were boiled at 96 o 
C for 10 mins. After boiling the samples were either frozen at -20 oC or analysed 
directly by SDS-PAGE.  
 
2.11 CD46!Deglycosylation!
T cells were left unstimulated or stimulated in the presence of αCD3 (5 x 106 per 
condition) as described in section 2.4. After 5 days activation, T cells were 
harvested and collected in 1.5 ml eppendorf tubes. The samples were washed 
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twice in PBS and CD46 was immunoprecipitated as described in section 2.10. 
However, instead of adding the sample buffer in the final step, the protein G 
pellets were washed once with deionised dH2O, and were resuspended in 60 µl of 
deionised dH2O. Both N- and O- glycans were removed from CD46 using the 
GlycoPro™ Enzymatic Deglycosylation Kit for N-Linked & Simple O-Linked 
Glycans (PROzyme, CA ,USA). Complex core 2 O-glycans were removed using 
the PRO-LINK Extender™ (PROzyme, CA, USA). Deglycosylation was carried 
out according to the manufacturers guidelines and all reagents used were supplied 
in the kits. In brief, 20 µl of reaction solution and 5 µl of the denaturation solution 
was added to each eppendorf. The samples were heated at 100 oC for 5 mins. 
Once the eppendorfs had returned to room temperature 5 µl of detergent solution 
was added and mixed by flicking each tube. This suspension was split into two 
fresh eppendorfs tubes, one labelled “untreated” and the other labelled “treated”.  
Then 1 µl of each of the deglycosylating enzymes (N-glycanase (PNGase F), O-
glycanase (endo-α-N-acetylgalactosaminidase), sialidase A, β(1-4)-Galactosidase 
and β-N-Acetylglucosaminidase) was added to the ‘treated’ eppendorf, nothing 
was added to the ‘untreated’ samples. Both ‘untreated’ and ‘treated’ tubes were 
incubated for 24 hrs on an orbital rotator at 37 oC. Finally, 15 µl of 3x sample 
buffer was added to each sample and heated at 96 oC for 10 mins. The Mw of 
CD46 samples was then analysed by SDS-PAGE or the samples were frozen at – 
20 oC for analysis at a later date. 
 
2.12 SDSLPAGE!and!Western!blot!
In order assess CD46 expression and Mw, protein samples were first separated on 
an 8% acrylamide (Fisher Scientific, Loughborough, UK) gel by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to a 
polyvinylidene difluoride (PDVF, Millipore, Fisher Scientific, UK) membrane 





The stacking and 8% acrylamide resolving gel were prepared using Bio-Rad 
equipment. The gels were placed in the electrophoresis tanks with running buffer 
(glycine 192 mM, Tris base 25 mM, SDS 0.1% in ddH2O). Before loading 
samples onto the gel, the total cell lysates (cell pellets lysed in RIPA buffer) or 
CD46 immunoprecipitates were denatured using a 3x reducing sample buffer 
(described in section 2.10). The samples, a protein ladder (7-175 kDa, New 
England Biolabs, USA) and a total cell lysate (TCL) control (for CD46 
immunoprecipitates) were reheated at 96 o C for 10 mins immediately prior to 
loading. After loading the samples, the gels were run at 150 V for ~10-15 mins 
and then at 200 V for 45 mins using a Bio-Rad powerpack. Following 
electrophoresis, the stacking gel was gently removed and the gels were washed 
twice with deionised water. 
 
2.12.2 Western!Blot!
After SDS-PAGE was preformed, the separated proteins within the acrylamide 
gels were transferred onto PDVF paper using Bio-Rad transfer equipment. One 
PDVF membrane per gel was wet with 100 % ethanol and pre-soaked for ~20 
mins in transfer buffer  (Tris 20 mM, glycine 150 mM, ethanol 20% in ddH2O). 
The gel and the PDVF membrane were tightly packed into transfer cassettes 
within a sandwich of Whatman chromatography paper and sponges.  Each layer 
of the sandwich was pre-wet in transfer buffer and was placed on top of the 
previous layer in the absence of air bubbles. The cassette was closed and placed 
into the transfer tank with the black side of the cassette facing the black side of 
the electrode plate. The tank was filled to the top with transfer buffer and the lid 
secured ensuring that the colour-coded cables are matched with the electrode 
cards of the same colour. The transfer tanks were run at 100 V for 1 hr. Following 
the transfer of the proteins onto the membrane, the membrane was carefully 
removed and incubated for 1 hr on an orbital shaker in blocking buffer (5% w/v 
nonfat dry milk (Carnation, Nestle) in Tris-buffered saline and Tween 20 (TBST) 
(50 mM Tris base, NaCl 150 mM and 0.05% v/v Tween 20)). After blocking, the 
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membranes were incubated with a polyclonal rabbit αCD46 (2 µl in 10 mls of 
blocking buffer, Santa Cruz, USA) for 2 hrs at room temperature or overnight at 4 
oC. The membranes were washed five times with TBST over a period of 1 hr on 
an orbital shaker. Antibody bound proteins were then labelled with HRP-linked 
anti-rabbit IgG (1 µl in 10 mls of TBST, Promega, Madison, USA) for 1 hr.  
Following this incubation, the membranes were again washed 5 times over a 
period of 1 hr. Finally, the proteins stained with HRP were detected using the 
Lumiglo® chemiluminescent substrate (Cell Signaling, Beverly, USA). The 
emitted light was captured using X-ray film (Amersham Hyperfilm ECL, GE 
Healthcare, UK). The X-ray film was then scanned into a digital format using the 
KODAK ESP scanner and figures were prepared using Photoshop CS4. As a 
loading control, the membranes were also reblotted with a mouse anti-GAPDH 
monoclonal antibody (1 µl in 10 mls of blocking buffer, clone 6C5, 
Immunochemistry, Bloomington, USA) and a HRP-linked αmouse IgG 
secondary (1 µl in 10 mls of TBST, Promega, Madison, USA). 
 
2.13 Confocal!microscopy!
The localisation of the ectodomain of CD46 and the intracellular tails, Cyt1 and 
Cyt2 were examined using confocal microscopy. Chamber slides (16 well, Nunc, 
VWR International Ltd, UK) were pre-coated with poly-D-lysine (PDL) (Mw 
70,000-150,000, 2µg/ml) and dried thoroughly before coating the well with 
stimulating antibodies. The wells were pre-coated as described early with either 
mouse IgG (15 µg/ml) or αCD3 (5 µg/ml) and αCD46 (10 µg/ml). Freshly 
isolated CD4+ T cells were cultured for 2 or 4 days at a concentration of 2 x 105 
per well. At the defined activation timepoint, T cells were gently washed with 
pre-warmed PBS before fixating the cells for 10 mins with 4% paraformaldehyde 
(PFA).  The PFA was gently removed and the cells were washed twice with PBS. 
Following this step, PFA aldehyde groups were quenched with NH4Cl  (50 mM 
in PBS) for 15 mins. NH4Cl was removed and the cells were washed twice with 
PBS before permeabilisation with 0.5% v/v Triton X-100.  Then, non-specific 
binding sites were blocked by incubating the cells for 2 hrs, at room temperature, 
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in the presence of a blocking buffer (20% v/v goat serum in PBS, Cambridge 
Bioscience, UK). The blocking buffer was removed and the T cells were 
incubated with mouse αCD46 (clone MCI20.6), αCyt1 or αCyt2 monoclonal 
antibodies overnight on an orbital shaker at 4 oC. After extensive washing, cells 
were fluorescently labelled with the Fab (ab’)2 fragment of goat anti-mouse IgG 
Alexa Fluor-488 (Invitrogen, Carlsbad, CA, USA) for 1 hr at room temperature. 
After washing, the cells were counterstained with DAPI nuclear stain (2 µg/ml) 
and mounted using ProLong Gold (Invitrogen, Carlsbad, CA, USA). Images were 
acquired using the Leica SP5 and imported to ImageJ 1.42q for analysis. 
 
2.14 Statistical!analysis!
Statistical analysis was preformed using Graphpad Prism software. All data 
comparisons within the same donor group were analysed using a non-
parametric paired Friedman test and a Bonferroni-corrected Wilcoxon test. 
All data analysis between healthy control and patient groups used the non-
parametric unpaired Kruskal-Wallis test and Bonferroni-corrected Mann-
Whitney Test. All p-values are two-tails and with a 95% confidence interval. 
Bar charts are plotted as the mean and ± SEM (Standard Error Mean). Box 








Over 20 years ago, CD46 was identified as a member of the complement 
regulatory receptors (Cole et al., 1985, Seya et al., 1986, Lublin et al., 1988).  
Later, CD46 was identified as a T cell costimulatory receptor (Astier et al., 2000) 
that can induce a regulatory (Kemper et al., 2003, Cardone et al., 2010) or pro-
inflammatory response (Sanchez et al., 2004, Cardone et al., 2010). The 
importance of CD46 in T cell responses is underlined by its regulatory defects in 
multiple sclerosis (Astier et al., 2006, Martinez-Forero et al., 2008, Ma et al., 
2009), asthma (Xu et al., 2010, Tsai et al., 2012) and rheumatoid patients 
(Cardone et al., 2010). Moreover, the expression of CD46 is reduced in T cells 
from asthma patients (Tsai et al., 2012), SLE patients (Alegretti et al., 2012) and 
increased in cancer cells indicating a relationship between dysregulated 
expression and function. Two factors that are fundamental to receptor activity are 
the presence of its cognate ligand and its own expression levels. Therefore, 
determining CD46’s pattern of expression during activation may shed light on the 
role of CD46 during T cell activation. 
 
CD46’s effect on T cell phenotype is known to be plastic depending on the timing 
of its ligation (Oliaro et al., 2006) and soluble factors present in the milieu 
including IL-2 (Cardone et al., 2010), PGE-2 (Kickler et al., 2012) and vitamin D 
(manuscript in press).  The expression levels of CD46 isoforms Cyt1 and Cyt2 
also appear to play an important role in T cell responses (Marie et al., 2002, 
Cardone et al., 2010, Ni Choileain et al., 2011). Of note, in a transgenic mouse 
model, expression of the Cyt1 isoform in a contact hypersensitivity suppressed 
the inflammatory response, while Cyt2 promoted inflammation (Marie et al., 
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2002). Furthermore, increased expression of Cyt2 mRNA has been identified in 
multiple sclerosis (Astier et al., 2006) and asthma patients (Tsai et al., 2012). The 
contrasting roles of CD46 cytoplasmic isoforms on inflammation is becoming 
increasingly relevant as our understanding of T cell biology is changing to 
incorporate the magnitude of T cell plasticity (reviewed in (Zhou et al., 2009, 
Bluestone et al., 2009, Murphy and Stockinger, 2010, Nakayamada et al., 2012)). 
Therefore the expression levels of Cyt1 and Cyt2 could impact upon T cell 
phenotype and may have important consequences for the regulation of immune 
responses. 
 
Mechanisms that regulate CD46 expression have been previously reported. 
Specifically, downregulation of CD46 has been observed upon its ligation 
(Naniche et al., 1993, Gill et al., 2003, Elward et al., 2005, Hakulinen and Keski-
Oja, 2006, Cole et al., 2006, Sakurai et al., 2007, Lovkvist et al., 2008, Mahtout 
et al., 2009, Basmarke-Wehelie et al., 2011). CD46 surface cleavage by 
MMP/ADAM(s) in epithelial, neuronal and cancer cells has been documented 
during cell death or pathogen infection (Van Den Berg et al., 2002, Hakulinen 
and Keski-Oja, 2006, Cole et al., 2006, Mahtout et al., 2009, Weyand et al., 
Basmarke-Wehelie et al., 2011). After commencing this project, presenilin-γ-
secretase (PγS) cleavage of Cyt1 and Cyt2 intracellular tails was also shown to 
occur upon Neisseria infection of epithelial cells (Weyand et al.). However, prior 
to this investigation CD46 proteolysis had not been addressed in T cells (Ni 
Choileain et al., 2011).  Downregulation of CD46 has also been attributed to 
internalisation (Naniche et al., 1993, Crimeen-Irwin et al., 2003) which often 
precludes degradation. Proteolytic cleavage and internalisation can play a role in 
terminating receptor responses but they can also initiate receptor signalling (Parks 
and Curtis, 2007, Fortini, 2009). Thus, investigations of these pathways in T cells 




Herein, the previously unknown patterns of CD46 expression and processing 
during human T cell activation are elucidated. Upon CD46 costimulation, CD46 
expression levels are tightly regulated and undergo proteolytic cleavage within its 
extracellular and intracellular domains. Moreover, there is distinct expression 
levels of CD46 upon CD28 costimulation compared to CD46 costimulation. In 
addition, expression levels are inherently linked to TCR induced T cell activation 











In order to understand the role of CD46 in regulating CD4+ T cell activation, 
expression levels of CD46 were determined over a five-day period of activation. 
CD4+ T cells were activated in vitro by different combinations of plate bound 
antibodies (figure 3.1). Surface expression levels were determined alongside 
alterations in expression of the isoforms Cyt1 and Cyt2 (figure 3.1). Of note, in 
vitro stimulation is limited in its ability to imitate temporal and spatial factors of 
in vivo T cell activation. As discussed in Chapter 1, antigen signal strength, 
cytokines present in the environmental milieu and the complex array of 
costimulating signals that a T cell receives from an APC also play an important 
role in determining the differentiation state of a T cell upon activation. Very little 
is known about CD46 costimulation in vitro or in vivo and the simplified 
approach utilized here to analyse CD46 expression levels is an important initial 
step in understanding the role of CD46 in more complex in vivo studies. 
 
After analysis of CD46 expression levels during in vitro T cell activation, 
proteolytic cleavage of CD46 by MMPs and ADAMs was analysed using the 
broad-spectrum MMP/ADAM inhibitor, GM001 (figure 3.1). Culture 
supernatants were analysed for soluble CD46 (sCD46) fragments to confirm if 
any cleavage occurred. In order to examine if PγS cleavage of Cyt1 and Cyt2 also 
occurred, PγS cleavage was blocked using the inhibitor DAPT. 
 
The role of internalisation and degradation in regulating CD46 expression was 
also investigated. Firstly, intracellular staining by flow cytometry was performed 
to determine if internalisation of CD46 had occurred (without degradation) upon 
T cell activation. Secondly, broad-spectrum inhibitors of both lysosomal and 
proteasome degradation were used to determine if CD46 expression could be 


















































Figure 3.1: Experimental setup for T cell stimulation and CD46 expression 
analysis. T cells were left unstimulated (US) or activated in the presence of 
αCD3, αCD3/CD28, αCD3/CD46, and/or αCD3/CD28/CD46. In some 
experiments T cells were stimulated in the presence of broad-spectrum or 
specific inhibitors i.e. GM6001 (MMP/ADAM), DAPT (PγS), Chloroquine 
(lysosomal degradation) or MG132 (proteasome degradation). Expression of 
CD46 (extracellular and/or intracellular) and it’s intracellular cytoplasmic tails 
(Cyt1 and Cyt2) was determined by flow cytometry at different time-points over a 




3.4.1 CD46! is! downregulated! from! the! cell! surface!of! T! cells! upon!
CD46!costimulation!
To determine the cell surface expression levels of CD46 upon T cell activation, 
purified human CD4+ T cells were left unstimulated (US) or activated with αCD3 
or αCD3/CD46. Cell surface expression of CD46 was examined by flow 
cytometry after overnight stimulation. A striking downregulation of CD46 was 
observed upon costimulation compared to both unstimulated and CD3 stimulated 
T cells. A small but significant increase in CD46 expression was also observed 
upon CD3 stimulation (figure 3.2A, 3.2B). Surface expression was also 
determined using two different CD46 antibody clones MCI20.6 and E4.3. 
Downregulation of expression was observed with both clones, although with 
different kinetics (figure 3.2C). Therefore, CD46 cell surface expression is 




Figure 3.2: CD46 is downregulated from the cell surface of T cells upon 
CD46 costimulation. T cells were left unstimulated (US) or activated in the 
presence of αCD3 (CD3) or αCD3/CD46 (CD3/46). Surface expression was 
determined by flow cytometry after 1 or 2 days stimulation. (A) Representative 
expression of cell surface CD46 following overnight simulation. (B) Mean CD46 
expression after 1-2 days stimulation (n=25). (C) T cells were costimulated with 
either MC120.6 or E4.3 and surface CD46 expression was determined after 1 or 
3 days stimulation (n=1). NMFI – normalised mean fluorescence intensity. A 
Friedman test and a Bonferroni-corrected Wilcoxon test was performed for 




There was a dose-dependent decrease in cell surface CD46 expression in the 
presence of increasing concentrations of αCD46 (2, 10, 20 µg/ml). The presence 
of αCD3 (5 µg/ml) remained constant. Of note, a non-specific IgG1 antibody was 
added to lower concentrations to ensure an equal volume of plate bound antibody 
(figure 3.3).  In order to assess if decreasing surface expression of CD46 was due 
to cross-blocking by the stimulating antibodies, T cells were left unstimulated or 
activated overnight with either αCD3 alone or in the presence of αCD46 (10 
µg/ml). As the activating antibodies were of mouse origin an anti-mouse-FITC 
was used to detect any binding of the stimulating antibodies to cells. No positive 
staining was observed (figure 3.3B) suggesting that the stimulating antibodies did 
not detach from the plate and bind to the cell surface of cells. Therefore, these 





Figure 3.3: CD46 downregulation is dose-dependent. (A) T cells were left 
unstimulated or activated in the presence of αCD3 (CD3) alone or in the 
presence of an increasing dose of αCD46 (2, 10 or 20 µg/ml). Cell surface 
expression of CD46 was determined by flow cytometry after overnight 
stimulation, (n=1).  (B) T cells were left unstimulated or activated in the presence 
of αCD3 (CD3) alone or in the presence of αCD46. After overnight stimulation 




CD46 cell surface expression was then observed over several time-points: 1, 2, 3 
hrs and each day for 5 days. Upon CD46 costimulation, CD46 downregulation 
was observed as early as 2 hrs after activation and was maintained over 5 days of 
stimulation (figure 3.4). Although CD46 remains downregulated compared to 
controls, expression levels increase slightly from days 2-4 (figure 3.4B). 
Therefore CD46 downregulation is time-dependent. 
 
Figure 3.4: CD46 downregulation is time-dependent. T cells were left 
unstimulated (US) or activated in the presence of αCD3 (CD3) or αCD3/CD46 
(CD3/46). Surface expression was determined by flow cytometry over a period of 
5 days. (A) Representative plot of CD46 downregulation at 2, 3 and 24 hrs (n=3). 
(B) Mean expression of cell surface CD46 expression upon CD3 or CD3/46 
stimulation at different timepoints over a period of 5 days. (n=3). 
Chapter!3!
! 68!
3.4.4 In! the! absence! of! CD46! ligation! T! cell! activation! induces! an!
increase!in!surface!CD46!expression!!
CD28 is one of the most dominant T cell costimulatory molecules and inhibition 
of its signalling pathway results in suppressed immune responses (Sperling and 
Bluestone, 1996). Therefore, surface expression levels of CD46 upon CD28 
costimulation were also examined. Purified human CD4+ T cells were left 
unstimulated or activated with αCD3, αCD3/CD28 or αCD3/CD46.  CD46 
surface expression was determined after 1-2 days activation (early activation) or 
4-5 days activation (late activation). An increase in CD46 expression was 
observed upon CD28 costimulation at the early and late activation timepoints 
(figure 3.5A and figure 3.5B). In order to determine if a similar increase was 
observed with CD28’s natural ligand, recombinant B7 was also used to stimulate 
T cells in the presence of CD3. In the presence of B7 (2.5 µg/ml) costimulation 
there was an increase in CD46 expression compared to CD3 stimulation alone 
(figure 3.5C). Moreover, overnight stimulation with PMA and ionomycin also 
induced an increase in CD46 expression. The activation marker, CD69, was also 
increased upon PMA/ionomycin treated confirming that the T cells were 
activated  (figure 3.5D). Of note CD46 expression was also determined 
upon αCD3/CD28/CD46 (CD3/28/46) costimulation. Overall, these data indicate 




Figure 3.5: T cell activation increases CD46 expression in the absence of 
CD46 ligation. T cells were left unstimulated (US) or activated in the presence 
of αCD3 (CD3) alone or in the presence αCD28 (CD3/28) or αCD46 (CD3/46). 
CD46 expression was determined by flow cytometry. (A) Representative CD46 
expression after overnight stimulation.  (B) Mean CD46 expression after 1-2 
days stimulation (Early Activation) (n=25) and after 4-5 days stimulation (Late 
activation) (n=18) (C) T cells were left unstimulated or stimulated with αCD3 
alone or in the presence of αCD28 mAb (CD28) or B7 for 3 days (n=2). (D) T 
cells were left unstimulated (control) or stimulated with PMA/ionomycin (n=2). 
NMFI –normalised mean fluorescence intensity. A Friedman test and a 






As CD46 was strongly downregulated upon CD46 costimulation it was next 
investigated how surface expression was downregulated. The mechanism for 
CD46 downregulation could have important consequences for its function. As 
CD46 was previously shown to undergo surface proteolysis in cancer cells 
(Hakulinen et al., 2004), dying cells (Elward et al., 2005, Hakulinen and Keski-
Oja, 2006, Cole et al., 2006) and upon pathogen ligation (Van Den Berg et al., 
2002, Mahtout et al., 2009, Weyand et al., Basmarke-Wehelie et al., 2011), we 
examined the possibility that CD46 also underwent proteolysis upon its ligation 
in T cells. T cells were left unstimulated or activated with αCD3, αCD3/CD46, or 
αCD3/CD28. T cells were cultured in the presence of a broad-spectrum 
MMP/ADAM(s) inhibitor, GM6001, or DMSO as a control.  No effect of the 
inhibitor was observed in unstimulated, CD3 or CD28 costimulated cells. 
However, upon CD46 costimulation there was a significant increase in CD46 
expression compared to DMSO treated cells (figure 3.6A and figure 3.6B).  
CD28/CD46 costimulation also induced the downregulation of CD46, which was 
also partially restored in the presence of GM6001 (data not shown). The presence 
of sCD46 was also detected in the supernatant of CD3/CD46 and 
CD3/CD28/CD46 costimulated T cells. Importantly, upon the addition of 
GM6001, there was a decrease in the level of sCD46 (figure 3.6C- this 
experiment was kindly carried out by the BSc summer student Darragh 
Craughwell). This suggests that upon CD46 costimulation CD46 is 
proteolytically cleaved by MMP/ADAM(s). Proteolytic cleavage of CD46 could 
have important functional consequences for cell signalling and also the 




Figure 3.6: CD46 undergoes proteolytic cleavage by MMP/ADAM(s) upon 
CD46 costimulation. T cells were cultured in the presence of the MMP/ADAM 
inhibitor, GM6001, or DMSO as a control and left unstimulated or activated in the 
presence of αCD3 alone or in the presence of αCD46 and/or αCD28. (A) 
Representative CD46 expression determined by flow cytometry after overnight 
stimulation. (B) Mean CD46 expression (n=10), NMFI – normalised mean 
fluorescence intensity. (C) The level of sCD46 in the cell culture supernatants 
was determined by CD46 immunoprecipitation after the indicated stimulation. 
TCL = total cell lysate was loaded as a control for full length CD46 
(Representative of 2 experiments). A Friedman test and a Bonferroni-corrected 




CD46 costimulation induced a strong downregulation of cell surface CD46 
expression that was partially the result of proteolysis. However, the 
MMP/ADAM(s) did not entirely restore CD46 cell surface expression. It was 
therefore hypothesised that CD46 was also internalised upon CD46 
costimulation. Cross-linking of CD46 was previously shown to induce 
internalisation of CD46 in the Jurkat T cell leukaemia cell line (Crimeen-Irwin et 
al., 2003). In order to determine if CD46 was internalised upon CD46 
costimulation, intracellular CD46 expression was determined after CD46 
costimulation.  T cells were left unstimulated or activated in the presence of 
αCD3 or αCD3/CD46 and intracellular CD46 expression was determined 
following overnight stimulation. Similar to the cell surface expression of CD46, 
intracellular staining also showed a decrease in CD46 expression upon CD46 
costimulation compared to unstimulated cells (figure 3.7A). However, the 
decrease observed was slightly less than that observed at the cell surface. This 
may be due to the presence of intracellular stores of CD46. Total CD46 
expression was also determined by SDS-PAGE. Again a decrease in CD46 was 
observed (figure 3.7B). Of note, as a result of O-glycosylation in CD46’s STP 
region, CD46 can migrate as a single band or doublet, where the BC isoform 
migrates at ~66 kDa and the C isoform at ~56k kDa. In figure 3.7B, the blood 
donor expresses both isoforms and both have decreased expression upon CD46 
costimulation. Finally, preliminary confocal studies were also carried out to 
determine CD46 expression and localisation upon activation. Of note, there were 
insufficient cell numbers to obtain a definitive result. Nonetheless, the 
preliminary results appeared to confirm that there was a decrease in CD46 
expression upon CD46 costimulation (figure 3.7C). Therefore, CD46 is not 
retained intracellularly upon its ligation. However, this does not exclude the 
possibility that CD46 is internalised and then rapidly degraded. As such, CD46 




Figure 3.7: CD46 is not retained intracellularly upon costimulation. T cells 
were left unstimulated (US) or activated in the presence of αCD3 (CD3) or 
αCD3/CD46 (CD3/46). (A) CD46 cell surface and intracellular expression after 
overnight stimulation as determined by flow cytometry (representative of 6 
independent experiments) (B) CD46 expression after overnight stimulation as 
determined by SDS-PAGE (representative of 5 independent experiments). (C) 
CD46 surface expression was detected by confocal microscopy after over night 
stimulation.. (Top panel) CD46 staining, (Bottom panel) CD46 staining overlaid 
with DAPI, a nuclear counterstain. Scale bar 10 µm, (n=1). 
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3.4.7 CD46! expression! is! increased! upon! inhibition! of! a!
chloroquineLsensitive!pathway!
Inhibition of CD46 downregulation with the MMP/ADAM inhibitor, GM6001, 
did not completely inhibit CD46 downregulation suggesting that decreases in 
CD46 surface expression may also be the result of internalisation. However, 
CD46 did not accumulate intracellularly, therefore the possibility that CD46 was 
degraded after internalisation was investigated. Indeed, it is known that cross-
linking of receptors can target them for lysosomal degradation (Mellman, 1996) 
and CD46 contains the internalisation motif, YXXL motif, in the juxtamembrane 
of the Cyt1 and Cyt2 isoforms (Yant et al., 1997). Thus, both lysosome and 
proteasome degradation pathways were examined. Lysosomal degradation was 
firstly examined using the drug chloroquine. Chloroquine inhibits lysosomal 
degradation and prevents the fusion of endosomes, thereby inhibiting proper 
endosomal trafficking (Steinman et al., 1983). T cells were left unstimulated or 
activated with αCD3 or αCD3/CD46 in the presence or absence of increasing 
concentrations of chloroquine (2, 5, 10 µg/ml). At the highest dose, addition of 
chloroquine increased slightly the expression of surface CD46 upon 
costimulation (figure 3.8A). Upon CD46 costimulation intracellular expression of 
CD46 increased in the presence of both 5 and 10 µg/ml of chloroquine, with the 
strongest effect at the highest dose (figure 3.8A). At the highest dose there was 
also an increase in intracellular CD46 in all three activating conditions, with the 
strongest effect upon CD46 costimulation (figure 3.8A and figure 3.8C). 
Therefore, a chloroquine sensitive pathway negatively regulates CD46 expression 
and internalisation of CD46 via this pathway may have important consequences 




Figure 3.8: CD46 expression is increased upon inhibition of a chloroquine-
sensitive pathway. T cells were either left unstimulated (US) or activated with 
αCD3 (CD3) or αCD3/CD46 (CD3/46). Cells were cultured for 2 days in the 
presence or absence of chloroquine and CD46 expression was determined by 
flow cytometry (A) Representative surface and intracellular CD46 expression 
after T cells were activated and cultured overnight with chloroquine (1, 5 or 10 
µg/ml). CD46 expression of treated cells (blue) is overlaid with the untreated 
control (shaded grey). (B) Mean surface CD46 expression after cells were 
activated in the presence or absence of chloroquine (10 µg/ml) (n=3). (C) (Left 
panel) Mean intracellular CD46 expression after T cell activation in the presence 
or absence of chloroquine (10 µg/ml) (n=8). (Right panel) The percentage 
increase in intracellular CD46 expression in the presence of chloroquine 
compared to untreated controls (n=8). NMFI = normalised mean fluorescence 
intensity. Error bar = standard error mean. A Friedman test and a Bonferroni-
corrected Wilcoxon test was performed for statistical analysis *p≤0.0167 
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3.4.8 CD46! expression! is! decreased! in! the! presence! of! the!
proteasome!inhibitor,!MG132!
To examine if CD46 underwent proteosomal degradation, T cells were stimulated 
as above in the presence of increasing doses of the proteasome inhibitor MG132 
(1, 5, 10 µM), or DMSO as a control. At the two higher doses MG132 dose-
dependently decreased CD46 expression. The strongest effect was observed at the 
cell surface with smaller decreases observed intracellularly (figure 3.9). If indeed, 
CD46 were degraded by the proteasome, inhibition of its function would be 
expected to increase CD46 expression intracellularly. However, no increase in 
CD46 intracellular expression was observed and actually showed a slightly 
decreased expression of CD46 (figure 3.9). As CD46 expression was decreased in 
the presence of the inhibitor, it suggests that CD46 is not degraded by the 
proteasome after internalisation. However, further experiments need to be carried 
out to confirm this, as MG132 may indirectly affect CD46 expression levels. 
  
Figure 3.9: CD46 expression is decreased in the presence of the 
proteasome inhibitor MG132. T cells were cultured in the presence of the 
proteasome inhibitor, MG132, or DMSO as a control, left unstimulated (US) or 
activated in the presence of αCD3 (CD3) or αCD3/CD46 (CD3/46). CD46 
expression was determined by flow cytometry after overnight stimulation (A) 
CD46 cell surface expression and (B) intracellular CD46 expression in T cells 
cultured with MG132 (1, 5 or 10 µM) or DMSO as a control. CD46 expression of 
treated cells (blue) is overlaid with the untreated control (shaded grey) after 





In the transgenic mouse model that expressed either the Cyt1 or Cyt2 isoform, a 
contact sensitivity reaction was suppressed in the Cyt1 transgenic mouse and 
increased in the Cyt2 transgenic mouse (Marie et al., 2002). Due to the 
contrasting roles of the isoforms on inflammation in the murine model it was 
hypothesised that they would also play an important role in human T cell 
regulation. Therefore, the expression levels of Cyt1 and Cyt2 were observed over 
5 days of T cell activation. T cells were left unstimulated or activated with αCD3 
or αCD3/CD46. Expression levels of Cyt1 and Cyt2 were determined by flow 
cytometry using specific monoclonal antibodies designed by our collaborators Dr. 
Nathan Weyand and Prof. Maggie So (University of Arizona, Tucson).  
Expression levels were determined at an early activation timepoint (after 1-2 days 
stimulation) or at a late activation timepoint (after 4-5 days stimulation). Upon 
CD46 costimulation, there is a significant decrease in Cyt1 expression compared 
to CD3 stimulated cells at early but not at the late activation timepoint (figure 
3.10A and figure 3.10B).  However, Cyt2 expression had a contrasting expression 
pattern during T cell activation. At the early timepoint, CD46 costimulation 
increased Cyt2 expression, whereas during late activation Cyt2 was 
downregulated compared to controls (figure 3.10C and figure 3.10D). Upon the 
calculation of the Cyt2:Cyt1 ratio in CD46 activated cells during early activation 
there was an increase in Cyt2:Cyt1 compared to controls, whereas at the late 
timepoint the Cyt2:Cyt1 ratio this increase was absent (figure 3.10E). In 
summary, upon CD46 costimulation Cyt1 is downregulated during early 
activation whereas Cyt2 is upregulated. At the late timepoint, Cyt2 undergoes a 
timely downregulation. Taken together, these data indicate that Cyt1 and Cyt2 
have unique expression levels, suggesting that they have distinct functions during 




Figure 3.10: Cyt1 and Cyt2 undergo time-dependent downregulation upon 
CD46 costimulation. T cells were left unstimulated (US) or activated in the 
presence of αCD3 (CD3) alone or in the presence of αCD46 (CD3/46). Cyt1 and 
Cyt2 expression were determined by flow cytometry after intracellular staining. 
(A) Representative Cyt1 expression after 2 and 4 days stimulation. (B) Mean 
Cyt1 expression at the early (n=40) and late activation (n=29) timepoint. (C) 
Representative Cyt2 expression after 2 and 4 days stimulation. (D) Mean Cyt2 
expression at the early (n=40) and late activation (n=29) timepoint. (E) The ratio 
of Cyt2:Cyt1 expression. The timely downregulation of Cyt1 and Cyt2 is outlined 
by a blue box. NMFI – normalised mean fluorescence intensity. A Friedman test 






Both Cyt1 and Cyt2 underwent a time-dependent downregulation, suggesting an 
important functional significance. Thus, the downregulation of Cyt1 and Cyt2 
was investigated further. After commencing this project, it was demonstrated by 
our collaborators that Neisseria ligation of CD46 in epithelial cells induced MMP 
cleavage, followed by cleavage of both Cyt1 and Cyt2 by PγS (Weyand et al.). 
As CD46 T cell costimulation resulted in MMP/ADAM(s) cleavage of CD46 
(figure 3.6) it was hypothesised that the downregulation of Cyt1 and Cyt2 may be 
the result of PγS cleavage. Therefore, T cells were activated with αCD3/CD46 in 
the presence of the PγS inhibitor, DAPT, or DMSO as a control. Cyt1 and Cyt2 
expression were determined at day 2 or day 4 by flow cytometry. Indeed, DAPT 
inhibited Cyt1 downregulation at day 2 and Cyt2 downregulation at day 4 (figure 
3.11).  PγS proteolysis of other transmembrane proteins, such as Notch, release 
intracellular domains (ICDs) with potent signalling capacities (Parks and Curtis, 
2007). Therefore, the time-dependent proteolysis of Cyt1 and Cyt2 by PγS 
supports the hypothesis that Cyt1 and Cyt2 have distinct roles during T cell 
activation. 
 
Figure 3.11: Cyt1 and Cyt2 expression is increased in the presence of the 
PγS inhibitor DAPT. T cells were activated with αCD3/CD46 and cultured in the 
presence of the PγS inhibitor, DAPT (10 µM) (+) or DMSO as a control (-). 
Expression of Cyt1 and Cyt2 was determined by flow cytometry after 2 or 4 days 
activation. Positive stain (blue histogram), Isotype control (red histogram) 




3.4.11 In! the! absence! of! CD46! ligation,! Cyt1! and! Cyt2! are!
differentially!expressed!during!T!cell!activation!
CD28 costimulation increased the expression of cell surface CD46, therefore the 
role of CD28 costimulation in regulating Cyt1 and Cyt2 expression was also 
defined. T cells were left unstimulated or activated with αCD3 or αCD3/CD28. 
Expression levels were determined at an early activation timepoint (after 1-2 days 
stimulation) or at a late activation timepoint (after 4-5 days stimulation). At both 
the early and late activation timepoints Cyt1 was increased in CD3/CD28 
activated T cells. At the early timepoint Cyt1 was increased to a greater extent in 
the CD3/CD28 stimulated cells than CD3 stimulated cells (figure 3.12A and 
figure 3.12B). This increase in Cyt1 expression was in contrast to the observed 
results for CD46 costimulation where a downregulation of Cyt1 was observed at 
the early timepoint.  
 
Upon CD28 costimulation, Cyt2 expression followed a similar pattern to Cyt1 
expression during early activation and was increased in both CD3 and CD3/CD28 
stimulated cells, again with the strongest increase upon CD28 costimulation. 
However at the late timepoint, Cyt2 showed a decreasing trend (figure 3.12C and 
figure 3.12D) similar to that observed upon CD46 costimulation. The ratio of 
Cyt2:Cyt1 was calculated at both timepoints. At the early timepoint upon CD28 
costimulation, there was a decreasing trend in Cyt2:Cyt1 compared to CD3 
stimulation and this decrease became significant at the later timepoint (figure 
3.12E). As expected, costimulation in the presence of CD28 and CD46 ligation 
resulted in intermediate expression levels of Cyt1 and Cyt2 (data not shown). 
CD3 activation had similar patterns of Cyt1 and Cyt2 expression as CD28 
costimulation, although these were less pronounced (figure 3.12). Therefore, even 
in the absence of CD46 ligation, T cell activation regulates both Cyt1 and Cyt2 
expression during T cell activation and suggests an integral role for both Cyt1 




Figure 3.12: In the absence of CD46 ligation, Cyt1 and Cyt2 are 
differentially regulated upon T cell activation.  T cells were left unstimulated 
(US) or activated in the presence of αCD3 alone (CD3) or αCD28 (CD3/28). Cyt1 
and Cyt2 expression were determined by flow cytometry after intracellular 
staining. (A) Representative Cyt1 expression after 2 or 4 days stimulation (B) 
Mean Cyt1 expression during early activation (1-2 days stimulation) (n=40) or 
late activation (4-5 days stimulation) (n=29). (C) Representative Cyt2 expression 
after 2 or 4 days stimulation. (D) Mean Cyt2 expression during early activation 
(n=40) or late activation (n=29). (E) The ratio of Cyt2:Cyt1 expression during 
early and late activation. NMFI – normalised mean fluorescence intensity. A 
Friedman test and a Bonferroni-corrected Wilcoxon test was performed for 




Finally, as IL-2 is added to all αCD3/CD46 cultures to induce a regulatory 
phenotype, the role of IL-2 on CD46 surface expression was determined. T cells 
were costimulated in the absence or presence of Il-2 (10 U/ml) for four days. 
CD46 expression was determined by flow cytometry at an early activation (1-2 
days stimulation) or late activation (4-5 days stimulation) timepoint. There was a 
slight increase in CD46 surface expression upon the addition of IL-2 at the early 
timepoint. However, there was no significant difference during late activation 
(figure 3.13A).  
 
As IL-2 is an important determinant for the CD46 induced Tr1-like phenotype, its 
role in regulating both Cyt1 and Cyt2 expression was also monitored. T cells 
were left unstimulated or activated with αCD3 or αCD3/CD46 with/without IL-2. 
Cyt1 and Cyt2 expression was determined by flow cytometry during early and 
late activation. At the early timepoint, there was an increase of Cyt1 in the 
presence of IL-2 (figure 3.13B). Cyt2 also showed a slight increase in the 
presence of IL-2 but the effect was not significant (figure 3.13C). At the later 
timepoint, there was no effect on either Cyt1 or Cyt2 (figure 3.13B, 3.13C). 
Therefore, IL-2 promotes increased Cyt1 expression and this reflects the increase 




Figure 3.13: IL-2 modulates CD46 expression. CD46 costimulated cells were 
activated in the absence or presence of IL-2 (10 U/ml). (A) CD46 expression was 
analysed by flow cytometry at the early activation (1-2 days stimulation) or late 
activation (4-5 days stimulation) timepoint (n=5). (B) Cyt1 expression was 
determined by flow cytometry at the early activation (n =9) and late activation 
(n=7) timepoint. (C) Cyt2 expression was analysed by flow cytometry at the early 
activation (n =9) and late activation (n=7) timepoint. NMFI – normalised mean 





Surface regulation of CD46 expression 
CD46 expression is increased during activation except upon CD46 ligation 
(figure 3.5). Increased expression is observed upon TCR stimulation alone and is 
augmented in the presence of CD28 costimulation. Indeed, increased expression 
was also observed after stimulation with PMA/ionomycin (figure 3.5D). 
Therefore, T cell activation regulates CD46 expression even in the absence of its 
direct ligation. Upregulation of other costimulatory receptors have been reported 
upon T cell activation, including, CD28 (Turka et al., 1990), CD278 (ICOS) 
(Hutloff et al., 1999), CD167 (Dang et al., 2009) and CD27 (Hintzen et al., 1993). 
Upregulation of NF-kB signalling during T cell costimulation has been well 
characterised (reviewed in (Kane et al., 2002)) and recently has been shown to 
increase CD46 expression in breast cancer cells (Cui et al., 2012). Therefore, the 
upregulation of CD46 during T cell activation could potentially be enhanced by 
increased NF-kB signalling. The function of upregulated CD46 expression during 
activation remains to be determined. However, increases in CD46 likely enhance 
protection of effector T cells against complement during inflammation. It has 
been established that several tumour cells upregulate complement receptors, 
including CD46, to shield themselves from complement attack and mediate 
tumour metastasis (Fishelson et al., 2003, Anderson et al., 2004, Buettner et al., 
2007). Moreover, increased CD46 expression may augment the potential for its 
ligation and signalling during T cell responses.  Considering the role of CD46 in 
promoting IL-10 secretion (Kemper et al., 2003), this could provide a timely 
negative feedback loop for attenuating T cell responses. 
 
Upon CD46 costimulation in T cells there is a strong downregulation of CD46 
(figure 3.2) that is concentration (figure 3.3) and time-dependent (figure 3.4).  
Downregulation of CD46 in various cell types has been previously reported upon 
pathogen infection with measles virus (Naniche! et! al.,! 1993), adenovirus 
(Sakurai! et! al.,! 2007), Neisseria! gonorrhoea! (Gill! et! al.,! 2003),! Group A 
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streptococcus! (Lovkvist! et! al.,! 2008),! gingivalis! (Mahtout! et! al.,! 2009)! and!
Helicobacter pylori (Basmarke-Wehelie et al., 2011). CD46 is also 
downregulated in apoptotic and necrotic cells (Elward et al., 2005, Hakulinen and 
Keski-Oja, 2006, Cole et al., 2006).  However, this is the first report of CD46 
downregulation in primary human CD4+ T cells (Ni Choileain et al., 2011). The 
role of CD46 downregulation is likely to be multifold depending on the cell type, 
ligand and mechanism of downregulation. With respect to pathogens, CD46 
downregulation can enable pathogen entry and increase cell sensitivity to 
complement attack (Schnorr et al., 1995). Notably, an increase in CD55 
expression, which also protects against complement lysis, was observed in CD46 
costimulated T cells (data not shown). This upregulation may act to offset the 
increased complement susceptibility in the absence of CD46.  
!
In T cells, downregulation of CD46 is at least partially due to proteolytic 
cleavage by MMP/ADAM(s) (figure 3.6).  CD46 is also cleaved during apoptosis 
of neuronal and epithelial cells (Hakulinen and Keski-Oja, 2006, Cole et al., 
2006), infection of epithelial cells with gingivalis! (Mahtout! et! al.,! 2009) or 
Helicobacter pylori (Basmarke-Wehelie et al., 2011) and coculture of endothelial 
cells with Loxoceles venom (Van Den Berg et al., 2002). Proteolysis of surface 
receptors, such as Notch, ErbB4 and amyloid precursor protein (APP) have 
important signalling consequences (reviewed in (Parks and Curtis, 2007)). Prior 
to this research (Ni Choileain et al., 2011) there were no reports that addressed 
the functional role of cleaved CD46 in cell signalling. However, in Chapter 4, a 
functional role of CD46 proteolysis is demonstrated for the first time in CD4+ T 
cells.  Although, the exact protease(s) involved in the cleavage of CD46 from 
CD4+ T cells has not been identified, it is likely to involve several, as GM6001 is 
a broad-spectrum inhibitor of MMP/ADAM(S). Indeed, four proteases have been 
identified as being involved in the proteolysis of CD46 in other cells types. 
ADAM10 was implicated in the cleavage of CD46 after its release from apoptotic 
epithelial cells (Hakulinen and Keski-Oja, 2006). Venom from the spider 
Loxoceles also induces CD46 shedding from epithelial cells and neutrophils by a 
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member of the ADAM!family!(Van Den Berg et al., 2002). Furthermore, MMP3, -
8, -9 also contributed to the proteolysis of CD46 from apoptotic neuronal cell 
lines (Cole et al., 2006).  Therefore the expression of MMP/ADAMs in vivo 
could affect CD46 function. Dysregulated expression of MMP/ADAMs has been 
document in MS patients and could participate in the abnormal function of CD46 
in patients (Ni Choileain and Astier, 2011). 
Of note, the downregulation of surface CD46 in the presence of plate bound 
stimulating CD46 antibodies raises the question of whether CD46 
downregulation is due to cross-blocking of the stimulating CD46 antibody or 
stripping of cell surface CD46 from the cell membrane. However, increased 
soluble levels of CD46 with a decreased Mw upon CD46 costimulation (figure 
3.6C) and increased surface expression of CD46 in the presence of an 
MMP/ADAM inhibitor indicated that CD46 downregulation upon CD46 
costimulation is at least partially due to proteolysis and is not merely due to the 
cross-blocking or antibody stripping of cell surface CD46 by the stimulating 
antibody. Indeed, incubation of an anti-mouse-FITC antibody with cells that had 
been activated with CD46 antibodies did not result in a positive FITC staining 
suggesting that no significant levels of stimulating antibody were attached to the 
cell surface after T cell harvesting (figure 3.3B).  The concentration of the anti-
mouse-FITC antibody used was equivalent to that used for the detection of 
primary mouse antibodies to Cyt1 and Cyt2 and should have been sufficient to 
detect significant levels of mouse antibodies attached to the cell surface. 
Although low levels of cross-blocking or stripping by the stimulating antibody 
cannot be completely ruled out, these data suggest that CD46 cell surface 
downregulation is at least partially due to cell surface proteolysis. 
 
Soluble CD46 
Upon cleavage of CD46, a sCD46 fragment is released (figure 3.6C). The exact 
function of sCD46 during T cell activation remains to be determined. However, it 
is known that soluble forms of CD46 maintain their complement binding 
activities (Hakulinen et al., 2004) and recombinant soluble forms of CD46 can 
Chapter!3!
! 87!
protect tumour cells from complement attack (Gorter and Meri, 1999) and delay 
hyper acute graft rejection (Christiansen et al., 1996).  Proteolytic cleavage of 
CD46 occurs during cell death and acts to attenuate complement activation 
(Elward et al., 2005, Cole et al., 2006). In this respect, release of sCD46 may 
have a similar function during T cell activation, whereby its release from T cells 
acts to attenuate complement activation and potentially suppress excessive 
inflammatory responses. Of note, increased levels of sCD46 have been identified 
in SLE 70, MS (Kawano!et!al.,!1999,!Soldan!et!al.,!2001)!and cancer patient’s 
sera (Seya!et!al.,!1995) and may reflect increased levels of cell death and/or T 
cell activation alongside subsequent CD46 proteolytic cleavage. In support of the 
latter hypothesis, reduced levels of CD46 expression have been reported in 
lymphocytes isolated from SLE patients and in CD4+ cells from asthma patients 
(Tsai et al., 2012), whether this directly correlates with increased levels of sCD46 
remains to be addressed. Soluble CD46 is not limited to disease states and is 
found in healthy individuals tears, plasma and seminal fluid (Hara et al., 1992) 
suggesting a more general role in the immune system. Furthermore, a recent 
report has identified sCD46 as an anti-microbial agent to Helicobacter pylori that 
functions by blocking urease activity, which is required for bacterial survival. 
Interestingly, oral administration of a soluble CD46 peptide cleared Helicobacter 
pylori from infected mice and also increased the presence of IL-10 (Basmarke-
Wehelie et al., 2011).  Therefore, the presence sCD46 in bodily fluids may play a 
broader anti-bacterial role than previously anticipated. The release of sCD46 from 
CD46 activated T cells likely has more than one function upon its proteolysis 
from activated T cells. Further studies would need to be carried out to address the 
role of sCD46 from T cells and whether its function is dependent on the stimuli 
for proteolytic release, the tissue in which it is released and if other soluble 
factors can alter its function. 
 
Cyt1 and Cyt2 regulation  
The function and signalling pathways of the Cyt1 and Cyt2 isoforms are in the 
early stages of investigation. Herein, the tight regulation of both Cyt1 and Cyt2 
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during T cell activation is elucidated. Upon CD46 costimulation there is a timely 
downregulation of Cyt1 at the early timepoint and Cyt2 at the late timepoint. 
Upon CD28 costimulation, there is no downregulation of Cyt1 at the early 
timepoint and it is in fact strongly upregulated. However, at the late timepoint, 
Cyt2 shows a trend of downregulation, similar to that observed in CD46 
costimulation (summarised in table 3.1). The downregulation of Cyt1 specifically 
upon CD46 costimulation suggests that it may play a unique role in CD46 
induced responses, whereas, a shared pattern of Cyt2 downregulation may 
suggest a more general role for Cyt2 in T cell activation/shutdown.  
 
Table 3.1: Relative change in Cyt1 and Cyt2 expression upon either CD28 
or CD46 costimulation compared to CD3/TCR stimulation. !
! Early activation Late activation 
Isoform  Cyt1 Cyt2 Cyt2:Cyt1 Cyt1 Cyt2 Cyt2:Cyt1 
CD3/CD28 !! !! "! !! J! "!
CD3/CD46 "! J! !! "! "! J/"!
 
 
The importance Cyt1 and Cyt2 downregulation is suggested by their time-
dependent downregulation (figure 3.10) and the mechanism by which they are 
downregulated. Namely, Cyt1 and Cyt2 are cleaved proteolytically by PγS during 
early activation and late activation, respectively, and this proteolysis, at least 
partially, accounts for their downregulation  (figure 3.11). The proteolysis of 
receptors has important functional consequences. For example, upon PγS 
proteolytic cleavage of Notch, ErbB4 and the APP a functional ICD with 
transcriptional activity is released (reviewed in (Parks and Curtis, 2007)). Notably 
Notch can induce IL-10 secretion in Th1 T cells which is dependent on its 
proteolysis by PγS (Rutz et al., 2008). The specific downregulation of Cyt1 in 
CD46 costimulated cells and CD46’s function in promoting IL-10 secretion 
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suggests that CD46’s Cyt1 isoform may be an important regulator of CD46 
induced IL-10 secretion. Thus, the role of Cyt1 and Cyt2 proteolysis was 
addressed in Chapter 4. Furthermore, if downregulation of Cyt1 and Cyt2 is 
important for CD46 costimulation, it will be important to assess their 
downregulation in patients with MS and is discussed in Chapter 6. 
 
IL-2 is an important regulator of CD46’s regulatory function (Cardone et al., 
2010). Slight increases in cell surface CD46 expression and its cytoplasmic tails 
were observed in the presence of IL-2 (figure 3.14). IL-2 signalling is linked with 
the activation of nuclear NF-KB expression, which has been shown to upregulate 
CD46 (Cui et al., 2012). IL-2 also induces STAT3 serine phosphorylation (Fung 
et al., 2003) and STAT3 is known to bind to the CD46 promoter and induce its 
expression (Buettner et al., 2007). Therefore, at least two pathways downstream 
of IL-2R activation potentially regulate CD46 expression. Therefore, IL-2 may 
promote de novo CD46 expression upon T cell activation and enhance its 
potential for signalling. Further investigations are required to determine the exact 
contribution of IL-2 to the regulation of CD46 signalling pathways.  
 
In summary, a model depicting CD46 cleavage upon CD46 costimulation is 
shown in figure 3.14. Proteolysis of CD46 by MMP/ADAM(s) and PγS results in 
the release of sCD46 fragments. Both sCD46 and ICD fragments are likely to 
play a role in the regulation of inflammation. The function of the ICD fragments 
will be specifically addressed in Chapter 4. Finally, it is important to note that 
CD3 stimulation alone increases surface CD46 expression and Cyt1 and Cyt2 
expression during early activation (figure 3.2 and figure 3.12). This suggests that 
CD46 is inherently involved in T cell activation. The role of T cell activation in 
regulating CD46 function is addressed in more detail in Chapter 5. 
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Figure 3.14: Schematic diagram representing the proteolysis of CD46 upon 
CD46 costimulation  
 
CD46 Internalisation and degradation 
Downregulation of CD46 is likely to involve internalisation in addition to surface 
cleavage. Indeed it was previously reported to occur upon CD46 crosslinking in 
Jurkat T cells and PBMCs in a process similar to macropinocytosis (Crimeen-
Irwin et al., 2003). However, internalisation had not been addressed upon CD46 
costimulation in primary T cells. In the presence of chloroquine CD46 expression 
was strongly increased upon CD46 costimulation (figure 3.8) suggesting that 
CD46 is downregulated and degraded though an endosomal/lysosomal pathway. 
A slight increase was observed as early as 2 hrs post activation (data not shown), 
which suggests that the increase in expression observed is unlikely to be entirely 
the result of new protein production but rather inhibition of CD46 degradation via 
the endosomal pathway. Both Cyt1 and Cyt2 sequences contain the YXXL motif, 
present in the juxtamembrane, which is a known motif for endosomal and 
lysosomal targeting from the cell surface or trans-golgi network. (Hirano et al., 
1996, Yant et al., 1997). YXXL motifs can bind to the clathrin adaptor protein 
AP-2, inducing internalisation via clathrin coated pits (reviewed in (Boucrot et 
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al., 2010)). For example, CTLA-4 binds to AP-2, which tags it to the endosomal 
pathway and marks it for degradation in the lysosome (Shiratori et al., 1997). As 
CD46 also binds to the adaptor protein AP-2 (Crimeen-Irwin et al., 2003) 
internalisation of CD46 may also result in lysosome degradation. These data 
suggest that CD46 surface downregulation upon CD46 costimulation likely 
involved CD46 internalisation and degradation. Indeed, downregulation of CD46 
through the endosomal pathway has been reported previously upon measles virus 
infection of B cells. Furthermore, CD46 downregulation was required for MHC 
class II presentation of MV peptides (Gerlier et al., 1994) highlighting a 
functional role of CD46 downregulation other than degradation. 
  
In the presence of the proteasome inhibitor there was no increase in CD46 
expression. In fact there was a dose-dependent decrease upon CD46 expression 
that was most strongly observed at the surface upon CD46 costimulation (figure 
3.9). MG132 inhibits proteasome degradation and also decreases NF-kB 
expression (Wu et al., 2004). As NF-kB has been shown to positively regulate 
CD46 expression in cancer cells (Cui et al., 2012), reduced expression of CD46 
may be the result of decreased NF-kB. Alternatively, MG132 is capable of 
inducing apoptosis (Meriin et al., 1998) and may induce CD46 shedding. It has 
been previously demonstrated that CD46 is shed from the surface of apoptotic 
cells (Cole et al., 2006). As the effect was more strongly observed at the surface it 
is likely that cell death may be responsible for shedding of CD46. Colocalisation 
studies of CD46 and the proteasome/lysosome using confocal microscopy would 
be useful to shed further light on the mechanism of CD46 degradation. 
Nonetheless, previous reports and the data acquired here using the lysosomal and 
proteosomal inhibitors suggest that the lysosomal/endosomal pathway is more 
likely to be involved in CD46 downregulation and degradation. 
 
Endosomal downregulation is not solely a means of degradation (Miaczynska et 
al., 2004) and may be important for CD46 signalling. Interestingly, presenilin-1 
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that forms part of the PγS complex is localised in early endosomes (Lah and 
Levey, 2000) suggesting that downregulation of CD46 through the endosomal 
pathway may support its cleavage. Notch signalling is also supported by 
endocytosis and involves internal sorting to endosomes, the nucleus, lysosomes 
and possibly signalling endosomes (Fortini, 2009). Moreover, proteolytic 
cleavage of Notch at the surface and release of its ICD is followed by rapid 
degradation of the ICD in order to inhibit its potent signalling capacity (reviewed 
in (Mumm and Kopan, 2000, Fortini, 2009)). Trafficking of CD46, specifically 
its ICD, could undergo a similar downregulation process. Nonetheless, further 
experiments are required to confirm the role of endocytosis/lysosome in CD46 
trafficking, signalling and degradation. 
 
 
Figure 3.15: A Schematic representing a potential model of CD46 







• CD46 expression is increased upon T cell activation in the absence of 
CD46 ligation, and decreased upon CD46 ligation. 
• Upon CD46 costimulation Cyt1 is downregulated during early activation 
and Cyt2 is downregulated during late activation.  
• Upon CD28 costimulation, both Cyt1 and Cyt2 are increased during early 
activation. During late activation, Cyt1 remains upregulated, whereas 
Cyt2 is decreased. 
• Upon CD46 costimulation, CD46 is proteolytically cleaved, at the surface 
by MMP/ADAM(s) and intracellularly by PγS. 









In the previous chapter, a tight regulation of CD46 expression was observed 
during T cell activation. Moreover, specific expression levels of Cyt1 and Cyt2 
were observed throughout T cell activation and T cell shutdown (Ni Choileain et 
al., 2011) and were suggestive of a distinct functional role for both Cyt1 and 
Cyt2. Importantly, functional differences between Cyt1 and Cyt2 have previously 
been reported. For example, in a transgenic mouse model expressing either Cyt1 
or Cyt2, Cyt1 expression inhibited inflammation and Cyt2 expression promoted 
inflammation in a contact hypersensitivity reaction (Marie et al., 2002). Both 
Cyt1 and Cyt2 have different amino acid sequences (Seya et al., 1999) and it is 
therefore unsurprising that different cell functions have been observed.  For 
example, there is strong evidence implicating Cyt1 activation with T cell polarity 
changes (Marie et al., 2002, Ludford-Menting et al., 2002, Oliaro et al., 2006, 
Ludford-Menting et al., 2011) and autophagy (Joubert et al., 2009), whereas, 
Cyt2, but not Cyt1, is tyrosine phosphorylated upon CD46 cross-linking (Wang et 
al., 2000) and Neisseria gonorrhoeae infection (Lee et al., 2002). Nonetheless, 
much work remains to elucidate the signalling cascades of Cyt1 and Cyt2. 
Determining the specific functions of CD46’s isoforms is crucial to 
understanding of why CD46 function is dysregulated in MS patients. If Cyt1 or 
Cyt2 activation were specifically responsible for augmenting IL-10 production in 
healthy controls it would provide greater insights into T cell regulatory function 
in humans. 
 
In Chapter 3, it was also demonstrated that upon CD46 costimulation, CD46 is 
cleaved by both MMP/ADAM(s) and PγS (Ni Choileain et al., 2011). Cleavage 
of CD46’s ectodomain by MMP/ADAM(s) releases the soluble ectodomain and 
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the cytoplasmic transmembrane fragment (CTF). The CTF consists of the 
transmembrane domain and the cytoplasmic tails (either Cyt1 or Cyt2). The CTF 
can then be further cleaved by PγS, releasing the intracellular domain (ICD), 
which consists of the cytoplasmic tail only.  As mentioned previously, proteolytic 
cleavage of other type I transmembrane proteins; Notch, ErbB4 and APP result in 
the release of ICDs with important signalling functions in health and disease 
(Parks and Curtis, 2007).  Interestingly, Notch is involved in T cell 
differentiation, activation and IL-10 secretion, and the translocation of its ICD to 
the nucleus facilitates its signalling (Schroeter et al., 1998, Benson et al., 2005, 
Rutz et al., 2008, Kassner et al.). Therefore, the functional relevance of Cyt1 and 
Cyt2 CTFs and ICDs were examined during T cell activation. Herein, it is 
demonstrated that PγS cleavage of Cyt1 facilitates T cell activation whereas 
uncleaved Cyt2 promotes T cell activation. Furthermore, preliminary evidence 
suggests that Cyt1 and Cyt2 may also translocate to the nucleus in a time 
dependent fashion that reflects their cleavage by PγS. Therefore it is possible that 
both Cyt1 and Cyt2 ICDs, similar to that observed for the Notch ICD, could 
induce signalling within the nucleus. Furthermore, this thesis highlights CD46 
involvement in contracting T cell responses and emphasises its expanding 
functions in T cell biology. 
 
4.2 Aims 
1. To determine the function of Cyt1 and Cyt2 in human CD4+ T cells 





In Chapter 3 a time-dependent downregulation of Cyt1 during early T cell 
activation and Cyt2 during late activation was observed. It was also demonstrated 
that cell surface CD46 was cleaved by MMP/ADAM(s) and that the intracellular 
tails, Cyt1 and Cyt2, underwent PγS proteolysis. To determine if the proteolysis 
of Cyt1 and Cyt2 was important for shaping CD46 induced T cell responses, the 
effect of the MMP/ADAM and PγS inhibitors on T-cell proliferation and IL-10 
and IFNγ secretion was assessed.  
 
The experiments outlined above provide a general indication about how 
proteolysis of Cyt1 and Cyt2 might affect T cell activation. However, it is well 
known that broad-spectrum inhibitors to MMP/ADAM(s) and PγS have wide-
ranging effects and can also inhibit the proteolysis of other receptors. Thus to 
assess the specific function of the Cyt1 and Cyt2 isoforms and the functional role 
of their proteolysis during T cell activation, three further approaches were used. 
Firstly, wild type CTF proteins that consisted of the CD46 transmembrane 
domain and either the Cyt1 (CTF1) or Cyt2 (CTF2) intracellular tails were 
constructed (Nathan Weyand, University of Arizona) (figure 4.1) (Ni Choileain et 
al., 2011). In Chapter 3 it was demonstrated that the ectodomain of CD46 is 
cleaved by MMP/ADAM(s) upon CD46 costimulation. As such, these constructs, 
that lack the CD46 ectodomain, will help to determine the function of Cyt1 and 
Cyt2 after the release of their ectodomain during CD46 costimulation. To 
examine their role, CD4+ T cells were transfected with the vectors expressing 
CTF1, CTF2 or an empty plasmid called the control vector only (CVO). After 
transfection, the T cells were activated in vitro and their cytokine secretion (IL-10 
and IFNγ) was examined to determine if either CTF1 or CTF2 played a specific 
role in determining the phenotype of CD46 coactivated T cells. The activation 
state of T cells were also examined by analysing the expression levels of CD25, 
which is upregulated in human CD4+ T cells upon activation. T-cell proliferation 
levels were also examined using CFSE incorporation. Analysis of these activation 
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markers allowed for the role of CTF1 or CTF2 in initiating T cell activation to be 
examined.   
 
The second approach used to examine the role of Cyt1 and Cyt2 specifically 
assessed the function of proteolysis by PγS. Mutant CTF1 and CTF2 fragments 
that were resistant to PγS proteolysis were constructed (Nathan Weyand, 
University of Arizona) (Ni Choileain et al., 2011). Due to their uncleavable nature 
they were called UNCL.F1 (uncleavable CTF1) and UNCL.F2 (uncleavable 
CTF2) (figure 4.1). CD4+ T cells were transfected with the vectors expressing 
UNCL.F1, UNCL.F2 or the wild-type controls CTF1 or CTF2. Following 
activation, their cytokine and activation state was determined as above. By 
comparing the function of the cleavable and uncleavable fragments the function 
of PγS proteolysis could be ascertained. 
!
!
Figure 4.1: A schematic representation of the wild type and mutant 
uncleavable CTFs. Wild-type (CTF1, CTF2) and the mutant uncleavable CTFs 
(UNCL.F1, UNCL.F2) used in this study. CTF – cytoplasmic transmembrane 
domain. 
!
The CTF constructs do not have an extracellular domain and therefore could not 
be specifically activated at the surface. It has been shown previously that CD46 
ligation in T cells can alter its cellular location (Ludford-Menting et al., 2011). 
Thus, surface ligation could have an important role in altering localisation of 
CD46 upon CD46 costimulation, which may affect its signalling capacities and 
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function. Therefore the third approach used to investigate Cyt1 and Cyt2 function 
involved the construction of CD46 fusion proteins. The CD46 ectodomain was 
replaced with the ectodomain of CD19, a B cell marker that is not expressed on T 
cells. The CD19 ectodomain was fused to the CD46 transmembrane fragment and 
cytoplasmic tail, either Cyt1 or Cyt2 (Joelle Thomas, Université Lyon, France) 
(Ni Choileain et al., 2011). These constructs were called CD19-Cyt1 or CD19-
Cyt2 and allowed for the specific ligation of either Cyt1 or Cyt2 at the cell 
surface (figure 4.2). Similar to the CTF proteins above, these fusion proteins were 
transfected into CD4+ T cells and their effect on cytokine secretion and T cell 
activation was determined after T cell activation.  Expression of p-LAT and 
CTLA-4 were also determined to further elucidate the role of CD46 in T cell 
activation and contraction. Christian Neumann carried out the vast majority of the 
work utilising the CD19 fusion proteins during his Masters research project. I 
contributed to the work by carrying out preliminary experiments, supervising 
Christian within the lab and through critical review of his contribution to the 
publication. Christian Neumann performed the data analysis and presentation 
under the supervision of Dr. Anne Astier. 
 
!
Figure 4.2: A schematic representation of the CD19 fusion proteins used in 
this study. (From left to right) Wild type CD46-Cyt1 and CD46-Cyt2. CD19 
fusion proteins consisting of the CD19 ectodomain, the CD46 transmembrane 




4.4.1 The! effect! of! the! MMP/ADAM! inhibitor,! GM6001,! on! ILL10!
and!IFNγ!section!after!CD46!costimulation!
In the previous chapter, it was demonstrated that the ectodomain of CD46 was 
cleaved by MMP/ADAM(s) upon CD46 costimulation. Therefore, in order to 
determine if cleavage of the CD46 ectodomain was important for its function, the 
activity of MMP/ADAMs was inhibited using the broad-spectrum MMP/ADAM 
inhibitor – GM6001. CD4+ T cells were either left unstimulated or stimulated for 
5 days with αCD3, αCD3/CD28 or αCD3/CD46 in the presence of GM6001 or 
DMSO as a control. IL-10 and IFNγ secretion were then determined by ELISA 
and the ratio of IL-10:IFNγ was calculated. T-cell proliferation was also 
determined after 3 days of stimulation using 3H-thymidine incorporation. In the 
presence of GM6001, CD46 costimulation showed a trend for decreased IL-10 
secretion but had no effect on IFNγ secretion thereby showing a trend for a 
decreased IL-10:IFNγ ratio. Of note proliferation was not significantly affected in 
the presence of the inhibitor, although some donors actually showed an increase 
(figure 4.3). Similar results were observed upon CD28 costimulation. However, 
upon CD28 costimulation a decreasing trend in IFNγ secretion was also observed 
(figure 4.3). Although not significant, these results suggest that inhibition of 
MMP/ADAMs promoted a decreased ratio of IL-10:IFNγ production upon CD28 
and CD46 T cell costimulation. Whether the attenuation of IL-10 secretion 
involves the specific cleavage of CD46 will be addressed below using the 





Figure 4.3: The effect of the MMP/ADAM inhibitor, GM6001, on IL-10 and 
IFNγ secretion after CD46 costimulation. CD4+ T cells were left unstimulated 
or stimulated in the presence of αCD3, αCD3/CD28 or αCD3/CD46. The broad-
spectrum MMP/ADAM inhibitor, GM6001 (black bars) or DMSO (white bars) was 
added to each stimulating condition. At day 5, supernatants were collected in 
order to determine the concentration of IL-10 and IFNγ using ELISA. The ratio of 
IL-10:IFNγ was also calculated. Proliferation was determined after 3 days 
stimulation (n=8). A Friedman test and a Bonferroni-corrected Wilcoxon test was 
used for statistical analysis, *p≤0.01.  
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4.4.2 The! effect! of! the! PγS! inhibitor,! DAPT,! on! ILL10! and! IFNγ!
section!after!CD46!costimulation!
In Chapter 3 it was determined that Cyt1 and Cyt2 underwent proteolysis by PγS 
on day 2 and day 4 respectively. To determine if PγS proteolysis of the Cyt1 and 
Cyt2 intracellular tails was important for its function, PγS cleavage activity was 
targeted using the PγS inhibitor, DAPT. CD4+ T cells were left unstimulated or 
stimulated with αCD3, αCD3/CD28 or αCD3/CD46 in presence of DAPT or 
DMSO as a control. The concentration of IL-10 and IFNγ secretion was assessed 
after 5 days stimulation and the ratio of IL-10:IFNγ was calculated. Proliferation 
was determined after 3 days of stimulation using 3H-thymidine incorporation. In 
the presence of DAPT, CD46 stimulation resulted in decreased IL-10 secretion 
compared to DMSO control but had no significant effect on IFNγ or proliferation. 
There was also no change in the IL-10:IFNγ secretion ratio, suggesting that 
DAPT minimally affected IFNγ secretion upon CD46 costimulation (figure 4.4). 
Similar results were observed upon CD28 costimulation. Importantly for this 
study these results indicate that PγS affects IL-10 secretion upon CD46 
costimulation and to a lesser extent IFNγ secretion. Whether cleavage of CD46 






Figure 4.4: The effect of the PγS inhibitor, DAPT, on IL-10 and IFNγ 
secretion after CD46 costimulation. CD4+ T cells were left unstimulated or 
stimulated as indicated. The PγS inhibitor, DAPT (black bars) or DMSO (white 
bars) was added to each stimulating condition. At day 5, supernatants were 
collected in order to determine the concentration of IL-10 and IFNγ using ELISA. 
The ratio of IL-10:IFNγ was also calculated. After 3 days stimulation, proliferation 
was determined (n=8). A Friedman and Bonferroni-corrected Wilcoxon test was 





Surface CD46, Cyt1 and Cyt2 expression is downregulated as a result of 
proteolysis during CD46 costimulation (Chapter 3). Use of broad-spectrum 
inhibitors indicated that both MMP/ADAM(s) and PγS played a role in CD46 
induced cytokine secretion, especially IL-10. However, a direct link between 
CD46 cleavage and an increased IL-10:IFNγ ratio remained to be determined. 
Moreover, the effect that CD46 proteolysis had on T cell activation was still 
unknown. Therefore CD4+ T cells were transfected with the vectors containing 
different CD46 CTFs, as previously described.  Prior to examining the role of 
these vectors on T cell cytokine secretion and activation, the effect of the empty 
control vector only (CVO) on cytokine secretion was examined to assess if 
nucleofection of primary human T cells had any major effects on IL-10 or IFNγ 
cytokine secretion.  CD4+ T cells were transfected with the CVO plasmid and 
stimulated with αCD3/CD28, αCD3/CD46 or αCD3/CD28/CD46.  IL-10 and 
IFNγ secretion were analysed after 3 days of stimulation using a secretion assay. 
Cytokine secretion in all conditions was similar to that previously reported 
(figure 4.5A)(Kemper et al., 2003). Upon CD46 costimulation, there was a large 
percentage of IL-10+ cells and a low percentage of IFNγ+ cells. Conversely, upon 
CD28 costimulation there was a large percentage of IFNγ+ cells and a low 
percentage of IL-10+ cells. CD28/CD46 resulted in a moderate percentage of both 
IL-10+ and IFNγ+ T cells (figure 4.5A).  
 
As the CVO appeared to have no apparent effects on normal T cell activation, 
CD4+ T cells were then transfected with wild type CTF1 and CTF2 to determine 
their effects on T cell cytokine secretion. After transfection, the T cells were 
stimulated with αCD3/CD28, αCD3/CD46 or αCD3/CD28/CD46 for 3 days 
before assessing IL-10 and IFNγ secretion. The percentage of IL-10+, IFNγ+ and 
IL-10+IFNγ+ cells was calculated. No significant change in cytokine secretion 
was observed after transfection with either the CTF1 or CTF2 plasmid (figure 
4.5B, left panel). Of note there was a large variation of cytokine secretion 
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observed between donors, that could reflect donor variability, variations in the 
levels of transfection efficiency and/or variations in the CD4+ T cell subsets 
obtained from each donor. Importantly for the function of CD46 induced Tregs, 
after CD28/CD46 costimulation CTF1 increased the ratio of IL-10+:IL-10+IFNγ+ 
cells (figure 4.5B, right panel, red box). Cardone et al have demonstrated that 
CD46 stimulated cells can switch from a Th1-like to a Treg phenotype, 
transitioning from IL-10-IFNγ+ to IL-10+IFNγ+ and finally to IL-10+IFNγ- 
secreting cells (Cardone et al., 2011). Therefore, CTF1 may promote the 
transition to a more Treg phenotype. No significant affect of the CTF2 
transfection was observed under any stimulating condition, further experiments 
are required to determine the exact function of CTF2 during T cell activation. 
 
Next it was determined if CTF1’s promotion of ‘IL-10 only’ secreting cells was 
dependent upon PγS cleavage. In order to do this, CD4+ T cells were transfected 
with the mutant uncleavable plasmids, UNCL.F1 and UNCL.F2 and their effects 
on cytokine secretion was compared to that of their wild-type counterparts (CTF1 
and CTF2). After 3 days of stimulation, the percentage of IL-10+, IFNγ+ and IL-
10+IFNγ+ cells were determined (figure 4.5C, left panel) and the ratio of IL-
10:IL-10+IFNγ+ and IL-10:IL-10+IFNγ+ (figure 4.5C, right panel) was calculated. 
No significant effect of the uncleavable mutants was observed.  
 
In summary Cyt1 can promote a more regulatory T cell phenotype. Further 
experiments are required to determine the exact role, if any, of Cyt2 and PγS 





Figure 4.5: T cell cytokine secretion after transfection with cleavable and 
uncleavable CTFs. (A) T cells were transfected with the CVO plasmid and 
stimulated with αCD3/CD28 (CD28), αCD3/CD46 (CD46) or αCD3/CD28/CD46 
(CD28/46). IL-10 and IFNγ secretion was determined using a Miltenyi secretion 
assay after 3 days stimulation.  (B) CD4+ T cells were transfected with CVO, 
CTF1 or CTF2 vectors and stimulated as indicated. IL-10 and IFNγ secretion 
was determined after 3 days stimulation and the indicated ratios were calculated 
(n=8). A Friedman test and Bonferroni-corrected Wilcoxon test was used for 
statistical analysis, **p≤0.003 (C) CD4+ T cells were transfected with wild-type 
CTF1 or CTF2 or the uncleavable mutants UNCL.F1 or UNCL.F2. T cells were 
stimulated as indicated and the indicated ratios were calculated (n=6). A 
Friedman test and Bonferroni-corrected Wilcoxon test was used for statistical 





In the previous section it was demonstrated that CTF1 could affect a T cell’s 
cytokine secretion profile (figure 4.5). In light of their time dependent 
downregulation it was also hypothesised that Cyt1 and Cyt2 could have different 
effects on CD4+ T cell activation and proliferation. Therefore the role of the Cyt1 
and Cyt2 CTFs in T cell activation and proliferation was assessed. CD4+ T cells 
were transfected with either an empty control vector (CVO), wild-type CTF1 and 
CTF2 or the uncleavable mutants, UNCL.F1 and UNCL.F2. Prior to stimulation, 
T cells were labelled with the proliferation marker, CFSE and then stimulated 
with αCD3/CD28, αCD3/CD46 or αCD3/CD28/CD46. CD25 expression and 
proliferation was assessed by flow cytometry after four days of stimulation by 
flow cytometry. Proliferation was assessed using CFSE staining and the division 
index was calculated using Flowjo software. The division index measures the 
average number of cell divisions that a cell in the original population undergoes 
upon activation. Transfection of T cells with the UNCL.F1 proteins shows a 
decreased trend of cell proliferation upon CD28, CD46 and CD28/CD46 
costimulation compared to CTF1. A significant decrease in CD25 expression was 
also observed upon CD46 costimulation, which correlated with a decrease in 
proliferation. For some donors UNCL.F2 also showed a trend for a decrease in 
proliferation compared to the wild-type CTF2. Of note, although UNCL.F1 
transfected cells showed a decrease in CD25 expression that correlated with 
decreased proliferation, no decrease in CD25 expression was observed for the 
UNCL.F2 transfected cells. A representative example of proliferation and CD25 
expression upon CD28/CD46 costimulation is shown in figure 4.6A, and the 
mean proliferation and CD25 expression of several donors is shown in figure 
4.6B. These data suggest that cleavage of CTF1 facilitates T cell proliferation as 
inhibiting CTF1 cleavage attenuates proliferation and CD25 expression.  Further 





Figure 4.6: The effect of CD46 CTF expression on T cell activation and the 
role of PγS. CD4+ T cells were transfected with the control empty plasmid 
(CVO), wild-type CTF1 or CTF2 (cleavable +) or the uncleavable mutants 
UNCL.F1 or UNCL.F2 plasmids (cleavable -). Cells were labelled with CFSE 
before stimulation with αCD3/CD28 (CD28), αCD3/CD46 (CD46) or 
αCD3/CD28/CD46 (CD28/46). After 4 days stimulation, proliferation was 
assessed by flow cytometry in addition to CD25 expression. (A) Representative 
example of CFSE (n=5) and CD25 expression (n=8) upon CD28/CD46 
costimulation. (B) The mean division index, used to measure proliferation (n=5) 
and the mean CD25 expression is shown (n=8). A Friedman test and Bonferroni-
corrected Wilcoxon test was used for statistical analysis, *p≤0.008. Error bars = 




Transfection of CD4+ T cells with different CTF fragments indicates that CTF1 
and CTF2 have different effects on T cell cytokine secretion and activation. 
However, as the CTFs do not contain ectodomains, an additional approach using 
the CD19-CD46 fusion proteins was adopted. CD19 is not expressed in T cells 
and would therefore allow the specific ligation of either the Cyt1 or Cyt2 isoform 
at the cell surface. As described previously, these fusion constructs consisted of 
the extracellular domain of CD19, a B cell marker, fused to CTF1 or CTF2. 
These chimeric proteins were called CD19-Cyt1 and CD19-Cyt2 (figure 4.2). 
Firstly, to examine the correct expression of the chimeric proteins, human 
embryonic kidney (HEK293) cells were transfected with the fusion proteins. 
HEK293 cells do not express CD19 and are easily transfected, therefore making 
them a good choice of cells to examine the expression of the plasmids. After 
transfection, the ectodomain CD19 and intracellular Cyt1 and Cyt2 expression 
levels were determined by flow cytometry.  Expression levels of CD19 after 
transfection of both CD19-Cyt1 and CD19-Cyt2 were ~35%. Cyt1 expression 
was specific to the HEK293 cells that were transfected with CD19-Cyt1 and Cyt2 
expression was specific to the HEK293 cells that were transfected with CD19-
Cyt2 (figure 4.7A).  
 
Next, the transfection efficiency of the vectors in primary human T cells was 
examined. CD4+ T cells were transfected with either the control CVO, CD19-
Cyt1 or CD19-Cyt2 vectors and then stimulated with αCD3/CD28, 
αCD3/CD28/CD19, αCD3/CD46 or αCD3/CD28/CD46. After overnight 
stimulation CD19 expression levels were determined by flow cytometry. Similar 
levels of CD19 expression were observed in T cells as for the HEK293 cells 
(figure 4.7B). Of note, upon CD19 ligation there was also a downregulation of 
CD19 expression that was not observed in any other stimulating condition. This 
downregulation mirrors the downregulation of CD46 observed upon its ligation 
and suggests that the CD19-fusion proteins can undergo similar processing to that 
of wild type CD46. Moreover, CD19 downregulation was not due to masking of 
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the detection antibody epitopes by the activating CD19 antibody because there 
was no detection of CD19 upon staining with αIgG-FITC (data not shown). In 
summary, CD4+ T cells could be transfected efficiently with the CD19 fusion 
proteins and could therefore be used to assess the function of Cyt1 and Cyt2 in 
CD4+ T cells.  
 
Figure 4.7: CD19-CD46 fusion protein expression in HEK293 and T cells. 
(A) HEK293 cells were transfected with an empty control vector only (Control), 
CD19-Cyt1 (Cyt1) or CD19-Cyt2 (Cyt2), the next day expression of CD19 (cell 
surface), Cyt1 and Cyt2 (intracellular) were determined (n=3).  (B) CD4+ T cells 
were transfected with the control, CD19-Cyt1 (Cyt1) or CD19-Cyt2 (Cyt2) 
vectors. Then T cells were left unstimulated or stimulated with αCD3/CD28 
(CD28), αCD3/CD28/CD19 (CD28/CD19), αCD3/CD46 (CD46) or 
αCD3/CD28/CD46 (CD28/CD46). The next day, expression of CD19 was 




4.4.6 Specific! ligation! of! Cyt1! and! Cyt2! differently! affected! T! cell!
activation!
Using the CD19-Cyt1 and CD19-Cyt2 vectors described in the previous section, 
the function of Cyt1 and Cyt2 could be assessed upon their surface ligation in 
CD4+ T cells. This additional approach was used to support the findings observed 
using the CTF plasmids. CD4+ T cells were transfected with CD19-Cyt1, CD19-
Cyt2 or a control vector only (CVO).  Following transfection, the cells were 
stimulated with αCD3/CD46, αCD3/CD19, αCD3/CD28 or αCD3/CD28/CD19. 
In order to determine the role of CD19-Cyt1 and CD19-Cyt2 upon activation, 
proliferation levels of transfected T cells were examined alongside CD25 
expression after 4 days of stimulation. The level of activation was defined as 
CFSEloCD25+. Although neither CD19-Cyt1 nor CD19-Cyt2 transfected T cells 
significantly altered cytokine secretion upon T cell costimulation (data not 
shown), differences in T cell activation could be detected. In all stimulatory 
conditions, CD19-Cyt1 decreased T cell activation compared to the control 
transfection, whereas CD19-Cyt2 promoted activation.  Therefore, upon their 







Figure 4.8: Specific ligation of Cyt1 and Cyt2 differently affected T cell 
activation. CD4+ T cells transfected with the control vector only (Control), CD19-
Cyt1 (Cyt1) or CD19-Cyt2 (Cyt2) and were activated with αCD3/CD28 or 
αCD3/CD28/CD19. T cells were labelled with CFSE before stimulation with 
αCD3/CD46 (CD46), αCD3/CD28 (CD28) or αCD3/CD28/CD19 (CD28/CD19). 
After 4 days stimulation, proliferation was assessed by flow cytometry in addition 





In order to further assess the role of Cyt1 and Cyt2 during T cell activation the 
expression levels of CTLA-4, a T cell coinhibitory receptor, and phosphorylated 
LAT (p-LAT), an activatory signalling molecule that is phosphorylated upon 
CD46 activation (Astier et al., 2000), were examined. As above, T cells were 
transfected with CD19-Cyt1, CD19-Cyt2 or the CVO control. The next day, the 
cells were either stimulated with αCD3/CD28 or αCD3/CD28/CD19. CTLA-4 
expression levels upon CD3/CD28/CD19 costimulation were then compared to 
CD3/CD28 stimulated cells. There was no change in CTLA-4 expression in the 
control cells or the CD19-Cyt1 transfected cells. However, CD19-Cyt2 
transfected cells, which had been CD3/CD28/CD19 costimulated, increased 
CTLA-4 expression compared to CD3/CD28 stimulation alone (figure 4.9A).  
 
In order to determine any changes in LAT expression, T cells were either 
stimulated with CD3/CD28 or CD3/CD28/CD19 in the presence of a cross-linker 
for 5 min at 37 oC and p-LAT expression was determined by flow cytometry. 
Expression levels of p-LAT upon CD3/CD28/CD19 costimulation were 
compared with cells stimulated with CD3/CD28 alone. There was no change in p-
LAT expression in the control cells or the CD19-Cyt1 transfected cells. However, 
CD19-Cyt2 transfected T cells stimulated with CD3/CD28/CD19 stimulation 
induced a decreasing trend in p-LAT expression compared to CD3/CD28 
stimulation alone (figure 4.9B). Overall, Cyt2 ligation increases CTLA-4 
expression and induces a trend for decreased p-LAT expression.  These data 
suggest that Cyt2 ligation could promote a contraction of T cell responses, 





Figure 4.9: Specific ligation of Cyt2 increased CTLA-4 expression. CD4+ T 
cells were transfected with the control vector only (C), CD19-Cyt1 (Cyt1), CD19-
Cyt2 (Cyt2) and left unstimulated or stimulated with αCD3/CD28 (CD28) or 
αCD3/CD28/CD19 (CD28/CD19). (A) CTLA4 expression was determined by flow 
cytometry (Top panel) A representative example of CTLA4 expression. (Bottom 
panel) The normalised mean fluorescence intensity (NMFI) obtained for 6 
independent experiments. (B) Phosphorylated LAT (pLAT) was determined by 
intracellular flow cytometry staining after 5 min crosslinking. (Top panel) A 
representative example of pLAT expression. (Bottom panel) mean pLAT 
expression (NMFI) obtained for 5 independent experiments. A Friedman and 
Bonferroni-corrected Wilcoxon test was used for statistical analysis, *p≤0.006. 
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4.4.8 The! localisation! patterns! of! Cyt1! and! Cyt2! upon! T! cell!
activation!!
Other PγS substrates such as APP, Notch and ErbB4 release ICDs with nuclear 
transcriptional activity upon proteolytic cleavage (Parks and Curtis, 2007). Both 
CD46 cytoplasmic domains contain nuclear localization motifs (Seya et al., 1999, 
Wang et al., 2000) suggesting an ability to translocate to the nucleus and 
propagate cell signalling.  Therefore, the localisation of CD46 Cyt1 and Cyt2 was 
investigated using confocal laser scanning microscopy.  CD4+ T cells were 
cultured in chamber slides that had been pre-coated with either IgG1 or 
αCD3/CD46. After 2 or 5 days stimulation the localisation of Cyt1 or Cyt2 was 
determined. Due to photo-bleaching z stacks could not be taken of the cells, 
therefore, images were taken at the widest diameter of the nucleus. At day 2, in 
the absence of CD46 costimulation, Cyt1 and Cyt2 were strongly localised at the 
periphery with smaller amounts of intracellular staining. Of note, the peripheral 
Cyt1 staining was less uniform than Cyt2. Upon CD46 costimulation, Cyt1 but 
not Cyt2 expression is downregulated at the periphery and appears to localise in 
the vicinity of the nucleus. At day 5, unstimulated cells maintained uniform Cyt2 
staining at the periphery; however, upon CD46 stimulation there was an increase 
in Cyt2 staining within the vicinity of the nucleus (figure 4.10). These results 
suggest that there may be relocalisation of both Cyt1 and Cyt2 in activated cells 
from the periphery to the nucleus. Relocalisation appears to be temporal and 
corresponds to the downregulation of Cyt1 during early activation (day 2) and 
Cyt2 during late activation (day 5) (Chapter 3). These data suggest that 
proteolytic cleavage of Cyt1 and Cyt2 could promote transcriptional functions 
and that they are regulated by time. However, more extensive studies need to be 





Figure 4.10: The localisation patterns of Cyt1 and Cyt2 upon T cell 
activation. CD4+ T cells were left unstimulated (IgG1) or stimulated with 
αCD3/CD46 and for 2 or 5 days before confocal analysis. Cyt1 and Cyt2 (green 
signal), nucleus counterstain (red signal). Images were acquired with the 




The T cell phenotype induced by CD46 can be pro-inflammatory or anti-
inflammatory (Kemper et al., 2003, Sanchez et al., 2004). However, little is 
known about the signalling pathways that CD46 utilises for T cell regulation. 
Moreover, it is known that soluble factors such as IL-2, PGE-2 and vitamin D 
influence the type of immune responses initiated following CD46 costimulation 
(Cardone et al., 2010, Kickler et al., 2012) (and manuscript in press).  However, 
little is known about how CD46 isoforms regulate CD46 function in human T 
cells. This chapter expands on the known functions of CD46’s isoforms in T 
cells.  In light of the results described in this chapter, the role of the Cyt1 and 
Cyt2 isoforms in T cell activation and cytokine secretion is discussed below. 
 
Cyt1 and IL-10 secretion 
CD46 induced IL-10 secretion is fundamental to its ability to suppress bystander 
proliferation (Kemper et al., 2003). Furthermore figure 4.3 and figure 4.4 
demonstrate that MMP/ADAM(s) and PγS play a role in promoting IL-10 
production during CD46 costimulation. However, it remained to be determined if 
Cyt1 and/or Cyt2 specific proteolysis was involved. Therefore, determining if 
Cyt1 or Cyt2 could specifically promote IL-10 secretion would greatly enhance 
our understanding of CD46’s regulatory capacity. In this regard, transfection of 
CD4+ T cells with the wild type CTF1 constructs promoted a higher ratio of IL-
10+:IL-10+IFNγ+ secreting cells. Conversely, the CTF2 construct had no positive 
effect in promoting an increased ratio of IL-10 only secreting cells (figure 4.5 and 
figure 4.8A). Whilst preparing a manuscript describing these results (Ni Choileain 
et al., 2011), Cardone et al also demonstrated that Cyt1 expression in the Jurkat T 
cell line was responsible for CD46 induced IL-10 secretion and promoted the 
switch from IL-10+IFNγ+ to IL-10 only producing cells (Cardone et al., 2010). 
Therefore, Cyt1 acts to promote IL-10+ cells that do not produce IFNγ and may 
be an important target in understanding why there is defective IL-10 secretion 
from CD46 costimulated T cells in MS patients (Astier et al., 2006).  
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It remained to be determined if CD46 proteolysis was directly involved in 
promoting IL-10 secretion. To determine if PγS cleavage of CD46 was important 
for IL-10 secretion, CD4+ T cells were transfected with either the uncleavable 
UNCL.F1 or UNCL.F2 constructs. Transfection of T cells with the mutant 
uncleavable UNCL.F1 and UNCFL.F2 had no significant effect on the cytokine 
secretion profile (figure 4.5C). Failure to observe a significant result in this 
experiment is likely due to variations in transfection efficiency or a low n-number 
given the high level of variability. Further experiments are required to confirm 
the role of Cyt1 and Cyt2 PγS cleavage in T cells. Nonetheless it is interesting to 
note that Notch1 has the capacity to induce PγS dependent IL-10 secretion in Th1 
cells (Rutz et al., 2008, Kassner et al.) and therefore Notch could play a role in 
CD46 induced IL-10 secretion. PγS cleavage of Notch requires the prior cleavage 
of its ectodomain by MMPs.  Thus inhibition of Notch cleavage with the 
inhibitors could explain the decreased IL-10 secretion observed upon CD28 and 
CD46 costimulation (figure 4.4).  Whether PγS of CD46 plays an additional role 
in promoting IL-10 secretion remains to be determined.  
 
Cyt1 proteolysis and T cell activation 
In Chapter 3, it was demonstrated that Cyt1 undergoes PγS cleavage and 
downregulation after 1-2 days of CD46 costimulation. UNCL.F1, a mutant CTF1 
construct that inhibited PγS cleavage showed a strong trend of reduced T cell 
activation,, compared to wild type CTF1 and this trend correlated with a 
significant decrease in CD25 expression (figure 4.6). This indicated that cleavage 
of CTF1 was important for T cell activation. Moreover, under both CD46 and 
CD28 costimulating conditions, CD19-Cyt1 expression decreased T cell 
activation compared to cells transfected with the CVO (figure 4.8B). This could 
correlate with the uncleavable UNCL.F1 data since in the absence of CD19 
ligation cleavage of CD19-Cyt1 is predicted not to occur. Therefore in the 
absence of Cyt1 proteolysis by PγS, Cyt1 inhibits T cell activation. Conversely, 
cleavage of Cyt1 during T cell activation facilitates normal T cell activation.  
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Russell et al have previously shown that Cyt1 can compete with the 
immunological synapse (IS) for polarity. Prior to T cell activation, cross-linking 
of CD46, by antibodies or measles virus proteins (which bind CD46), strongly 
reduced IS formation and decreased T cell activation and function (Oliaro et al., 
2006). Cyt1 inhibited IS formation by recruiting lipid rafts and the microtubule-
organising centre (MTOC) to the CD46 ligation site (Oliaro et al., 2006, Ludford-
Menting et al., 2011). On a signalling level, Cyt1 interacts via its FTSL domain 
with the scaffold proteins; Golgi-associated PDZ and coiled-coil motif-containing 
protein (GOPC) and discs, large homolog 4 (DLG4) (Joubert et al., 2009). Both 
GOPC and DLG4 contain protein binding motifs called PDZ domains (Ludford-
Menting et al., 2002) that regulate T cell morphology and polarity during 
immunological synapse formation and T cell migration (Ludford-Menting et al., 
2005).  Therefore, there is strong evidence to support the role of Cyt1 in T cell 
polarity changes. Importantly, this competition with the TCR for T cell polarity 
was specific to Cyt1 and was not observed for Cyt2 (Oliaro et al., 2006, Ludford-
Menting et al., 2011). In line with these findings Marie et al reported that Cyt1 
transgenic mice reduced CD8+ T cell activation in a contact hypersensitivity 
model (Marie et al., 2002). Thus, in the absence of CTF cleavage, as is the case 
for the UNCLF.1 and CD19-Cyt1, (in the absence of CD19 ligation) there may be 
sustained signalling that competes with the IS for polarity. Herein, a model for 
Cyt1 proteolysis is proposed where proteolysis of Cyt1 prevents Cyt1 from 
diverting the axis of polarity away from the immunological synapse. By 
inhibiting Cyt1 cleavage it is possible that Cyt1 maintains signalling and polarity 
competition that diverts MTOC and lipid rafts away from the IS, thereby 
attenuating T cell activation. 
 
Cyt2 and T cell proliferation 
Upon CD46 costimulation, Cyt2 is initially upregulated during activation but is 
downregulated after 4-5 days of stimulation. This time-dependent downregulation 
of Cyt2 was at least partially the result of PγS cleavage and suggested that during 
late activation Cyt2 proteolysis had a distinct function (Chapter 3). Due to the 
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upregulation of Cyt2 during early activation and the timing of Cyt2 
downregulation, it was hypothesised that proteolysis of Cyt2 could facilitate the 
contraction of T cell responses. In order to determine if this was the case, T cells 
were transfected with the wild-type cleavable CTF2 fragment and the uncleavable 
UNCL.F2 fragment. However the uncleavable CTF2 mutant showed no increase 
in proliferation compared to the wild-type fragment and in some donors actually 
decreased proliferation as measured by the division index. Of note unlike CD19-
Cyt1 transfected cells, CD19-Cyt2 did not decrease CD25 expression (figure 4.6). 
Interestingly, transfection of T cells with the full length CD19-Cyt2 protein 
increased T cell activation compared to the control transfection group under all 
stimulating conditions indicating that full length Cyt2 plays a role in promoting T 
cell activation. Notably, upon the ligation of CD19-Cyt2, in the presence of 
CD28 costimulation, the percentage of activated T cells decreased compared to 
cells activated with CD28 costimulation alone (figure 4.8B). As surface ligation 
of the CD19 chimeric proteins also resulted in its surface downregulation (figure 
4.7B), it could indicate that Cyt2 is required in its full-length form and is perhaps 
required at the cell membrane to promote proliferation. This model is supported 
by evidence that CD19-Cyt2 ligation, which decreases CD19 surface expression, 
decreases p-LAT and promotes a T cell phenotype more susceptible to shutdown 
via the upregulation of CTLA4 expression (figure 4.9). It would be interesting to 
address the question of whether cleavage of Cyt2’s ectodomain is the key factor 
in regulating Cyt2’s function because inhibiting PγS’s proteolysis of Cyt2 does 
not restore Cyt2’s function in promoting proliferation. Indeed, although no 
significance was reached, the MMP inhibitor GM6001, increased proliferation in 
the majority of donors upon CD46 costimulation. This was not observed upon 
CD28 costimulation (figure 4.3) or in the presence of the PγS inhibitor, DAPT 
(figure 4.4). Therefore, full-length Cyt2 promotes T cell activation. Further 
experiments are required to determine if the loss of this function is due to 




Regulated T cell responses not only require correct T cell activation but also a 
timely termination of the response (Marrack et al., 2010).  Surface 
downregulation of CD46 has previously been reported during cell death of Jurkat, 
a human T cell line, and neuronal cells (Elward et al., 2005, Cole et al., 2006). 
For example, CD46 is released from apoptotic Jurkat cells, in a caspase-
dependent manner (Elward et al., 2005) and soluble levels of CD46 also increase 
in parallel with apoptotic caspase activity in epithelial cells (Hakulinen and 
Keski-Oja, 2006). Indeed, apoptosis induced in epithelial cells by the pathogen 
Streptococcus, which binds CD46, also results in CD46 shedding (Lovkvist et al., 
2008). Therefore the release of cell surface CD46 has previously been associated 
with cell death. This is the first report that suggests a link between  Cyt2 
processing and T cell shut down. Whether proteolysis of Cyt2 plays a direct role 
in inducing apoptosis of T cells or if apoptosis directly promotes Cyt2 cleavage 
remains to be elucidated. Of note, apoptosis has previously been shown to initiate 
PγS cleavage of the type 1 transmembrane protein ErbB4 thereby promoting the 
disassembly of epithelial adherence junctions. Moreover, PγS cleavage of ErbB4 
required prior proteolysis by an MMP/ADAM and its cleavage was caspase 
dependent (Marambaud et al., 2002). This example draws clear parallels to CD46 
processing, which also undergoes caspase dependent ADAM cleavage in 
epithelial cells during apoptosis (Hakulinen and Keski-Oja, 2006). Neisseria 
infection of epithelial cells also induces CD46 shedding (Gill et al., 2005) and 
PγS proteolysis (Weyand et al.). Therefore, CD46 and especially Cyt2 may be 
inherently linked to cell death and likely to play an important role in the 
contraction of T cell responses. 
 
The localisation and signalling of the intracellular domains 
The question that remains to be addressed is the localisation of the ICDs after γ-
secretase cleavage. Their localisation likely has important consequences for 
CD46 signalling and may offer further avenues of investigation when assessing 
dysfunctional CD46 signalling in MS patients. PγS cleavage of Notch results in 
relocalisation of its ICD to the nucleus and is crucial for it signal transduction. 
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Moreover, the transport to the nucleus of the Notch ICD involves endocytosis at 
the surface, endosomal trafficking and importantly cessation of signalling upon 
degradation, all of which are fundamental to the regulation of its signalling (Bray, 
2006, Fortini, 2009). These facts raise questions about CD46’s ICDs cellular 
trafficking. For example, is endosomal trafficking important for their function 
and do they translocate to the nucleus? In Chapter 3, it was demonstrated that 
CD46 is downregulated through the endosomal pathway suggesting that CD46 
cleaved fragments may also traffic through the endosomal pathway. Their 
subsequent degradation could be a key factor in attenuating CD46 signalling. In 
an attempt to discover the localisation of Cyt1 and Cyt2 upon activation, 
preliminary confocal studies were carried out that suggest potential relocalisation 
of both Cyt1 and Cyt2 to the nucleus. Their translocation to the vicinity of the 
nucleus coincided with the defined timepoint of PγS cleavage- Cyt1 translocation 
during early activation and Cyt2 translocation during late activation (figure 4.10). 
Despite it’s preliminary nature, it is worth emphasising that both Cyt1 and Cyt2 
contain nuclear localisation motifs suggesting a biological significance (Seya et 
al., 1999, Wang et al., 2000).  Thus, trafficking of the Cyt1 and Cyt2 ICDs may 
involve the endosomal pathway, which facilitates their translocation to the 
nucleus and subsequent degradation. However, more work would need to be 
carried out to determine it CD46 endosomal trafficking, localisation and 
degradation is important for CD46’s function. 
 
It is also important to note that ICDs may also form signalling complexes within 
the cytoplasm.  One possible signal complex may involve E-cadherin and the 
actin cytoskeleton. E-cadherin is an important adhesion molecule in epithelial 
cells and like CD46 is a substrate for γ-secretase cleavage (Marambaud et al., 
2002). CD46 binds E-cadherin and α-E-catenin a molecule that links E-cadherin 
to the actin cytoskeleton (Cardone et al., 2011). Interestingly, in epithelial cells γ-
secretase cleavage results in the release of E-cadherin from actin cytoskeleton and 
initiates the disassembly of adherens junctions (Marambaud et al., 2002). CD46 is 
also cleaved by γ-secretase in epithelial cells upon its ligation (Weyand et al.). 
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Furthermore, CD46 ligation on epithelial cells also augmented the permeability 
of epithelial monolayers and induced epithelial cell proliferation and wound 
healing (Cardone et al., 2011). Given the proximity of CD46, E-cadherin, E-
catenin and PγS in epithelial cells there may be a role for PγS cleavage of CD46 
in the proliferation of epithelial cells, similar to that observed in T cells. 
Moreover, considering the role of Cyt1 in T cell proliferation and alterations in 
polarity, it would be interesting to determine if the role of CD46 in wound 
healing was specific to Cyt1. This also raises the question of whether Cyt1 PγS 
proteolysis releases the ICD from the signalling complex attached to the actin 
cytoskeleton in T cells, thereby inhibiting Cyt1 from competing with the IS for 
polarity and facilitating normal T cell activation. 
 
 
Figure 4.11: Proposed model of Cyt1 and Cyt2 function in T cell activation.  
 
To conclude, proteolytic cleavage of CD46 supports CD46 dynamic responses 
and demonstrates for the first time that proteolytic cleavage of Cyt1 and possibly 
Cyt2 regulates T cell activation (figure 4.11).  Aberrant regulation of Cyt1 and 
Cyt2 cleavage could partially explain the defect of CD46 function in autoimmune 
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diseases. Further studies, addressing the localisation and interaction of CD46’s 
ICDs will shed light on important regulatory mechanisms related to CD46’s 
diverse signalling functions. 
 
4.6 Conclusions!
• Similar to that observed after CD28 costimulation, inhibition of 
MMP/ADAM(s) and PγS cleavage, using broad-spectrum inhibitors, 
decreases IL-10 secretion upon CD46 costimulation.  
• Cyt1 expression increases the ratio of IL-10+ secreting cells compared to 
those that secrete both IL-10 and IFNγ. 
• Inhibiting Cyt1’s PγS proteolysis decreases CD25 expression, which 
correlates with a decreasing trend in proliferation. 
• Full length Cyt2 promotes T cell activation. Upon the specific ligation of 
CD19-Cyt2 there is an increase in CTLA-4 expression in addition to a 








Protease cleavage of receptors plays an influential role in receptor activity by 
regulating surface expression and propagating signals (Katzmann et al., 2002, 
Parks and Curtis, 2007, Fortini, 2009). Chapter 4 demonstrated that cleavage of 
CD46 by metalloproteinases/ADAM(s) occur upon T cell activation and plays a 
role in initiating and possibly in terminating T cell responses (Chapter 5).  Given 
that the cleavage of CD46 alters CD46 function and T cell responses, the 
regulation of CD46 surface expression was further investigated.  At a basic level 
T cell stimulation is a two-step process involving TCR ligation and a co-
stimulatory signal. It was shown in Chapter 3 that TCR stimulation increased 
CD46 cell surface expression and suggested that there was an inherent link 
between CD46 and T cell activation. Therefore, the role of the TCR in regulating 
CD46 surface expression was investigated.  
 
CD46 like the majority of immune receptors is glycosylated (figure 5.1) (Ballard 
et al., 1988). Glycosylation has previously been shown to alter the surface 
expression of important immunological receptors, such as the TCR, CD4, CD45 
and CTLA-4 (Pulido and Sanchez-Madrid, 1992, Tifft et al., 1992, Demetriou et 
al., 2001, Partridge et al., 2004, Chen et al., 2009). Glycosylation can either 
promote or attenuate surface retention of receptors. For example, O-glycosylation 
can inhibit protease degradation of proteins while they are expressed on the 
surface or in endosomes (Reddy et al., 1989, Maryon et al., 2009) and may also 




Of note, activation of T cells induces changes in glycosylation (Piller et al., 1988, 
Galvan et al., 1998, Comelli et al., 2006, Clark and Baum, 2012) that can alter T 
cell activation and functions (Demetriou et al., 2001, Lau et al., 2007, Chen et al., 
2009, Kuball et al., 2009, Clark and Baum, 2012). For example, T cells modulate 
the glycosylation of CD45, a cell surface glycoprotein, during development and 
activation (Clark and Baum, 2012), and alterations of its N- and O- glycans can 
modulate both CD45 clustering, TCR signalling and T cell apoptosis (Nguyen et 
al., 2001, Amano et al., 2003, Clark and Baum, 2012). We therefore proposed 
that TCR activation would not only affect CD46 expression but also its state of 
glycosylation. Furthermore, it was predicted that these changes in glycosylation 
could regulate CD46 expression and function.  CD46 contains both N- and O-
glycosylation attachments sites (figure 5.1). Therefore, the contribution of each 
glycan subtype to CD46 function was assessed. In this chapter we identify the 
TCR as a key regulator of CD46 surface expression and glycosylation. This thesis 
also provides evidence for a role of CD46 glycans in CD46 surface 
downregulation and function during T cell activation. 
 
 
Figure 5.1: Schematic representation of CD46 with N- and O-glycans. Both 
the BC and C isoforms of CD46 are represented. SCR - short consensus 







1. To determine the role of T cell activation (by the TCR) in regulating 
CD46 cell surface expression. 
2. To determine if the TCR alters CD46 glycosylation state upon 
activation. 
3. To determine the role of N- and O-glycans in CD46 cell surface 




CD46’s role as a costimulatory molecule is dependent on TCR activation (Astier 
et al., 2000). As CD46’s proteolytic cleavage is important for T cell activation 
(Chapter 4) (Ni Choileain et al., 2011)), the role of the TCR in regulating CD46 
downregulation and proteolysis was investigated. Firstly, CD46 cell surface 
expression was monitored at various time-points upon CD46 ligation in the 
absence or presence of αCD3 stimulation. Secondly, intracellular levels of CD46 
were examined to identify any retention of CD46 intracellularly. Finally, sCD46 
was measured in the supernatants to determine if any changes in CD46 surface 
expression were the result of proteolytic cleavage.  
 
Given the role of glycosylation in regulating cell surface expression of other 
receptors, it was also determined if TCR activation induced changes in CD46 
glycosylation. Firstly, the Mw of CD46 following T cell activation was monitored 
in unstimulated or TCR stimulated T cells. Mw changes often reflect differences 
in glycosylation. Thus, if a difference in Mw was observed between unstimulated 
and stimulated T cells, it would then be determined if the change in Mw reflected 
changes in glycosylation. In order to do this, unstimulated and TCR activated T 
cells would be stripped of their glycans using deglycosylating enzymes 
(glycanases). If deglycosylation eliminated the differences in Mw observed 
between unstimulated and stimulated cells, then it would be concluded that 
changes in Mw were the result of glycosylation alterations upon activation. 
 
CD46 contains 3 potential sites for N-glycosylation and several sites for O-
glycosylation (figure 5.1). In order to determine if either N-glycans or O-glycans 
were specifically involved in CD46 downregulation and function, two different 
approaches were adopted. Firstly, broad-spectrum N- and O-glycosylation 
inhibitors were used to assess the effect of N- and O-glycans on CD46 cell 
surface downregulation. In order to determine the effect of N- and O-
glycosylation on T cell activation, CD69 expression was determined in the 
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presence or absence of the inhibitors. IL-10 and IFNγ secretion was also 
examined to determine if N- or O-glycosylation could affect CD46 function. 
 
 As broad-spectrum inhibitors affect the glycosylation of all proteins, this initial 
approach was supported by the expression of several mutants of CD46, lacking 
specific attachment sites for N- and O-glycosylation (section 5.4.3, table 5.1). 
These mutants were stably expressed in Chinese hamster ovary (CHO) cells that 
lack endogenous CD46 (Maisner et al., 1996, Liszewski et al., 1998) and were 
kindly provided by the Atkinson lab (University of Washington, St Louis, MO). 
CHO cells expressing these mutants of CD46 were cultured in the presence or 
absence of αCD46 to determine the effect of specific N-glycans or O-
glycosylation on CD46 downregulation. T cells were then transfected with the 
mutant CD46 plasmids and cell surface expression was assessed upon CD46 
costimulation. Finally, T cells that had been transfected with the mutant plasmids, 
were activated in the presence or absence of CD46 costimulation, and cytokine 
secretion and proliferation were analysed. Together, the data obtained from these 
experiments would identify the function of specific glycans in CD46 





The expression levels of CD46 were first determined in the presence of TCR 
engagement in order to determine the role of TCR signalling in regulating CD46 
expression.  Purified human CD4+ T cells were left unstimulated or activated in 
the presence of αCD3, αCD3/CD46 or αCD46. Cell surface expression of CD46 
was examined by flow cytometry at 1 hr, 2 hrs, 3 hrs and 24 hrs. CD46 ligation in 
the presence of TCR stimulation induced a downregulation of CD46 surface 
expression as early as 1 hr after stimulation and was more strongly 
downregulated at 3 hrs and 24 hrs compared to CD46 ligation alone (figure 5.2A). 
TCR induced downregulation of CD46 is αCD3 dose dependent in Jurkat cells 
(data not shown – Dana Photiou, Honours Student). Decreased staining was not 
due to masking of the epitopes by the stimulating CD46 antibodies, as there was 
no staining present with an α-mouse IgG1 FITC secondary antibody (Chapter 3). 
Analysis of CD46 intracellular staining also revealed a decrease in CD46 
expression following αCD3/CD46 or αCD46 ligation compared to unstimulated 
cells (figure 5.2B). To determine if the increased downregulation of CD46 
expression observed upon αCD3/CD46 stimulated cells compared to αCD46 
ligation was due to increased proteolytic cleavage of CD46, T cells were cultured 
under the stimulating conditions described above and the supernatants were 
collected after 24 hrs of stimulation. The early timepoint of 24 hrs was chosen to 
minimise differences in protein quantity as a result of proliferation. Soluble CD46 
(sCD46) was immunoprecipitated from the supernatants and analysed by western 
blot (figure 5.2C). Upon αCD3/CD46 stimulation there was a band present at ~55 
kDa that corresponds to the size of cleaved sCD46 (Van Den Berg et al., 2002, 
Hakulinen et al., 2004, Hakulinen and Keski-Oja, 2006). This band is absent or 
reduced upon αCD46 ligation alone, indicating that TCR ligation increased 
cleavage of CD46 at the surface. Therefore, CD46 ligation in the presence of 
TCR activation increases CD46 surface downregulation and this was at least 




Figure 5.2: TCR activation promotes the cleavage of CD46. CD4+ T cells 
were left unstimulated (US) or stimulated with αCD3, αCD3/CD46 or αCD46 
alone. (A) Samples were collected at the indicated time points to analyse CD46 
surface expression by flow cytometry (representative of 3 independent 
experiments). (B) After 24 hrs stimulation, surface CD46 and intracellular 
expression was determined by flow cytometry (representative of 3 independent 
experiments). (C) Immunoprecipitation (IP) of soluble CD46 (sCD46) in 
supernatant after 24 hrs stimulation of CD4+ T cells. HC (IP IgG heavy chain), 




T cell activation induces alterations in T cell glycosylation that are important for 
T cell function (Demetriou et al., 2001, Lau et al., 2007, Chen et al., 2009, Kuball 
et al., 2009, Clark and Baum, 2012). Therefore, it was determined if TCR 
activation induced changes in CD46 glycosylation. First, the Mw of CD46 was 
examined by SDS-PAGE and western blotting from T cells that had been left 
unstimulated or activated with αCD3, αCD3/CD46 or αCD46. There was a 
systematic decrease of ~2 kDa in the Mw of CD46 upon TCR activation (αCD3). 
This decrease is observed after 2 days and 4 days activation (figure 5.3A). These 
donors expressed both the BC and C CD46 isoforms and both isoforms had 
decreased Mw upon activation. This decrease in Mw was also observed upon 
CD46 co-stimulation (figure 5.3A) and CD28 co-stimulation (figure 5.3B). After 
T cells were stimulated with an increasing dose of αCD3 (0.2-25.0 µg/ml), there 
was a dose dependent decrease in the Mw of CD46 (figure 5.3C). Nonetheless, 
TCR activation is required to induce a decrease in the Mw of CD46, as CD46 
ligation in the absence of CD3 stimulation does not affect its Mw (figure 5.3D).  
Therefore, TCR activation induced a dose dependent decrease in the Mw of CD46 
that was also observed upon CD28 and CD46 costimulation. These data indicate 
that glycosylation of CD46 may change upon activation and this is further 




Figure 5.3: The Mw of CD46 is decreased upon T cell activation. (A) (Left 
panel) T cells were left US or stimulated with αCD3 alone or in the presence of 
αCD46 (CD3/46) for 4 days. (Right panel) T cells were left US or stimulated with 
αCD3 for 2 or 4 days.  (representative of 5 independent donors) and the Mw of 
CD46 was determined using SDS-PAGE.  (B) T cells were stimulated with 
αCD3/CD28 (CD3/28) for 2 days in addition to the stimulating conditions 
described in (A). (Representative of 3 independent donors).   (C) T cells were left 
US or stimulated with increasing doses of αCD3 (0.2 – 25 µg/ml) for 5 days. (D) 
T cells were stimulated overnight with αCD3/CD46, or αCD46. (Representative 




As CD46 contains three N-glycosylation sites and multiple O-glycosylation sites 
(figure 5.1), it was possible that the reduction in CD46’s Mw observed in figure 
5.3 was the result of deglycosylation upon TCR activation.  In order to 
investigate this, T cells were left unstimulated or activated with αCD3 for five 
days. T cells were lysed and a small fraction of the lysate was used to assess the 
Mw of CD46 by SDS-PAGE, to confirm that a decrease in Mw occurred upon 
activation (figure 5.4A).  The remaining total cell lysate was used to 
immunoprecipitate and deglycosylate CD46. If deglycosylation eliminated the 
differences in Mw observed between unstimulated and stimulated cells, then it 
would be concluded that changes in Mw were the result of glycosylation 
alterations upon activation. The immunoprecipitate was denatured and split into 
two equal aliquots, one was untreated and the other aliquot underwent O- and N-
deglycosylation using the ProZyme Enzymatic deglycosylation kit and ProZyme 
prO-Link Extender™. Deglycosylation was carried out according to the 
manufacturers protocol. In brief, the kits contain N-glycanase PNGase F®, 
sialidase A, O-glycanase® (ProZyme Enzymatic deglycosylation kit) and β(1-4)- 
specific galactosidase and β-N-acetylglucosaminidase (ProZyme prO-Link 
Extender™). N-glycanase® cleaves the N-glycan linkage between the first sugar 
of the N-glycan core and the asparagnine residue of the glycosylated protein. This 
enzyme functions for all known human N-glycans. A similar enzyme for 
removing all O-glycans does not exist and several enzymes must be used to 
remove commonly expressed O-glycans on human T cells. Therefore the 
combination of O-glycanase®, sialidase A™, β(1-4)- specific galactosidase and 
β-N-acetylglucosaminidase was used to remove the O-glycans. Untreated and 
glycosidase treated samples were incubated overnight at 37 oC and the following 
day CD46 Mw was determined by SDS-PAGE. In the absence of glycanase 
treatment a decrease in CD46 Mw was observed upon αCD3 stimulation (figure 
5.4B) similar to that observed in the total cell lysate (figure 5.4A). Upon 
glycanase treatment the Mw of CD46 was reduced to 42 kDa in both the 
unstimulated and αCD3 stimulated immunoprecipitates. This is the reported Mw 
of deglycosylated CD46 (Cervoni et al., 1992, Maisner et al., 1994, Hara et al., 
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1998). These data suggested that the decrease in Mw observed in activated T cells 
is due to a decrease in glycosylation. Overall therefore, T cell activation induces a 
decrease in the Mw of CD46 either as a result of deglycosylating existing CD46 or 





Figure 5.4: A decrease in the Mw of CD46 upon TCR activation is the result 
of decreased CD46 glycosylation. CD4+ T cells were left unstimulated (US) or 
activated with αCD3 (CD3) for 5 days. Cells were lysed and SDS-PAGE was 
carried out on the (A) total cell lysate (TCL) and (B) CD46 immunoprecipitate 
(IP). The CD46:IPs were untreated (-) or treated with N-glycanase, O-glycanase, 
Sialidase and the ProZyme extender kit to remove N and O-glycans (+), 
(representative of 2 independent experiments).  
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5.4.4 BroadLspectrum! inhibitors! of! OL! and! NLglycosylation! have!
opposite!effects!on!cell!surface!CD46!expression!!
T cell activation induced a decrease in the level of CD46 glycosylation. 
Glycosylation alters the surface expression of immunological receptors, such as 
the TCR, CD4, CD45 and CTLA-4 (Pulido and Sanchez-Madrid, 1992, Tifft et 
al., 1992, Demetriou et al., 2001, Partridge et al., 2004, Chen et al., 2009). It 
remained to be determined however, if a reduction in CD46 glycosylation was 
associated with the downregulation of cell surface CD46 observed upon TCR 
activation. Changes in glycosylation could, for example, alter the conformation of 
surface CD46 and enhance its sensitivity to proteolysis or internalisation. In order 
to determine whether a decrease in O- or N-glycans could enhance CD46 
downregulation, O- and N-glycosylation was inhibited using broad-spectrum 
inhibitors. O-glycosylation was inhibited with Benzyl-α-GalNAc (5 mM) and N-
glycosylation was inhibited with tunicamycin (15  µg/ml). T cells were incubated 
overnight with the O- or N-glycosylation inhibitors or their respective controls, 
methanol and DMSO. The following day the T cells were left unstimulated or 
stimulated with αCD3, αCD3/CD46 or αCD46 alone. After 24 hrs stimulation 
CD46 cell surface expression was determined. Despite having no effect on 
unstimulated, αCD3 or αCD46 stimulated cells, treatment with the O-
glycosylation inhibitor, Benzyl-α-GalNAc, attenuated the downregulation of 
CD46 upon αCD3/CD46 stimulation (figure 5.5A). In contrast, the N-
glycosylation inhibitor, tunicamycin, induced a reduction in CD46 expression 
upon αCD3/CD46 and αCD46 stimulation, with the greatest reduction observed 
upon αCD3/CD46 stimulation (figure 5.5B(i)). This reduction in CD46 
expression was also observed after intracellular staining for CD46 (figure 
5.5B(ii)) suggesting that the decrease was not due to internalisation (excluding 
degradation).  These data indicate that inhibition of N-glycosylation promotes 
CD46 downregulation, and in contrast inhibition of O-glycosylation attenuates 
CD46 downregulation upon CD46 costimulation. Therefore it is possible that 







Figure 5.5: Broad-spectrum inhibition of O- and N-glycosylation have 
opposing effects on CD46 expression. CD4+ T cells were incubated overnight 
with Benzyl-α-GalNAc (O-glycan inhibitor)(5 mM) or tunicamycin (15 µg/ml)(N-
glycan inhibitor) and their respective controls, methanol or DMSO. The next day, 
cells were left unstimulated (US) or activated for 24 hrs with αCD3 (CD3), 
αCD3/CD46 (CD3/46) or αCD46 (CD46) and CD46 expression was determined 
by flow cytometry. (A) Surface CD46 expression of T cells incubated with the O-
glycan inhibitor (representative of 2 independent experiments). (B) CD46 
expression of cells treated with N-glycan inhibitor (i) Surface CD46 expression 
(representative of 9 independent experiments) and (ii) Intracellular CD46 
expression (representative of 4 independent experiments).  
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5.4.5 The! effect! of! the! OL! and! NLglycosylation! inhibitors! on! CD69!
and!cytoplasmic!tail!expression!
Chapter 4 demonstrated that proteolysis of CD46 can regulate T cell activation. 
Therefore, as inhibition of N- and O-glycosylation regulated surface expression 
of CD46 it was hypothesised that N- and O-glycosylation may also affect T cell 
activation. To examine the state of activation of cells treated with the O- or N-
glycosylation inhibitors, CD69 expression was determined after overnight 
activation. Inhibition of O-glycosylation appeared not to affect CD69 expression 
whereas the inhibition of N-glycosylation decreased CD69 expression. Of note, 
under all conditions increased CD69 expression correlated with the 
downregulation of CD46 (figure 5.6A). These data support the conclusion made 
in Chapter 4 that downregulation of CD46 is important for T cell activation. 
 
 It was demonstrated in Chapter 4 that the downregulation of CD46 and the 
proteolytic cleavage of its intracellular tail Cyt1, facilitated T cell activation.  As 
inhibition of N-glycosylation promoted the downregulation of CD46 it was also 
examined if cell surface downregulation correlated with alterations in the 
expression of the cytoplasmic tails. The expression levels of both cytoplasmic 
isoforms were determined by flow cytometry after overnight activation in the 
presence of the N-glycosylation inhibitor, tunicamycin. Upon αCD3/CD46 
activation there was an increased downregulation of both tails, although, the 
effect was stronger for Cyt1 than Cyt2 (figure 5.6B). Overall these results 
indicate that a lack of N-glycans on CD46 increases its cell surface 







Figure 5.6: The effect of the O- and N- glycosylation inhibitors on CD69 and 
cytoplasmic tail expression. (A) T cells were incubated overnight with the O-
glycosylation inhibitor (Benzyl-α-GalNAc) or the N-glycosylation inhibitor 
(tunicamycin), alongside their respective controls, and activated as indicated the 
following day.  After overnight stimulation CD69 expression was determined by 
flow cytometry (left panel is representative of 4 independent experiments, right 
panel is representative of 2 independent experiments). (B) Cyt1 and Cyt2 
expression was determined by flow cytometry. The percentage change (%Δ) in 
cyt1 and cyt2 downregulation in the presence of the N-glycosylation inhibitor 







TCR activation synergises with CD46 to promote its cleavage (Figure 5.2). and 
also induced the expression of a lower glycosylated variant of CD46 (figure 5.4). 
Glycosylation changes have been shown previously to alter the surface 
expression of other receptors (Tifft et al., 1992, Demetriou et al., 2001, Partridge 
et al., 2004, Lau et al., 2007, Chen et al., 2009, Grigorian et al., 2012). Thus, by 
decreasing the Mw of CD46, TCR activation may regulate CD46 cleavage and 
also its function. Therefore, as the O- and N-glycosylation inhibitors had 
contrasting roles on CD46 expression, it was also determined if the inhibitors 
altered CD46 induced cytokine secretion. T cells were treated with the O-
glycosylation inhibitor (1 mM and 3 mM) and were cultured for 5 days before 
collecting the supernatants to analyse IFNγ and IL-10 secretion by ELISA. The 
O-glycosylation inhibitor increased IFNγ secretion, in a dose dependent manner 
following both αCD3 and αCD3/CD46 stimulation. Upon calculation of the IL-
10:IFNγ ratio there was a dose dependent decrease in the ratio upon both αCD3 
and αCD3/CD46 stimulation compared to the controls (figure 5.7A). These 
results indicate that inhibition of O-glycosylation attenuates CD46 cell surface 
downregulation and that this correlates with a decreased ratio of IL-10:IFNγ.  
 
Neither IFNγ nor IL-10 could be detected by ELISA in the presence of the N-
glycosylation inhibitor (data not shown) because the inhibitor had significantly 
reduced the activation state of the T cells. In attempt to detect changes in cytokine 
secretion, an IFNγ and IL-10 secretion assay was used to detect cytokine 
secretion after overnight stimulation. A few cells secreted IFNγ but there was 
almost no detection of IL-10 (data not shown). This may be due to the sensitivity 
of the IL-10 secretion assay or that IL-10 is secreted at a later timepoint as 
previously described (Cardone et al., 2010). Although, there was minimal IFNγ 
secretion, only the cells that had downregulated CD46 were positive for IFN-γ 
(figure 5.7B). These data indicate that N-glycosylation is crucial to T cell 
activation.  However, these results also suggest the T cells that downregulate 
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CD46 are more activated than those that do not as these were the only cells that 
were positive for cytokine secretion, emphasising the importance of CD46 
downregulation during CD46 costimulation. 
 
Figure 5.7: The effect of the O- and N- glycosylation inhibitors on cytokine 
secretion upon CD46 costimulation. (A) CD4+ T cells were incubated 
overnight with the O-glycosylation inhibitor (1 mM or 3 mM), or methanol as a 
control, then stimulated as indicated for 5 days. The concentration of IFNγ and 
IL-10 were quantified by ELISA. (n=1) (B) CD4+ T cells were incubated overnight 
with an N-glycosylation inhibitor and stimulated overnight with αCD3 (CD3) or 
αCD3/CD46 (CD3/46). IFNγ secretion was detected using the Miltenyi secretion 




5.4.7 Specific! inhibition! of! CD46! glycosylation! differently! affects!
CD46!cell!surface!expression!in!CHO!cells!
Broad-spectrum inhibition of either N- or O-glycosylation strongly affected 
CD46 cell surface expression. However, broad-spectrum inhibitors may also 
affect the glycosylation of other proteins involved in regulating T cell activation 
that may have indirect effects on CD46 surface expression. As CD46 surface 
expression is inherently linked with regulating its function, ascertaining which 
glycans affect CD46 cell surface expression would indicate a potential role of the 
glycans in regulating CD46 function during T cell activation. Alterations in 
CD46’s glycosylation may possibly explain defective IL-10 secretion in patients 
with MS. Therefore mutant CD46 constructs were utilised to determine the 
specific effect of O- and N-glycosylation of CD46 on its cell surface expression. 
These constructs utilised the BC1 CD46 isoform as a template and were kindly 
provided by the Atkinson lab (Washington University, St. Louis, MO) (Maisner 
et al., 1996, Liszewski et al., 1998). CD46 contains multiple O-glycosylation sites 
and 3 N-glycosylation sites (figure 5.1). Specific mutations at these sites inhibited 
either N-glycosylation or O-glycosylation and therefore helped determine if N- or 
O-glycosylation of CD46 affected CD46 surface expression.  As the STP region 
contains numerous O-glycosylation sites a single mutant with the STP region 
deleted (ΔSTP) was used to assess the effect of O-glycosylation. Specific 
mutations of asparagine (N) to glutamine (Q) at each of the three N-glycosylation 
sites, in the SCR1, SCR2 and SCR4 regions, were performed, thereby inhibiting 
specific N-glycosylation. These CD46 mutants were called NQ1, NQ2 and NQ4 
respectively. A wild type BC1 CD46 isoform was used as a positive control. 
These constructs were expressed in CHO cells lines that did not express 
endogenous CD46 but had stable expression of each one of the mutants listed in 
table 5.1. A CHO cell line also expressed an unreadable reversed CD46 cDNA 
(BC1 (-)) and was utilised as a negative control (CHO cell lines were also 





Table 5.1: Control and mutant CD46 DNA constructs. 
 
Firstly, the Mw of the BC1 mutants was determined by SDS-PAGE to confirm 
that the mutations in CD46 resulted in a decreased Mw that reflected the absence 
of their specific glycans. The mobility of the wild-type BC1 was similar to that 
reported previously (~67 kDa) (Maisner et al., 1996, Liszewski et al., 1998). 
ΔSTP had the lowest Mw (~55 kDa as it lacks numerous O-glycans) and all three 
of the N- mutants had a decreased Mw, consistent with the loss of one glycan, 
(~62 kDa) (figure 5.8A). Therefore, the mutant CD46 CHO cells lines expressed 
lower Mw CD46 isoforms that reflected the inhibition of glycosylation at either a 
specific N-glycosylation site or the STP O-glycosylation region. 
 
The specific effects of the mutant CD46 variants on surface downregulation were 
investigated. As CHO cells do not express endogenous CD46, the effects of the 
glycan mutants could be easily determined. CHO cells expressing the different 
CD46 mutants were plated with either IgG1 or αCD46, and CD46 expression was 
observed by flow cytometry after 24 hrs of stimulation. Although, variable levels 
of CD46 expression were observed for each cell line, CD46 ligation induced a 
downregulation of CD46 expression in all conditions. However, the strongest 
downregulation was observed in the BC1, NQ1, NQ2 and NQ4 CHO cells. In 
contrast, ΔSTP attenuated CD46 downregulation (figure 5.8B) suggesting that O-
glycans were important for CD46 downregulation. Therefore, in CHO cells the 






Figure 5.8: Specific inhibition of CD46 glycosylation differently affects 
CD46 expression in CHO cells. (A) The Mw of CD46 in CHO cells expressing 
no CD46 (BC1 (-)), the BC1 isoform (BC1), or CD46 BC1 mutants with specific 
point mutations in SCR1 (NQ1), SCR2 (NQ2), SCR4 (NQ4) or an STP deletion 
(ΔSTP) were determined by SDS-PAGE (representative of 2 independent 
experiments). GAPDH was used as a loading control. (B) CHO cells expressing 
the mutants described in (A) were stimulated with plate bound IgG1 or αCD46 
(CD46) for 24 hrs. After overnight stimulation CD46 expression was analysed by 
flow cytometry (representative of 3 independent experiments).  
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5.4.8 Specific! inhibition! of! CD46! OLglycosylation! attenuates! CD46!
cell!surface!downregulation!in!T!cells!
The ∆STP mutant cell line attenuated CD46 downregulation in CHO cells. These 
results correlate with figure 5.5 which demonstrate that inhibiting O-
glycosylation in T cells attenuated CD46 downregulation. In order to determine if 
the specific inhibition of CD46 O-glycosylation also attenuated CD46 
downregulation in human T cells, T cells were transfected with the ∆STP 
plasmid, wild-type BC1 plasmid or a control vector only (CVO) plasmid, as a 
negative control. Then the cells were left unstimulated or activated with αCD3, 
αCD3/CD46 or αCD46. CD46 expression was analysed by flow cytometry after 
overnight stimulation. Upon CD46 costimulation there is a strong downregulation 
of surface CD46 in all conditions. However, upon transfection with the ∆STP 
plasmids there was a slight increase in CD46 expression compared to cells 
transfected with the BC1 or CVO plasmids. This increase was more pronounced 
in the absence of TCR stimulation. However, no increase in CD46 expression in 
the ∆STP transfected cells was observed when the cells were left unstimulated or 
activated with CD3 alone (figure 5.9A). These data suggest that ∆STP CD46 
attenuates CD46 downregulation in T cells.  
 
In Chapter 3, it was demonstrated that CD46 downregulation occurred as early as 
5 hrs post ligation and was most strongly downregulated after overnight 
stimulation. As only a small effect of the ∆STP plasmid was observed after 
overnight CD46 costimulation it was hypothesised that overnight stimulation may 
have been too late to observe a significant effect of the ∆STP plasmid. Therefore, 
T cells were transfected with the ∆STP plasmid and were stimulated for a period 
of 5 hrs.  Increasing doses of ∆STP (1 µg and 2 µg) were also used to maximise 
the transfection efficiency potential. Upon CD46 costimulation, a dose dependent 
increase in CD46 expression was observed compared to the control (figure 5.9B). 
These data confirm that ∆STP transfected T cells have increased expression of 




CD46 expression was also assessed by SDS-PAGE in an effort to distinguish 
mutant CD46 expression from endogenous CD46 and assess if increased CD46 
expression in the ∆STP transfected cells represented the mutant ∆STP CD46 or 
endogenous CD46. Detection of CD46 by SDS-PAGE demonstrated increased 
CD46 expression in ∆STP transfected cells compared to controls. This increase in 
CD46 expression may be due to a lower Mw band that reflected the size of the 
∆STP mutant, however this is difficult to confirm due to variations in protein 
concentration on the blot. (figure 5.9C). Overall, these data indicate that the 
∆STP mutant CD46 attenuates CD46 downregulation in human T cells. As the 
STP region is rich in O-glycans, these results suggest that O-glycosylation 




Figure 5.9: In CD4+ T cells, over expression of CD46, lacking the STP 
domain (ΔSTP) attenuates CD46 downregulation at the surface. (A) T cells 
were transfected with 1 µg of the control vector only (CVO) as a negative control 
(control), wild-type BC1 or the ΔSTP mutant. Cells were left unstimulated or 
stimulated with αCD3 (CD3), αCD3/CD46 (CD3/46) or αCD46 (CD46) alone. 
CD46 expression was determined by flow cytometry after overnight stimulation 
(representative of 5 independent experiments). (B) T cells were transfected with 
1 µg or 2 µg of the ΔSTP mutant cDNA and stimulated as indicated. CD46 
expression was determined by flow cytometry after 5 hrs of stimulation (n=1). (C) 
Cells were transfected and stimulated as in (B). After 5 days stimulation, CD46 
expression was determined by SDS-PAGE (n=1).  
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5.4.9 Transfection! of! T! cells!with! CD46! glycosylation!mutants! and!
its!effect!on!CD46!surface!expression!and!cytokine!secretion!
TCR activation promoted the expression of lower glycosylated forms of CD46 
and its surface downregulation. Inhibition of N-glycosylation in T cells using the 
inhibitor tunicamycin suggests that the absence of N-glycan(s) promotes the 
downregulation of surface CD46. In contrast the presence of O-glycosylation 
appears to promote downregulation. These data suggest that reduced levels of N-
glycans on CD46 could promote CD46 downregulation. The roles of N-glycans 
in regulating CD46 expression were therefore examined. T cells were transfected 
with the N-glycan mutants, NQ1, NQ2 and NQ4 alongside the wild-type BC1, 
the STP mutant and the negative CVO control. The cells were left unstimulated 
or activated with αCD3, αCD3/CD46 or αCD46 and CD46 cell surface 
expression was determined after overnight stimulation. No significant effects 
were observed in unstimulated or αCD3 stimulated cells (data not shown). Upon 
CD46 costimulation, both NQ1 and NQ4 had similar levels of CD46 expression 
as BC1. However, NQ2 showed an increase in CD46 expression (figure 5.10A 
and figure 5.10B). Of, note there was a large standard deviation in CD46 
expression for the STP mutant, this is likely due to variations in transfection 
efficiency or the fact that CD46 expression was determined after overnight 
stimulation and not after 5 hours activation, which may be a more sensitive 
timepoint. Therefore, these results suggest that NQ2 could attenuate CD46 
downregulation, and suggests that the N-glycan at the SCR2 domain may aid 
CD46 downregulation. The absence of glycans at SCR1 and SCR4 appear to play 
no significant role or may in fact reflect glycans that are removed upon TCR 
activation.  
 
Downregulation of cell surface CD46, particularly the Cyt1 isoform, as a result of 
proteolysis plays an important role in regulating CD46 activation. As both the N-
glycans and O-glycans appear to regulate cell surface CD46 expression, their 
effect on CD46 function was also assessed. T cells were transfected with the 
mutant plasmids as described above and were activated with αCD3/CD46. After 5 
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days stimulation, the concentration of IL-10 and IFNγ was determined by an IL-
10 or IFNγ specific ELISA assay, respectively. Of note, in some conditions there 
was a large standard error mean which is likely due to differences in individual 
donor responses and may also be the result of differences in transfection 
efficiency. Over expression of CD46 mutants inhibiting N-glycosylation 
generally show a trend of increased IL-10 and IFNγ secretion compared to BC1. 
This is in contrast to the ∆STP mutant that tends to decrease IL-10 but not IFNγ 
(figure 5.10B(i) and (ii)). The ratio of IL-10:IFNγ was also determined (figure 
5.10B(iii)). ∆STP showed a decreasing trend in IL-10:IFNγ compared to BC1. 
The mutants with higher levels of CD46 surface expression, NQ2 and ∆STP, also 
appeared to have slightly lower ratios of IL-10:IFNγ secretion and NQ1 and 
NQ4, which had the lowest CD46 expression of the mutants had the highest ratio 
of IL-10:IFNγ secretion (figure 5.10). These data suggest that CD46 glycans 
could regulate CD46 surface expression and that this may be associated with the 
phenotype of cytokine secretion. Alterations in proliferation were also determined 
by [3H] thymidine incorporation at day 3. The N-glycan mutants NQ1 and NQ2 
showed a trend of increased proliferation compared to BC1, however the O-
glycan mutant ∆STP inhibited proliferation (figure 5.10B(iv)). Therefore, 
different glycosylation states may also affect T cell proliferation. Most notably, 
expression of ∆STP CD46 that was shown to attenuate CD46 downregulation in 
some donors also attenuated T cell proliferation. The variation of results may 
reflect differences in transfection efficiency. Therefore, the glycosylation of 
CD46 in T cells affects surface expression of CD46 and this may correlate with 
its function. Further experiments examining the role of CD46 glycosylation in 
regulating cytokine secretion are required to confirm a direct link between CD46 




Figure 5.10: Transfection of T cells with CD46 glycosylation mutants and 
their effect on CD46 surface expression and cytokine secretion. T cells 
were transfected with an empty plasmid (CVO), the BC1 isoform (BC1) or a 
mutant BC1 isoform. Then, T cells were left unstimulated or stimulated with 
αCD3/CD46. (A) CD46 expression was determined by flow cytometry after 
overnight stimulation. (i) CD46 expression (blue) overlaid with the BC1 control 
(tinted grey) (ii) Mean CD46 surface expression upon αCD3/CD46 stimulation 
(n=5). (B) After 5 days αCD3/CD46 stimulation, the concentration of IL-10 and 
IFNγ were assessed by ELISA (i and ii) and the ratio of IL-10:IFNγ was 
calculated (iii). Proliferation was determined after 3 days stimulation using 





TCR induced changes in CD46 proteolysis and glycosylation 
TCR activation regulates CD46 surface expression by promoting its 
downregulation and proteolytic release of sCD46 (figure 5.2). TCR induced 
shedding has been previously described for the ITIM receptor CD31 (Fornasa et 
al., 2010). We have shown previously that cleavage of Cyt1 facilitates T cell 
activation (Chapter 4). TCR activation also induces a dose dependent decrease in 
the Mw of CD46 that is also observed upon CD46 and CD28 costimulation, but 
not upon CD46 ligation alone demonstrating that TCR engagement induces a 
decrease in CD46 Mw (figure 5.3). Indeed, preliminary data indicate that 
PMA/ionomycin treatment can also induce a decrease in the Mw of CD46 (data 
not shown) suggesting that a decrease in CD46’s Mw may be inherently linked to 
T cell activation. The decrease observed in CD46’s Mw is the result of a reduction 
in CD46 glycosylation (figure 5.4). Three possible scenarios could explain the 
expression of a lower Mw CD46; (i) TCR signalling induces the expression of 
newly synthesised CD46 with a decreased glycosylation state, (ii) there is a 
readily available pool of CD46 with a lower Mw that is inaccessible to antibody 
detection in unstimulated cells but is accessible upon activation or (iii) 
deglycosylation of pre-existing CD46 occurs at the cell surface/within endosomes 
upon activation. 
 
In the first scenario, expression of lower glycosylated forms of CD46 would also 
involve a rapid degradation of the higher glycosylated isoforms from the surface 
as the mobility of CD46 on SDS-PAGE is not observed as a blur but rather as a 
clean shift in Mw (figure 5.3). This scenario is possible with respect to rapid new 
protein synthesis as mature protein expression has been reported to occur in 90 
min in a monocyte cell line (Ballard et al., 1988). Nonetheless, such a rapid 
turnover seems unlikely considering the energy required and inefficiency of a 
complete change of protein expression within the cell. Scenario (ii) would 
involve the presence of a pre-existing pool of CD46 with a lower Mw that is 
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recruited to the surface upon activation. However, as a lower Mw CD46 is not 
observed in unstimulated cells this scenario would indicate that the pool was 
resistant to lysis buffer used in these experiments. CD46 may for example be 
located in multivesicular bodies and be rapidly sent to the surface for cleavage 
and downregulation. Indeed, it has long been known that cross-linking of 
receptors has the capacity to divert receptors away from cell surface recycling to 
the lysosomes for degradation (Mellman, 1996). However, lysis buffers similar to 
the one used in this study have been reported to readily lyse endosomal vesicles 
including multivesicular bodies (German and Howe, 2009) suggesting that this 
scenario is also unlikely. Scenario (iii) would involve deglycosylation of existing 
CD46 directly at the surface or intracellularly after endocytosis and seems more 
probable. Sialidase, which removes the sugar sialic acid from N- and O-glycans, 
is present at the surface membrane and in recycling endosomes (Zanchetti et al., 
2007). Moreover, upon CD46 ligation, CD46 has been shown to translocate to 
lipid rafts (Ludford-Menting et al., 2011) where sialidases reside (Kalka et al., 
2001).  Furthermore, upon TCR ligation there is an upregulation of the sialidases, 
NEU1 and NEU3, in T cells (Wang et al., 2004, Nan et al., 2007). Therefore, it is 
possible that sialic acid from N- and/or O-glycans is removed upon T cell 
activation. However, deglycosylation is not limited to the removal of sialic acid. 
PNGase, that cleaves N-glycans, is also known to exist in mammalian cells 
(Suzuki et al., 1993) and can act to deglycosylate specific N-glycans (Suzuki et 
al., 1997). Removal of TCR and MHC class I N-glycans have also been reported 
to occur in the cytosol (Wiertz et al., 1996, Huppa and Ploegh, 1997) and in the 
endosomal/lysosomal pathway (Schmitt and Grand-Perret, 1999). Using the drug 
chloroquine in Chapter 3, it was determined that CD46 downregulation involved 
the endosomal pathway. Therefore, decreases in the Mw of CD46 could occur 
after downregulation into the endosomal pathway.  Further experiments would be 
required to determine which of these scenarios is correct. 
 
The determination of the exact changes in CD46 glycosylation upon T cell 
activation would require complex mass spectrometry studies that were outside the 
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timeframe of this project. However, from these experiments it can be noted that 
the observed decrease in glycosylation upon activation is ~2 kDa (figure 5.3) and 
this decrease could potentially correspond to the removal of a N-glycan which is 
reported to be of similar Mw (Ballard et al., 1988) or trimming of decorating 
sugars that are attached to N- or O-glycans, such as sialic acid. Importantly, lower 
levels of both N- and O-glycosylation have been previously implicated in the 
decrease of cell surface protein expression due to endocytosis and proteolytic 
cleavage (Lau et al., 2007, Van den Steen et al., 1998, Rudd et al., 1999).  In 
accordance with the literature increased cleavage of CD46 as a result of TCR 
stimulation is demonstrated in figure 5.2. These results suggest that TCR induced 
CD46 cleavage and deglycosylation are inherently linked. A potential model that 
encompasses TCR induced deglycosylation and cleavage is depicted in figure 
5.11. In this model, TCR activation (1) decreases glycosylation of CD46 either 
through deglycosylation or the expression of newly recruited CD46 with a lower 
level of glycosylation (2). Lower Mw CD46 is more susceptible to cleavage and 
results in the release of the sCD46 domain and ICDs (3).  
 






The role of glycosylation in CD46 downregulation  
The specific role of both N- and O-glycans in CD46 downregulation and function 
was examined using N- and O- glycosylation inhibitors and then by expressing 
mutant CD46 in CHO cells and T cells. These CD46 variants inhibited specific 
N-glycan attachment to CD46 using point mutations in the N-glycosylation sites 
or inhibited O-glycosylation by removing the STP region. 
 
!O-glycans 
Both the inhibition of O-glycosylation (figure 5.5) and the expression of ∆STP 
CD46 in CHO and T cells attenuated CD46 downregulation (figure 5.8 and figure 
5.9). Indeed attenuation of CD46 downregulation was dose-dependent in T cells 
and was also observed upon CD46 ligation alone (figure 5.9).  Therefore, O-
glycosylation facilitates CD46 downregulation at the surface. Previous reports 
have shown that O-glycans provide protein rigidity or extension that protect 
against protease degradation (Reddy et al., 1989, Van den Steen et al., 1998) but 
in our system removal of the STP domain, and O-glycans, actually attenuated 
CD46 downregulation. Indeed, O-glycosylation can have varied effects 
depending on the receptor involved. CD44 is a transmembrane glycoprotein that 
binds hyaluronic acid (HA), which is involved in lymphocyte activation and the 
migration of cells (Gasbarri et al., 2003). Similar to CD46, CD44 also undergoes 
cell activation induced proteolytic cleavage. Importantly, PMA treatment induced 
proteolysis of a heavily O-glycosylated variant of CD44 in an O-glycan 
dependent fashion (Gasbarri et al., 2003). This report supports the role of CD46 
O-glycans in facilitating TCR induced proteolysis. 
!
 N-glycans 
Treatment of T cells with the N-glycosylation inhibitor, tunicamycin, suggests 
that N-deglycosylation of CD46 promotes its downregulation. Although, 
inhibition of N-glycosylation induced a slight decrease in CD46 in all conditions, 
there was a stronger decrease upon CD46 costimulation. The small decrease 
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observed is likely due to decreased protein stability and subsequent degradation, 
as previously reported (Maisner and Herrler, 1995). CD46 downregulation 
occurred at the surface and intracellularly after 24 hrs indicating that 
downregulation does not result in accumulation of CD46 intracellularly and may 
be the result of increased proteolytic cleavage (figure 5.5B). This does not 
however, exclude the possibility that CD46 is degraded upon internalization. In 
an attempt to examine this possibility, CD46 surface expression was determined 
at the surface and intracellularly at an early timepoint of 5 hrs. However no effect 
of tunicamycin was observed at this timepoint upon CD46 co-stimulation (data 
not shown). This may be due to insufficient time for new protein synthesis 
lacking N-glycans and/or the time taken for these proteins to repopulate the 
surface. Indeed, this also argues against the scenario (i) of deglycosylation 
previously discussed, where upon TCR activation there is rapid de novo protein 
synthesis and a complete protein turnover of lower glycosylated forms of CD46.   
!
It is generally accepted that broad-spectrum inhibitors can have varying effects on 
protein expression and function. Therefore, in order to eliminate unspecific 
effects of the inhibitors in the analysis of CD46 N-glycosylation, CD46 mutants 
were utilised. Specifically, site-specific mutations were carried out at the 3 N-
glycosylation sites of the BC1 isoform. These mutants, NQ1, NQ2 and NQ4 were 
stably expressed in CHO cells (Maisner et al., 1996, Liszewski et al., 1998). 
Upon CD46 ligation, all of the N-glycan mutants induced downregulation of cell 
surface CD46 (figure 5.8). After transfection of these mutants into human T cells, 
BC1, NQ1 and NQ4 transfected cells showed the strongest levels of 
downregulation (figure 5.10). Of note, transfection of T cells with the NQ2 
mutant induced a small increase in CD46 expression compared to controls. 
Attenuation of CD46 downregulation in the NQ2 mutants suggests that N-
glycosylation at SCR2 promotes CD46 downregulation. Interestingly, the SCR2 
N-glycan is essential for measles virus infection (Maisner et al., 1996). Measles 
virus induces downregulation and internalisation of CD46 (Naniche et al., 1993) 
and can activate T cells via CD46 (Marie et al., 2002). Whether binding of 
measles virus induces shedding has not been addressed. However, binding of 
Chapter!5!
! 155!
measles virus to CD46 alters its conformation from bent to straight (Santiago et 
al., Persson et al., 2010) and N-glycosylation at SCR2 is believed to support the 
conformation required for measles virus ligation (Maisner et al., 1994, Maisner et 
al., 1996).  This change in conformation may play a role in its downregulation 
and increase accessibility of proteases that cleave CD46.  
 
As neither O-glycans nor the SCR2 N-glycan promote CD46 cleavage upon 
costimulation, the question of what glycans are removed/trimmed upon TCR 
ligation needs to be addressed. Neither the N-glycan on SCR1 or SCR4 had a 
considerable effect on CD46 expression compared to the BC1 control. However, 
it is worth highlighting that the expression of the BC1 wild type protein in T cells 
should, in theory, undergo deglycosylation similarly to endogenous CD46 upon 
activation. Therefore, if endogenous BC1 undergoes deglycosylation at SCR1 
and/or SCR4 upon activation, CD46 expression levels observed would be similar 
to that of the mutants with a fixed deglycosylation state (i.e. the NQ1 and NQ4 
mutants). Therefore, N-glycan mutants NQ1 and NQ4 may reflect native 
deglycosylation of the BC1 isoform upon T cell activation. In accordance with 
this hypothesis, treatment of T cells with the N-glycosylation inhibitor, 
tunicamycin, resulted in decreased CD46 expression (figure 5.5), suggesting that 
deglycosylation of N-glycans, namely N-glycans at SCR1 and/or SCR4, may play 
a role in promoting CD46 downregulation. It was shown in figure 5.2 that the 
TCR synergises with CD46 to increase cleavage and deglycosylation. It is 
therefore proposed that the downregulation of cell surface CD46 observed upon 
N-glycosylation inhibition with tunicamycin and the expression of mutant N-
glycan CD46 variants is at least partially the result of cleavage. Proteolytic 
cleavage of low-density lipoprotein (Kozarsky et al., 1988) and APP (Galbete et 
al., 2000) are also regulated by their glycosylation and suggest that glycosylation 
of CD46 could play a direct role in its proteolysis. Nonetheless, further 
experiments are required to confirm if decreases in CD46 glycosylation at the 




Glycosylation and CD46 function 
Chapter 3 demonstrated that the cleavage of CD46 is important for its function in 
activation. Therefore, given that changes in glycosylation have differential effects 
on CD46 expression it is highly suggestive of a role for CD46 glycans in CD46 
function in T cell activation. 
 
 The function of CD46’s O-glycans 
The removal of the STP attenuated downregulation of CD46 in T cells (figure 5.9 
and figure 5.10) and appeared to decrease T cell proliferation and the ratio of IL-
10:IFNγ (figure 5.10). Although the removal of the STP region is a blunt tool for 
inhibiting O-glycosylation, broad-spectrum O-glycosylation inhibition suggests 
that O-glycosylation itself is required for CD46 downregulation (figure 5.5). 
Moreover, the O-glycosylation inhibitor also attenuated the IL-10:IFNγ ratio 
(figure 5.7). Thus, removal of O-glycans attenuate CD46 cell surface 
downregulation resulting in decreased T cell proliferation and IL-10:IFNγ 
secretion. Therefore CD46’s O-glycans may be important for promoting CD46 
induced regulatory T cells.  
 
The mechanism of O-glycan support for CD46 downregulation and function 
remains to be determined. Using crystallography studies, it has been previously 
reported that STP splicing and O-glycosylation could affect the conformation of 
CD46 and the subsequent strength of ligand binding (Persson et al., 2010). 
Therefore, upon stimulation, CD46 O-glycans in the STP region may provide 
conformational support for ligand binding facilitating subsequent 
downregulation. The importance of O-glycans for CD46’s function has been 
previously reported for complement inactivation and pathogen binding 
(Liszewski and Atkinson, 1996, Kurita et al., 1995, Liszewski et al., 1998). The 
splicing of the STP region is inherently linked to the level of CD46’s O-
glycosylation.  CD46 isoforms that contain all 3 exons of the STP region, ABC 
have 18 O-glycosylation sites, whereas CD46 isoforms that consist of the C exon 
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only have 2 O-glycosylation sites (http://www.uniprot.org/uniprot/P15529, 
accessed 09/02/12). Cell and tissue specific expression of STP isoforms suggests 
a biological significance. For example, STPABC that is less commonly expressed 
but has increased expression in intestinal epithelial cell lines (Xing et al., 1994). 
Cardone et al have demonstrated that CD46 activation in epithelial cells 
promoted proliferation and wound repair upon bacterial infection (Cardone et al., 
2011). It was demonstrated in Chapter 4 that Cyt1 facilitates T cell activation, as 
measured by CD25 expression and proliferation. Therefore, increased O-
glycosylation of CD46 in intestinal cells could also help promote CD46 cleavage 
and promote proliferation in the intestine. Higher O-glycosylated forms of CD46 
(56-80 kDa) are also expressed in granulocytes conferring them with stronger co-
factor I mediated cleavage of C3/C4 components (Seya et al., 1988, Kurita et al., 
1995).  Therefore O-glycans likely play various roles in CD46 function. 
Moreover, if O-glycans promote proteolysis of CD46 in T cells it is likely that 
they may also regulate CD46 processing in other cells types, emphasising the 
need for further investigation in this area. 
 
!The function of CD46’s N-glycans 
Despite several isoforms of CD46, it is worth taking note that N-glycosylation 
sites at SCR2 and SCR4 are conserved across humans, several old world 
monkeys and new world monkeys.  Both humans and old world monkeys also 
retain the SCR1 glycan site (Hsu et al., 1997). This evolutionary conservation of 
N-glycan sites in CD46 emphasises their importance to its function. Upon CD46 
costimulation, CD46 is cleaved at the surface by MMP/ADAM(s) and 
intracellularly by PγS, releasing functional ICD. Chapter 3 proposes a model in 
which Cyt1 is cleaved early during T cell activation, facilitating T cell activation 
and cleavage of Cyt2 followed at a later time point and may promote T cell 
shutdown (Chapter 4 and (Ni Choileain et al., 2011)). Indeed, upon the addition 
of the N-glycosylation inhibitor, CD46 surface downregulation is promoted and 
correlated with a strong downregulation of Cyt1 but not Cyt2 (figure 5.6). 
Although, tunicamycin suppresses normal T cell activation, it is worth noting that 
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the cells with strong CD46 downregulation increase CD69 expression and 
cytokine secretion compared to cells that retain CD46 expression (figure 5.6 and 
figure 5.7).  This data supports the role of CD46 downregulation, specifically 
Cyt1, in promoting T cell activation.  
 
In assessing N-glycan function using the mutant CD46 isoforms, all three N-
glycan mutants showed a general trend for increased proliferation, IL-10 and 
IFNγ secretion compared to BC1. However, there are variations in the extent to 
which each mutant increases IL-10 and IFNγ secretion which gives rise to 
different ratios of IL-10:IFNγ (figure 5.10). Of note, there is a resemblance 
between the pattern of CD46 surface expression in the mutants and their IL-
10:IFNγ secretion profile. Increased CD46 expression appears to inversely 
correlate with decreased IL-10:IFNγ (i.e. STP and NQ2). Conversely, stronger 
downregulation of surface CD46 expression in the mutant plasmids correlates 
with an increased IL-10:IFNγ ratio (i.e. NQ1 and NQ4) (figure 5.10). In 
summary, these data suggest that deglycosylation of CD46; at different 
glycosylation sites may alter its expression levels and its cytokine secretion 







• The! ΔSTP! and! NQ2! mutants! attenuate! CD46! surface!
downregulation. !
• T cells transfected with the NQ1 and NQ4 mutants had a similar level 
of CD46 cell surface downregulation as wild-type BC1 transfected T 
cells.!
• NJdeglycosylation! at! different! NJglycan! sites! of! CD46!may! affect!
the!ILJ10:IFNγ!ratio!secretion!profile!upon!CD46!costimulation.!
• OJdeglycosylation!and!ΔSTP!transfection!of!T!cells!shows!a!trend!











As previously discussed, CD46 induced IL-10 secretion by T cells is 
dysfunctional in MS patients (Astier et al., 2006, Martinez-Forero et al., 2008, 
Ma et al., 2009). Moreover, CD46 dysfunction is not limited to MS and is also 
present in asthma (Xu et al., 2010, Tsai et al., 2012) and rheumatoid arthritis 
(Cardone et al., 2010) suggesting a more widespread role of CD46 in immune 
regulation. Understanding the mechanism of CD46 costimulation in healthy 
controls is key to understanding its dysregulation in MS patients and other 
pathologies. 
 
In Chapter 3, regulated expression of surface CD46 and the Cyt1 and Cyt2 
isoforms was described. Importantly, upon CD46 costimulation CD46 was 
proteolytically cleaved at the surface by MMP/ADAM(s) and intracellularly by 
PγS. The cleavage of Cyt1 and Cyt2 correlated with a time-dependent 
downregulation of expression. The cleavage of Cyt1 and possibly Cyt2 was 
important for their function in regulating T cell activation. (Chapter 4) (Ni 
Choileain et al., 2011). Moreover, it was also found that a decrease in CD46 
glycosylation occurred upon T cell activation and could play a role in regulating 
CD46’s expression and function (Chapter 5).  These novel data have helped shed 
light on how CD46 expression and processing regulates cytokine secretion by T 
cells from healthy controls.  Importantly, these new findings can now be used to 
investigate the pathways that are dysregulated in CD46 activated T cells from MS 
patients, which could explain why there is little or no IL-10 secretion in CD46 




In order to determine why CD46 function is dysregulated in T cells from 
relapsing-remitting MS (RRMS) patients, the expression levels of surface CD46 
and intracellular Cyt1 and Cyt2 were first assessed. Herein, the dysregulated 
expression of CD46 by T cells from MS patients is reported. Specifically it is 
shown that upon CD46 costimulation there was no downregulation of Cyt1 or 
Cyt2 in MS patients, irrespective of interferon-β (IFNβ) treatment. Secondly, 
preliminary studies also suggest that T cells from RRMS patients have aberrant 
levels of CD46 glycosylation upon activation compared to healthy controls. 
Based on these results, it is hypothesised that dysregulated CD46 expression 
and/or glycosylation may disrupt CD46 processing, which is important for CD46-
induced IL-10 secretion. 
 
6.2 Aims!
1. To determine CD46 cell surface expression by CD4+ T cells from RRMS 
patients. 
2. To examine the expression of the Cyt1 and Cyt2 isoforms in CD4+ T cells 
from RRMS patients. 
3. To assess the Mw of CD46 in unstimulated and activated CD4+ T cells 











In order to determine if dysregulated CD46 expression played a role in reducing 
IL-10 secretion in RRMS patients, the findings observed in Chapter 3 and 
Chapter 5 regarding CD46 expression levels and glycosylation during T cell 
activation were examined in a cohort of RRMS patients. These findings were 
compared to healthy controls in order to assess if there was defective expression 
or glycosylation of CD46 in patients. 
 
Firstly, the expression levels of cell surface CD46 in CD4+ T cells from RRMS 
patients were compared to controls. Similar to the experiments carried out using 
healthy control donors in Chapter 3, cell surface CD46 expression on CD4+ T 
cells was determined throughout a five-day period. T cells were either left 
unstimulated or stimulated with αCD3, αCD3/CD46 or αCD3/CD28. Expression 
levels were then assessed at an early timepoint (day 1 or day 2) and a later 
timepoint (day 4 or day 5) and the results were compared with those obtained for 
healthy controls in Chapter 3.  Due to limited numbers of patient donors, the MS 
cohort consisted of those who were both untreated and IFNβ treated at the time of 
donation. However, in an attempt to determine if treatment affected CD46 cell 
surface expression (despite low numbers), the patient cohort was also split into 
two groups (treated and untreated) and these results were compared to CD46 
expression levels in healthy controls. In addition to cell surface CD46 expression, 
Cyt1 and Cyt2 expression were also assessed in RRMS patients at both the early 
and late timepoint. Expression levels of Cyt1 and Cyt2 were first compared 
between healthy donors and patients with MS (untreated and treated).  Then, 
expression levels were compared between healthy donors, untreated patients and 
treated patients.  
 
In Chapter 5, glycosylation was shown to play a potential role in regulating 
CD46’s function. Therefore, preliminary experiments were also performed to 
explore the possibility that differences in glycosylation could be responsible for 
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the dysregulated IL-10 secretion in MS patients. Therefore the Mw of CD46 upon 
activation was examined in T cells from a small group of MS patients. 
 
6.4 Results!
6.4.1 Cell! surface! CD46! expression! is! downregulated! upon! CD46!
costimulation!in!CD4+!T!cells!from!patients!with!MS!
As downregulation and cleavage of CD46 is important for its function in CD46 
costimulated cells, cell surface CD46 downregulation was assessed in CD4+ T 
cells isolated from MS patients. T cells were left unstimulated or activated with 
αCD3 or αCD3/CD46 and CD46 expression was determined by flow cytometry at 
either an early activation timepoint  (after 1-2 days stimulation) or a late 
activation timepoint (after 4-5 days stimulation). These results were then 
compared to those described in Chapter 3 for healthy controls, where CD46 
expression was determined under comparable conditions. At both timepoints, 
upon CD46 costimulation, T cells from MS patients, downregulated CD46 cell 
surface expression compared to unstimulated and CD3 activated T cells. These 
findings were similar to that observed in healthy controls. However, at the later 
timepoint, αCD3 activated T cells from MS patients showed an increased CD46 
expression compared to healthy controls (figure 6.1). Thus, despite the initial 
downregulation of CD46 at the earlier timepoints, T cells from MS patients 
exhibit increased expression of CD46 at the later timepoint in CD3 activated T 
cells.  Overall this suggests that dysregulated CD46 expression may be present in 




Figure 6.1: CD46 is downregulated upon CD46 costimulation in CD4+ T 
cells from MS patients. T cells from MS patients were left unstimulated or 
activated in the presence of αCD3 alone or in the presence of αCD46. Cell 
surface CD46 expression was determined by flow cytometry at an early 
activation (1-2 days stimulation) or late activation (4-5 days stimulation) 
timepoint. Normalised mean fluorescence intensity (NMFI) was calculated. For 
comparison MS CD46 expression (grey) is presented alongside expression 
levels previously obtained for healthy controls (white) under similar conditions 
(Chapter 3). (Left Panel) CD46 expression during early activation (healthy 
controls (HC) n=25, MS patients n=21) (Right Panel). CD46 expression during 
late activation (HC n=18, MS patients n=15). A Friedman Test and Bonferroni-
corrected Wilcoxon test was used for statistical analysis within the same donors, 
A Kruskal-Wallis Bonferroni-corrected Mann-Whitney test was used for statistical 






Anti-CD3 activation of CD4+ T cells from MS patients suggested that there was 
increased expression of cell surface CD46 surface compared to healthy controls 
(figure 6.1). It is possible that this dysregulated expression of CD46 could play a 
role in attenuating IL-10 secretion upon CD46 costimulation in MS patients. 
Dysregulated CD46 expression in activated T cells prior to CD46 ligation could 
also modify CD46 function. Thus, cell surface CD46 expression was also 
determined upon CD28 costimulation in order to elucidate if activated T cells 
from MS patients could have altered expression of CD46. CD4+ T cells were left 
unstimulated or activated with αCD3 or αCD3/CD28. CD46 expression was then 
determined by flow cytometry at either an early activation timepoint or a late 
activation timepoint. Upon CD28 costimulation, T cells from MS patients and 
healthy controls appeared to have similar levels of CD46 expression at the early 
timepoint. However, upon CD28 costimulation at the later timepoint, MS patients 
had increased trend of CD46 compared to T cells from healthy controls (figure 
6.2). Therefore, CD46 cell surface expression may be dysregulated in CD28 
costimulated T cells from MS patients and could participate in altered CD46 





Figure 6.2: CD46 expression upon CD28 costimulation in T cells from MS 
patients compared to healthy controls. T cells from MS patients were left 
unstimulated or activated in the presence of αCD3 alone or in the presence of 
αCD28. Surface CD46 expression was determined by flow cytometry during 
early activation (1-2 days stimulation) or late activation (4-5 days stimulation) 
and the normalised mean fluorescence intensity (NMFI) was calculated. For 
comparison, MS CD46 expression (grey) is presented alongside expression 
levels previously obtained for healthy controls (white) under similar conditions 
(Chapter 3). (Left Panel) CD46 expression during early activation, (HC n=25, 
MS patients n=21). (Right Panel) CD46 expression during late activation, (HC 
n=18, MS patients n=16). A Friedman Test and Bonferroni-corrected Wilcoxon 
test was used for statistical analysis within the same donors, A Kruskal-Wallis 
Bonferroni-corrected Mann-Whitney test was used for statistical analysis 




In order to determine any potential effect of IFNβ treatment on CD46 expression 
in T cells from MS patients, CD46 expression levels in untreated and treated 
groups were compared separately to the expression levels previously observed for 
healthy controls. At the time of blood donation the treated group were receiving 
IFNβ treatment and the untreated group were not receiving any disease modifying 
drugs. At the early activation timepoint untreated patients tend to have lower 
levels of CD46 expression in all conditions compared to healthy controls, 
although this observation was not significant. In contrast, patients receiving IFNβ 
treatment appear to have higher expression levels compared to healthy controls 
(figure 6.3). At the later timepoint, CD4+ T cells from MS patients, irrespective of 
treatment, appear to have increased levels of CD46 upon CD28 costimulation, 
compared to T cells from healthy controls. (figure 6.3). As the numbers within 
untreated and treated groups are low, these data are preliminary only. Despite 
this, however, these data suggest that CD46 expression could inherently defective 




Figure 6.3: CD46 expression levels in treated and untreated MS patients. 
CD46 expression was determined by flow cytometry upon activation, as 
indicated, in healthy controls (HC), untreated MS patients and IFNβ treated MS 
patients and normalised mean fluorescence intensity (NMFI) was calculated. 
(Top Panel) CD46 expression during early activation, (HC n=27, untreated MS 
patients n=8, treated MS patients n=13). (Bottom Panel) CD46 expression 
during late activation, (HC n=18, untreated MS patients n=7, treated MS patients 
n=9). A Kruskal-Wallis Bonferroni-corrected Mann-Whitney test was used for 
statistical analysis between HC and MS cohorts, *p≤0.01. 
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6.4.4 !Cyt1!and!Cyt2!expression! levels!upon!CD46!costimulation! in!
MS!patients!
As downregulation and cleavage of Cyt1 and potentially Cyt2 is important for 
their function in CD46 costimulated cells (Chapter 3), this downregulation was 
assessed in CD4+ T cells from MS patients. As with T cells from healthy donors, 
T cells from MS patients were either left unstimulated or activated with αCD3 or 
αCD3/CD46. The expression of Cyt1 and Cyt2 were then determined at an early 
activation timepoint and a late activation timepoint. As previously described, 
upon CD46 costimulation in healthy controls Cyt1 was downregulated at the 
early timepoint; however, this downregulation was not observed in MS patients 
(boxed, figure 6.4). These data could suggest that the expression of Cyt1 and its 
downregulation is dysfunctional in MS patients. In healthy controls, upon CD46 
costimulation, Cyt2 expression was also downregulated at the late timepoint.  
However, upon CD46 costimulation of T cells from MS patients, there was no 
downregulation of Cyt2 (boxed, figure 6.4).  Overall, therefore these data suggest 
that the downregulation of Cyt1 and Cyt2 may be defective in T cells from MS 
patients. Determining why there is no downregulation of either Cyt1 or Cyt2 
upon CD46 costimulation in T cells from MS patients could shed light on the 
mechanism behind defective IL-10 production in MS patients. However, further 
experiments are required to confirm that the downregulation of Cyt1 and Cyt2 is 




Figure 6.4: Cyt1 and Cyt2 expression levels upon CD46 costimulation in 
MS patients. T cells from MS patients were left unstimulated or activated in the 
presence of αCD3 alone or in the presence of αCD46. Cyt1 and Cyt2 expression 
were determined by flow cytometry during early activation (1-2 days stimulation) 
or late activation (4-5 days stimulation), normalised mean fluorescence intensity 
(NMFI) was calculated. For comparison MS CD46 expression (grey) is presented 
alongside expression levels previously obtained for healthy controls (HC) (white) 
under similar conditions (Chapter 3). (Left Panes) Cyt1 and Cyt2 expression 
during early activation (HC n=40, MS (treated and untreated) n = 17). (Right 
Panel) Cyt1 and Cyt2 expression during late activation (HC n=29, MS (treated 
and untreated) n = 12). A Friedman Test and Bonferroni-corrected Wilcoxon test 
was used for statistical analysis within the same donors, A Kruskal-Wallis 
Bonferroni-corrected Mann-Whitney test was used for statistical analysis 
between HC and MS cohorts, *** p≤0.0003 **p≤0.003, *p≤0.0167. 
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6.4.5 Cyt1! and! Cyt2! expression! upon! CD28! costimulation! in! MS!
patients!and!healthy!controls!
Surface expression of CD46 had an increased trend upon CD28 costimulation in 
MS patients compared to healthy controls, indicating that CD46 expression may 
be dysregulated in activated T cells from these patients. Similar to healthy 
controls, Cyt1 and Cyt2 expression were also analysed upon CD28 costimulation. 
T cells from MS patients (untreated and IFNβ treated) were left unstimulated or 
activated with αCD3 or αCD3/CD28 and Cyt1 and Cyt2 expression levels were 
determined at the early activation timepoint or the late activation timepoint.  
Upon CD28 costimulation, at the early and late timepoint, there was no 
significant difference in Cyt1 or Cyt2 expression in patients compared to healthy 
control (figure 6.5). Of note, upon CD28 costimulation there appeared to be no 
trend towards Cyt2 downregulation (figure 6.5). This could correlate with the 
failure in MS patients to downregulate Cyt2 upon CD46 costimulation. Thus, 
these data suggest that failed downregulation of Cyt2 expression in MS patients 
may not be limited to CD46 costimulation. Further experiments will be required 
to examine why Cyt1 and Cyt2 are not downregulated in MS patients as it may 




Figure 6.5: Cyt1 and Cyt2 expression upon CD28 costimulation in CD4+ T 
cells from MS patients and healthy controls. T cells from MS patients were 
left unstimulated or activated in the presence of αCD3 alone or in the presence 
of αCD28. Cyt1 and Cyt2 expression were then determined by flow cytometry at 
the early activation (1-2 days stimulation) or late activation (4-5 days stimulation) 
timepoint and the normalised mean fluorescence intensity (NMFI) was 
calculated. As a control, MS CD46 expression (grey) is presented alongside 
expression levels previously obtained for healthy controls (white) under similar 
conditions (Chapter 3). (Left Panel) Cyt1 and Cyt2 expression during early 
activation, (HC n=40, MS (treated and untreated) n=17). (Right Panel) Cyt1 and 
Cyt2 expression during late activation, (HC n=29, MS n=12). A Friedman Test 
and Bonferroni-corrected Wilcoxon test was used for statistical analysis within 
the same donors, A Kruskal-Wallis Bonferroni-corrected Mann-Whitney test was 




6.4.6 Normalised! Cyt1! and! Cyt2! expression! in! IFNβLtreated! and!
untreated!MS!patients!!
The percentage increase in expression of Cyt1 and Cyt2 compared to 
unstimulated T cells was also calculated to assess any relative changes in Cyt1 
and Cyt2 expression upon CD46 or CD28 T cell costimulation in healthy control, 
untreated MS patients and IFNβ treated patients. Of note, in contrast to healthy 
controls no downregulation of Cyt1 or Cyt2 was observed in either the untreated 
or treated patient groups upon CD46 costimulation (figure 6.6).  
 
Upon CD46 costimulation, there was no significant differences between healthy 
controls and patients’ Cyt1 and Cyt2 expression, however, there was an overall 
trend for increased Cyt1 and Cyt2 at both timepoints in patients, irrespective of 
treatment, compared to controls (figure 6.6). Upon CD28 costimulation, at the 
early and late timepoint, untreated patients show a trend of increased Cyt1 and 
Cyt2 expression compared to healthy controls (figure 6.6). Although not 
significant IFNβ treated patients also show a trend of increased levels of Cyt1 and 
Cyt2, upon CD28 costimulation, compared to healthy controls. However these 
increases are not as striking as those observed in untreated patients (figure 6.6).  
 
In summary, these data indicate that upon CD46 costimulation there may be a 
lack of Cyt1 and Cyt2 downregulation in MS patients, irrespective of treatment. 
Furthermore, upon CD28 costimulation, and to a lesser extent upon CD46 
costimulation, there may be increased expression of Cyt1 and Cyt2 in MS 
patients compared to healthy controls. This dysregulation of Cyt1 and Cyt2 
expression could have important consequences for CD46 function in T cells from 
MS patients and importantly may contribute to defective IL-10 production. 
Nonetheless, it is important to stress that this is a small cohort of patient samples 




Figure 6.6: Normalised Cyt1 and Cyt2 expression in IFNβ-treated and 
untreated MS patients. The percentage change (%Δ) in Cyt1 or Cyt2 
expression upon activation compared to unstimulated T cells was calculated 
based on the MFI expression determined by flow cytometry. The %Δ in 
expression was then compared between the three groups; healthy controls (HC), 
untreated MS patients (UT), and IFNβ treated patients (T). Cyt1 and Cyt2 
expression at the early activation timepoint: HC n=40, UT MS patients n=9, T MS 
patients n=11. Cyt1 and Cyt2 expression at the late activation timepoint: HC 
n=29, UT MS n=6, T MS patients n=7. A Friedman Test and Bonferroni-
corrected Wilcoxon test was used for statistical analysis within the same donors, 
*** p≤0.0003 **p≤0.003, *p≤0.0167. A Kruskal-Wallis Bonferroni-corrected Mann-




6.4.7 CXCR3! expression! upon! CD46! costimulation! in! MS! patients!
compared!to!healthy!controls!
In order to further assess the phenotype of CD46 activated T cells in patients with 
MS the expression of the chemokine receptors CXCR3 and CXCR4 were 
assessed. Chemokine receptors can be associated with specific T cell phenotypes; 
CXCR3 is upregulated on Th1 type T cells, whereas CXCR4 is linked with Th2 
type T cells. CXCR3 is generally upregulated in activated T cells, especially Th1 
cells, whereas, CXCR4 expression is usually downregulated upon activation 
(Sallusto et al., 1998).  Furthermore, CXCR3 has been implicated in the 
migration of T cells into the CNS (Balashov!et!al.,!1999,!Sorensen!et!al.,!2002). 
Therefore both CXCR3 and CXCR4 expression levels were assessed in T cells 
from healthy controls and MS patients.  MS patients consist of untreated (n=9) 
and treated patients (n=5) and were pooled together due to low numbers. T cells 
were left unstimulated or stimulated with αCD3, αCD3/CD28 or αCD3/CD46 and 
the percentage change in CXCR3 expression on activated T cells compared to 
unstimulated controls was calculated. There was no significant change in CXCR3 
expression in αCD3 activated T cells or CD28 costimulated cells from MS 
patients compared to healthy controls. However, there was a trend for increased  
CXCR3 expression upon CD46 costimulation. CXCR4 expression levels were 
analysed similarly to CXCR3 expression; however, there was no change in 
CXCR4 expression under any condition examined (figure 6.7). Therefore, T cells 
from MS patients that have been costimulated with CD46 may have increased 
expression of CXCR3 compared to healthy controls. These data suggest that 
CD46 costimulated T cells from patients could preferentially migrate to the CNS 





Figure 6.7: CXCR3 expression upon CD46 costimulation in MS patients 
compared to healthy controls. T cells from healthy controls (HC) and MS 
patients were activated as indicated. CXCR3 and CXCR4 expression was 
determined by flow cytometry. The percentage change (%Δ) in CXCR3 (left) and 
CXCR4 (right) upon activation compared to unstimulated T cells was calculated 
based on the normalised mean fluorescence intensity (NMFI), (HC n=9, MS=14). 
Kruskal-Wallis and Bonferroni corrected Mann-Whitney test was used for 




6.4.8 The!Mw!of!CD46! in!activated!CD4+!T!cells! from!patients!with!
MS!
Previously it was shown that upon T cell activation in healthy controls, there was 
a reduction in the Mw of CD46 (Chapter 5 and figure 6.8), which reflected a 
decrease in CD46 glycosylation. CD46 glycosylation was also shown to play a 
role in the downregulation of cell surface CD46 that may also affect T cell 
cytokine secretion (Chapter 5). Therefore, differences in cell surface CD46 
expression and cytokine secretion in MS patients could be the result of aberrant 
glycosylation in T cells from MS patients. In order to assess this, preliminary 
experiments were carried out to determine if there was a reduction in the Mw of 
CD46 upon T cell activation in T cells isolated from MS patients. Under similar 
conditions performed to assess the Mw of CD46 from healthy controls, T cells 
were left unstimulated or activated in the presence of αCD3, αCD3/CD46 or 
αCD3/CD28 for 5 days.  The Mw of CD46 was determined using SDS-PAGE. In 
contrast to healthy controls, there was no decrease in the Mw of CD46 expressed 
on CD4+ T cells from MS patients following αCD3, αCD3/CD46 or αCD3/CD28 
activation (figure 6.8). Therefore, this suggests that the glycosylation pattern of 
CD46 upon T cell activation appears to be different in MS patients. This potential 
difference in glycosylation may alter CD46 surface downregulation and 
subsequent cytokine production in T cells from MS patients.  However, further 




Figure 6.8: The Mw of CD46 in activated CD4+ T cells from patients with MS.  
T cells from healthy controls (HC) (A) or MS patients (B) were left US or 
stimulated with αCD3 alone or in the presence of αCD28 (CD28) or αCD46 
(CD46) for 5 days (n=4). CD46 expression and Mw were determined by SDS-
PAGE. MS patients at the time of donation were untreated or receiving IFNβ 




The dysregulation of CD46 function in T cells from RRMS patients was first 
demonstrated by Astier et al. T cells costimulated with CD46 had a 4-6 fold 
decrease in IL-10 production compared to healthy controls, IFNγ secretion was 
not affected (Astier et al., 2006).  The most widely used MS treatment is IFNβ, 
which has been shown to reduce the relapse rate and slow the course of disease in 
RRMS patients (Yong et al., 1998). Studies have demonstrated that IFNβ 
negatively regulates T cell activation, proliferation, migration across the BBB and 
Th1 cytokine production (Noronha et al., 1993, Stuve et al., 1996, Rep et al., 
1996, Durelli et al., 2009). Moreover, IL-10 producing T cells are increased 
during relapse in MS patients and are also increased by IFNβ treatment (Rudick 
et al., 1996, Rep et al., 1999). However, in the study by Astier et al, IFNβ therapy 
did not correct the dysfunction in CD46 induced IL-10 secretion observed in 
RRMS patients (Astier et al., 2006). This suggests that IFNβ therapy does not act 
directly on CD46 induced T regulatory cells. Uncovering the mechanisms that 
inhibit CD46 induced IL-10 secretion could aid the development of new therapies 
that harness the potential of anti-inflammatory IL-10 secreting T cells. Therefore 
understanding the defects of CD46 induced IL-10 producing cells in MS was 
addressed. 
 
Surface regulation of CD46 expression in multiple sclerosis 
At the early activation timepoint, a trend for decreased cell surface CD46 
expression was observed in unstimulated and activated T cells from untreated MS 
patients compared to healthy controls (figure 6.3). Although this observation 
needs to be confirmed in a larger cohort of patients it is interesting to note that 
increased levels of sCD46 have been observed in the serum and cerebral spinal 
fluid of MS patients (Soldan et al., 2001) and sCD46 has been found bound to its 
ligand HHV-6 in the serum of MS patients (Soldan et al., 2001, Fogdell-Hahn et 
al., 2005).  Therefore, increased levels of sCD46 may reflect increased CD46 
ligation and cleavage that correlate with decreases in CD46 surface expression. 
Kemper et al have demonstrated that CD28 activated T cells produce C3b and 
Chapter!6!
! 180!
provide autologous ligation of CD46 (Cardone et al., 2010). Ligation of CD46 by 
complement may also result in decreased CD46 expression in unstimulated cells. 
This also raises the question of whether a decrease in CD46 expression in 
untreated MS patients could reflects different subsets of T cells in MS patients 
compared to healthy controls. Further experiments are required to determine if 
this is the case. Interestingly, IL-10 production from CD46 activated CD4+ T 
cells from asthma patients is also reduced and peripheral blood T cells from mite-
sensitive asthmatics also had a decreased percentage of CD46+CD4+ T cells 
compared to non-asthmatic controls (Tsai et al., 2012). Therefore reduced 
expression of CD46 could be symptomatic of an over reactive immune system 
and its ligation in vivo by complement, pathogens or other unknown ligands. An 
apparently contrasting report on CD46 surface expression documented increased 
levels of CD46 at the RNA level in PBMCs from untreated RRMS patients 
(Alvarez-Lafuente et al., 2009). Nonetheless, discrepancies can be explained by 
differences of CD46 expression within the PBMC population or T cell 
population. Furthermore, T cells that undergo surface cleavage of CD46 may 
upregulate CD46 at the RNA levels to maintain minimal levels of CD46 surface 
expression in order to inhibit autologous complement activation. 
 
Although IFNβ had no effect on CD46 induced IL-10 secretion (Astier et al., 
2006), the preliminary results shown here suggest that treatment may increase 
CD46 surface expression (figure 6.3). Increased expression of CD46 may be the 
result of reduced MMP-9 expression, which is decreased by IFNβ treatment (Yen 
et al., 2010).  MMP-9 is known to cleave CD46 (Cole et al., 2006) and therefore 
IFNβ treatment may result in decreased cleavage and increased expression of 
CD46. Investigating the expression levels of MMP-9 and its natural inhibitor, 
tissue inhibitor (TIMP)-1, upon CD46 costimulation in healthy controls and 
patients could shed light on why there appears to be altered expression levels of 
CD46 in patients. A previous report demonstrated that 44% of RRMS patients 
treated with IFNβ for 1 year had increased levels of CD46. Increased expression 
of CD46 at the mRNA level was also linked to decreased responsiveness to IFNβ 
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(Alvarez-Lafuente et al., 2011). As activated T cells upregulate CD46 expression 
(Chapter 3), increased expression of CD46 in unresponsive patients may reflect 
increased T cell activation. Determining how IFNβ upregulated CD46 expression 
and what role (if any) this plays in ameliorating disease remains to be determined. 
However, if CD46 pathways are inherently skewed towards enhancing 
inflammation in MS patients, inhibiting its cleavage may prevent further pro-
inflammatory signalling in T cells.  Interestingly, CD46 is also expressed on 
astrocytes and oligodendrocytes (Gasque and Morgan, 1996). If upregulation of 
CD46 expression upon treatment also occurs on these glial cells it could help 
protect them from complement attack and slow neurodegeneration. 
 
Cyt1 and Cyt2 expression in multiple sclerosis 
The time-dependent downregulation of Cyt1 and Cyt2 was at least partially the 
result of its proteolysis, which was important for the function of Cyt1 and 
possibly Cyt2’s functions (Chapter 3 and Chapter 4). Upon CD46 costimulation 
of T cells from MS patients, irrespective of treatment, these preliminary results 
suggest that there is an absence of both Cyt1 downregulation during early 
activation and Cyt2 downregulation during late activation (figure 6.4). This lack 
of downregulation was also observed when the basal levels of Cyt1 and Cyt2 
expression in unstimulated T cells were taken into account (figure 6.6). Further 
investigations are required to confirm that downregulation of Cyt1 and Cyt2 does 
not occur. However, it is tempting to hypothesise that the aberrant 
downregulation of Cyt1 and Cyt2 expression is the result of altered processing 
and/or localisation, which may in turn effect CD46’s cytokine secretion profile. 
Of note, nuclear transportation of the notch ICD, the product of PγS proteolysis 
of Notch, is inhibited in chronic demyelinated lesions due to upregulation of the 
nuclear transport inhibitor protein (TIP) 3, thereby inhibiting oligodendrocyte 
differentiation and myelination (Nakahara et al., 2009). Therefore, a lack of Cyt1 
and Cyt2 downregulation in MS patients could reflect failed transport of the Cyt1 
and Cyt2 tails after proteolysis. Transportation defects could affect their 
signalling capacities and may also prevent their rapid degradation. Failure to 
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downregulate Cyt1 and Cyt2 may also be the result of increased expression at the 
RNA level. Indeed, an upregulation of Cyt2 mRNA was previously reported after 
24 hrs CD46 costimulation in MS patients (Astier et al., 2006) and 5 days 
stimulation in asthma patients (Tsai et al., 2012). In MS patients, there was a 
general trend for increased expression of both Cyt1 and Cyt2 (relative to 
unstimulated T cells) upon T cell activation, compared to healthy controls, (figure 
6.6) suggesting that T cell activation in MS patients could increase the translation 
of Cyt1 and Cyt2 expression.  Nonetheless, time course analysis of Cyt1 and 
Cyt2 RNA and protein expression are required, alongside confocal analysis of 
Cyt1 and Cyt2 localisation, to determine the cause of deficient Cyt1 and Cyt2 
downregulation in MS patients. 
 
CD46 and T cell migration in multiple sclerosis 
The influx of inflammatory cells across the BBB is characteristic of the 
pathogenesis of MS. It is well understood that chemokines and expression of their 
cognate receptors play a key role in directing the migration of inflammatory cells, 
including T cells into the CNS. Indeed, IFNβ therapy is known to modulate 
chemokine expression and T cell migration (Sorensen et al., 2002, Sorensen and 
Sellebjerg, 2002, Sorensen et al., 2004, Sellebjerg et al., 2009).  CXCR3 is a 
chemokine receptor, characteristic of Th1 T cells that binds the chemokines 
CXCL9, CXCL10 and CXCL11 and is implicated in the pathogenesis of MS 
(Muller et al., 2010). For example, increased expression of CXCR3 in T cells is 
present during MS relapses (Mahad et al., 2003) and in progressive MS 
(Balashov et al., 1999). In addition, CXCR3 positive cells have been found in 
areas of plaque formation and their ligand CXCL10 is expressed by astrocytes in 
lesions (Balashov et al., 1999). CD46 T cell costimulation showed a trend of 
increased CXCR3 expression in MS patients compared to healthy controls (figure 
6.7) and could highlight a potential role for CD46 activation in the CNS. 
Moreover, Cardone et al, have recently identified the inability of CD46 activated 
T cells from RA patients to switch from a Th1 phenotype to a regulatory 
phenotype (Cardone et al., 2010). Increased expression of CXCR3 may therefore 
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reflect the Th1 phenotype of CD46 activated T cell in MS and their inability to 
switch to an anti-inflammatory IL-10 secreting phenotype. Indeed, recent reports 
have highlighted the plasticity of Treg cells (Beriou et al., 2009, Zhou et al., 
2009b, Voo et al., 2009, Chowdary Venigalla et al., 2012) and Dominguez-Villar 
et al have identified an increase in the frequency of Th1-like IFNγ secreting 
FOXP3+ T cells in MS patients. These cells have a reduced suppressive capacity 
and are characterised by the upregulation of the Th1 transcriptor factor TBET and 
CXCR3 (Dominguez-Villar et al., 2011).  These data suggest that the 
environment milieu may inhibit the suppressive capacity of Tregs during 
autoimmune diseases and promote their transition to inflammatory phenotype. 
Indeed, the environmental milieu may condition T cells towards a pro-
inflammatory phenotype upon CD46 costimulation. 
 
The role of glycosylation in multiple sclerosis 
Glycosylation plays a role in CD46 surface retention and likely also affects CD46 
induced cytokine production (Chapter 5). Therefore the glycosylation of CD46 
was assessed in a small cohort of MS patients to determine if there were 
alterations in CD46’s Mw upon activation. In both treated and untreated MS 
patients, there was little or no decrease in CD46’s Mw upon CD3 stimulation 
suggesting that CD46 glycosylation levels may be dysregulated in MS patients 
(figure 6.8). In Chapter 5, decreased glycosylation upon CD3 activation 
promoted CD46 downregulation and cleavage. Increased surface downregulation 
of CD46 correlated with an increased ratio of IL-10:IFNγ. If the higher Mw of 
CD46 reflects a higher degree of glycosylation it may attenuate CD46 
downregulation and consequentially the IL-10:IFNγ ratio. In line with this 
hypothesis, at the late timepoint, there was a general pattern of increased CD46 
surface expression in MS patients compared to healthy controls (figure 6.2). 
Furthermore there was no downregulation of Cyt1 or Cyt2 upon CD46 
costimulation in MS patients, treated or untreated (figure 6.4 and figure 6.6). 
Therefore, aberrant patterns of glycosylation in T cells from MS patients could 
dysregulate CD46 downregulation and cytokine secretion. A key study by 
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Demetriou et al has identified Golgi N-glycosylation as the first dysregulated 
biochemical pathway in autoimmune diseases to account for both genetic and 
environmental risk factors (Mkhikian et al., 2011). This study reports how cell 
metabolism and vitamin D modulate N-glycosylation and can converge with MS 
genetic risk factors in IL-7R, IL-2R, CTLA-4 and MGAT1, a glycotransferase to 
regulate susceptibility to disease (Mkhikian et al., 2011). Indeed, our group has 
also demonstrated that vitamin D promotes CD46 down regulation and an 
increase in the IL-10:IFNγ ratio, upon CD46 costimulation, in healthy controls 
and MS patients (manuscript in press). IL-2 is also a key factor in regulating the 
CD46 Treg phenotype and the role of IL-2 in regulating CD46 glycosylation 
requires further investigation. As such, dysregulated N-glycosylation and 
environmental cues could also interfere with CD46 regulatory function in patients 
with MS.  
 
It is important to emphasise that these studies examining CD46 expression and 
glycosylation in T cells, isolated from patients, represent a pilot study.  Results 
obtained in small studies may give rise to skewed results based on individual 
donor or experimental variability. This pilot study used aged matched donors 
(healthy controls 35.1±7.9 and MS patients 42.5±9.5), however, there was a 
stronger female:male ratio in the patient cohort (healthy controls 1:1 and MS 
patients 3.6:1) (Chapter 2, table 2.1). Given the known correlation of sex with 
disease (Sospedra et al., 2005) the role of sex in regulating CD46 expression and 
glycosylation needs to be investigated in a larger group of patients. Furthermore, 
a larger cohort of samples from both healthy controls and patient samples, 
analysed in parallel, should be carried out to confirm the observations noted in 
this pilot study.  
 
In summary, the plasticity of Treg cells and their dysfunction in autoimmune 
diseases is now well-documented (Sakaguchi et al., 2008, Costantino et al., 2008, 
Zhou et al., 2009a, Bluestone et al., 2009, Zhu and Paul, 2010, Lowther and 
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Hafler, 2012). However, the mechanisms and pathways that inhibit their 
suppressive capacity remain to be fully elucidated. It is likely that a combination 
of T cell’s external cues and internal defects are responsible for maintaining or 
switching T cells to an inflammatory phenotype. Future studies will aim to link 
both functional and genetic defects in Tregs to identify dysregulated pathways in 
MS. As CD46 is ubiquitously expressed and given its role in regulating the innate 
and adaptive immune systems (Ni Choileain and Astier, 2011), CD46 is likely to 
play an important role in directing an integrated and appropriate inflammatory 
response. Understanding CD46’s signalling pathways will broaden our 
understanding of common defective pathways that are shared amongst several 






• Preliminary results show that T cells from MS patients, irrespective of 
IFNβ treatment, fail to downregulate Cyt1 and Cyt2 expression upon 
CD46 costimulation. 
• The relative increase in Cyt1 and Cyt2 expression upon CD28 and CD46 
costimulation may be enhanced in both untreated and IFNβ treated MS 
patients compared to healthy controls. 
• Preliminary results show that upon T cell activation there is no decrease in 
the Mw of CD46 in patients with MS and this dysregulation could suggest 








Dysregulation of the immune system can cause chronic inflammatory diseases, 
such as MS, which causes physical and emotional suffering to ~2.5 million 
people worldwide (Sospedra and Martin, 2005, Astier and Hafler, 2007, Nylander 
and Hafler, 2012). Tregs are a key factor in inhibiting excessive inflammation 
and autoimmune diseases (Sakaguchi, 2004, Costantino et al., 2008b, Sakaguchi 
et al., 2010) and use of Tregs as a potential therapy is under extensive 
investigation (Costantino et al., 2008a, Stephens et al., 2009, Sabatos-Peyton et 
al., 2010, Bluestone, 2011, Lowther and Hafler, 2012). The primary focus of this 
thesis was to address the expression, regulation and function of the T cell 
costimulatory molecule, CD46. Interest in the regulation of CD46’s expression 
and function was driven by its role in promoting a T regulatory phenotype, 
characterised by the secretion of IL-10 (Kemper et al., 2003), and because that 
pathway was defective in MS (Astier et al., 2006). Evidence from a transgenic 
mouse model expressing one of the CD46 isoforms, Cyt1 or Cyt2 demonstrated 
that CD46’s isoforms had contrasting roles in regulating inflammation (Marie et 
al., 2002). This led to the hypothesis that Cyt1 and Cyt2 could have distinct 
functions in human T cells and that dysregulation of their expression and/or 
processing could contribute to the lack of IL-10 secretion observed in MS 
patients. Thus, the specific aims of this work were to elucidate: (1) the expression 
levels of cell surface CD46 and intracellular Cyt1 and Cyt2 during T cell 
activation in healthy controls; (2) the function of the cytoplasmic tails, Cyt1 and 
Cyt2 during human T cell activation in healthy controls; (3) the mechanisms of 
the regulation of CD46 expression; and (4) to determine if defective expression or 
processing of CD46 was responsible for limited IL-10 production in CD46 
costimulated T cells from MS patients. These points were addressed and their 
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The expression levels of surface CD46 and/or its isoforms, Cyt1 and Cyt2, had 
not been previously assessed throughout the activation of human primary T cells. 
It has been established that CD46 expression levels are tightly regulated during T 
cell activation (Chapter 3). Proteolytic cleavage of CD46 by MMP/ADAM(s) 
had been documented in apoptotic neuronal and epithelial cells (Elward et al., 
2005, Cole et al., 2006, Hakulinen and Keski-Oja, 2006), during the incubation of 
various cell types with Loxoceles’ venom (Van Den Berg et al., 2002) and upon 
the ligation of CD46 in epithelial cells with Neisseria (Weyand et al.). Proteolysis 
of CD46 was known to play a role in regulating complement induced cell death 
(Elward et al., 2005, Cole et al., 2006, Hakulinen and Keski-Oja, 2006), however 
CD46 proteolysis in human T cells had not been addressed. Importantly, this 
study was the first to report a function of CD46 proteolysis in T cell activation 
(Ni Choileain et al., 2011). Upon CD46 costimulation of T cells, surface CD46 
expression was downregulated and this was at least partially the result of 
cleavage of the extracellular domain by MMP/ADAM(s) (Chapter 4). There was 
also specific regulation of the expression of CD46 isoforms, Cyt1 and Cyt2, 
during T cell activation. Upon CD46 costimulation, Cyt1 expression was 
downregulated after 1-2 days activation, whereas Cyt2 expression was 
downregulated after 4-5 days stimulation. The time-dependent downregulation of 
Cyt1 and Cyt2 was at least partially the result of PγS cleavage (Chapter 4). 
MMP/ADAM and PγS cleavage of type I transmembrane proteins has been 
extensively studied for proteins such as Notch (Bray, 2006, Parks and Curtis, 
2007, Fortini, 2009). Proteolysis of Notch’s extracellular domain by MMPs, 
followed by its intracellular cleavage by PγS, facilitate the release of an ICD, 
which trafficks to the nucleus via the endosomal pathway. Nuclear translocation 
of the Notch ICD allows direct transcriptional regulation of target genes (Bray, 
2006, Parks and Curtis, 2007, Fortini, 2009). Indeed, CD46 is also downregulated 
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through an endosomal pathway upon CD46 costimulation (chapter 3) and 
proteolytic cleavage of Cyt1 was important for its function (Chapter 4). Cyt1 
promotes T cell activation and this function is dependent on its cleavage by PγS. 
Cyt2 was also shown to promote T cell proliferation when expressed in a full-
length CD19-Cyt2 form but not when expressed in a smaller CTF protein. These 
results suggest that Cyt2’s function in regulation T cell activation may be 
dependant on it’s proteolysis and/or its cellular location at the membrane, 
however, further experiments are required to confirm this conclusion (Chapter 4). 
These results also established that Cyt1 promotes an increased IL-10+:IL-10+ 
IFNγ+ secretion ratio. In accordance with Kemper et al (Cardone et al., 2012), 
these data demonstrate that Cyt1 is therefore important in promoting a more 
regulatory like T cell phenotype. Importantly, proteolytic cleavage of Cyt1 and 
potentially Cyt2 is an important factor in regulating their function. 
 
Determining how CD46 proteolysis was regulated led to the investigation of the 
TCR’s role in regulating CD46 T cell activation. Indeed, TCR activation alone 
increased CD46 expression (Chapter 3) and decreased the level of CD46 
glycosylation (Chapter 5). Upon CD46 costimulation, decreased glycosylation 
correlated with increased levels of sCD46 suggesting that lower levels of CD46 
glycosylation could promote CD46 cleavage by MMP/ADAM(s) (Chapter 5). 
These novel data implicating the TCR in regulating the expression and cleavage 
of CD46 highlights the inherent role of CD46 during T cell activation.  
 
The role of glycosylation in regulating CD46’s expression and function was 
further addressed using glycosylation inhibitors and mutant CD46 proteins that 
lacked specific glycosylation sites. These investigations suggested that the 
glycosylation of CD46 not only regulates its surface expression but also the IL-10 
and IFNγ secretion profile. O-deglycosylation attenuated CD46 downregulation 
and the ratio of IL-10:IFNγ secretion. Conversely, deglycosylation of the N-
glycans at the SCR1 and/or SCR4 domain may promote CD46 surface 
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downregulation and an increased the IL-10:IFNγ ratio (Chapter 5). The role of 
CD46 glycosylation was known to regulate CD46’s function as a complement 
(Liszewski and Atkinson, 1996, Liszewski et al., 1998) and pathogen receptor 
(Maisner et al., 1996, Kallstrom et al., 2001) but had not be addressed in CD46’s 
capacity as a costimulatory receptor. Therefore, alterations in CD46 glycosylation 
levels offer a novel mechanism whereby CD46 may regulate inflammatory and 
anti-inflammatory T cell responses. Glycosylation levels of proteins are 
dependent on the metabolic state, environmental milieu and cell activation 
(Wagers et al., 1998, Grabie et al., 2002, Comelli et al., 2006, Toscano et al., 
2007, Mkhikian et al., 2011, Grigorian et al., 2012). Thus, alterations in CD46 
glycosylation could also be responsive to soluble factors in the environmental 
milieu such as IL-2 or Vitamin D, both of which have previously been shown to 
regulate CD46’s T cell function (Kemper et al., 2003, Cardone et al., 2010) 
(manuscript in press).   
 
In light of the data gathered in this thesis and literature available on other type 1 
membrane receptors, a model for CD46 processing is proposed: TCR activation 
(1) induces deglycosylation or expression of lower glycosylated forms of CD46 
(2); Lower glycosylated CD46 is more susceptible to proteolytic cleavage, which 
occurs either at the membrane or after endocytosis (3); After cleavage, CD46’s 
ICDs can have unique signalling capacities that could involve gene transcription 
in the nucleus (4); CD46’s ICDs are degraded to attenuate signalling prior to/post 




Figure 7.1: Proposed model of CD46 processing and signalling. 
 
Understanding the regulation of CD46 expression and processing in healthy 
controls is fundamental to understanding CD46 dysfunction during inflammatory 
disease. In an effort to understand why there was defective IL-10 production 
upon CD46 costimulation in T cells from MS patients, the expression levels of 
CD46, Cyt1 and Cyt2 were analysed in comparison to healthy controls. In healthy 
controls, the time-dependent downregulation of Cyt1 and Cyt2 by PγS was 
observed. In T cells from RRMS patients, there was no downregulation of Cyt1 
or Cyt2, irrespective of IFNβ treatment. Indeed, in the original study by Astier et 
al IFNβ treatment did not restore IL-10 secretion in CD46 costimulated T cells 
(Astier et al., 2006). Although the role of Cyt1 and Cyt2 downregulation in 
regulating cytokine secretion remains to be determined, a lack of Cyt1 
downregulation, which promotes IL-10 secretion, could also be partially 
responsible for limited IL-10 secretion in MS patients. The functional outcome of 
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failed Cyt2 downregulation warrants further investigation. However, considering 
the role of Cyt2 in regulating T cell proliferation, it could promote prolonged T 
cell activation and inflammatory responses in MS patients. Failure to 
downregulate Cyt1 and Cyt2 could be the result of the following defects (1) PγS 
cleavage (2) transport and degradation of ICDs (3) dysregulated glycosylation of 
CD46 (4) increased Cyt1 or Cyt2 protein translation in MS patients compared to 
healthy controls. Further experiments are required to determine if one or more of 
these hypothesis are correct and if they contribute to reduced IL-10 secretion 
from CD46 activated T cells in MS (discussed below). Notably, preliminary 
results suggest that TCR activation in MS patient does not decrease the Mw of 
CD46 (Chapter 5) and support the hypothesis that dysregulated glycosylation of 
CD46 in MS patients could contribute to a lack of isoform downregulation and 





Further investigations into CD46 processing will pave the way for increased 
understanding of the defects observed in MS patients and other autoimmune 
diseases. Future work will focus on (1) the localisation of CD46 and CD46’s 
ICDs upon activation; (2) glycosylation of CD46 during T cell activation; (3) the 
kinetics of CD46 expression in specific T cell subsets.  
 
Localisation of CD46 and CD46’s ICD 
To further elucidate CD46’s signalling pathways it is key to understand what 
happens to the ICD fragments after their release. Preliminary studies suggested 
that both Cyt1 and Cyt2 translocated to the nucleus upon CD46 costimulation 
(Chapter 4), which implies that Cyt1 and Cyt2’s ICDs could regulate gene 
transcription, for example, ChIP-sequencing assays may confirm direct links with 
Cyt1 and Il-10 related genes. Defects in the transport of the Notch ICD to the 
nucleus have already been documented in MS patients (Nakahara et al., 2009) 
and suggest that CD46 ICD could be trapped in the cytoplasm. This would 
explain why no downregulation of Cyt1 or Cyt2 was observed in MS patients 
upon CD46 costimulation. If the Cyt1-ICD or the Cyt2-ICD could not translocate 
to the nucleus it could partially explain why there was reduced IL-10 secretion 
upon CD46 costimulation in T cells from patients with MS. Detailed confocal 
microscopy studies are required to examine CD46’s ICD trafficking after 
cleavage and would include fluorescent labelling of early, late and recycling 
endosomes in addition to nuclear and lysosomal markers. These studies may 
confirm localisation of Cyt1 and Cyt2 ICDs within the nucleus. In order to 
determine a potential defect in translocation in MS patients, the expression levels 
of proteins involved in the transport of ICDs e.g. the transport inhibitor TIP30 
whose expression is dysregulated in MS (Nakahara et al., 2009), would also be 
examined. Expression levels of these proteins would be examined at the RNA 
and protein level using PCR, SDS-PAGE and/or flow cytometry upon T cell 
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activation in both healthy controls and MS patients.  These studies would 
determine if CD46 ICD trafficking is defective in MS patients. 
 
Glycosylation of CD46 during T cell activation 
Detailed mass spectronomy analysis of CD46 glycosylation in unstimulated, TCR 
activated and CD46 costimulated T cells in a cohort of both healthy controls and 
RRMS patients will shed light of the exact changes of CD46 glycosylation during 
T cell activation.  Alterations in glycosylation levels would also be determined in 
the presence of vitamin D and IL-2, as these factors are known to regulate CD46 
cytokine secretion. Mkhikian et al, have recently identified how the convergence 
of genetics (e.g. an IL-2 receptor variant) and vitamin D levels can result in the 
dysregulation of the N-glycosylation pathway in MS patients (Mkhikian et al., 
2011). Studies investigating CD46 glycosylation would further develop our 
understanding of the role of glycosylation in autoimmune diseases.  
 
Expression level kinetics of CD46 in specific T cell subsets 
CD4+ T cells are a heterogeneous group of cells that include naïve and memory 
effector T cells alongside various subtypes of Tregs. To address the question of 
whether dysregulated expression of Cyt1 and Cyt2 is due to differences in 
different T cell subsets between healthy controls and MS patients, kinetic studies 
of Cyt1 and Cyt2 expression over the 5-day period of activation need to be 
carried out in the different T cell populations.   Expression levels would be 
assessed at the protein level using flow cytometry and at the RNA level using 
PCR. Assessing the RNA levels alongside the protein levels would indicate if 
increased expression of Cyt1 and Cyt2 compared to CD3 activated T cells was 




By examining CD46 expression levels and processing in healthy controls and MS 
patients, it is possible to determine why there is defective IL-10 production in 
patients with MS and other autoimmune diseases. The field of glycosylation is 
complex and its role in autoimmune disease is only beginning to emerge. 
Understanding how CD46’s glycosylation phenotype adapts to the environmental 
milieu may offer an explanation as to how T cells regulate their function in a 
changing immunological environment. Moreover, CD46 expression is ubiquitous 
and its functions are diverse during immunological responses. Therefore 
unravelling the mechanisms of CD46 processing could have wide ranging 
implications for the study of the human immune system. This thesis has advanced 
our knowledge of CD46 function in T cells and has raised questions about how 
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Abstract
Background: Adequate termination of an immune response is as important as the induction of an appropriate response.
CD46, a regulator of complement activity, promotes T cell activation and differentiation towards a regulatory Tr1
phenotype. This Tr1 differentiation pathway is defective in patients with MS, asthma and rheumatoid arthritis, underlying its
importance in controlling T cell function and the need to understand its regulatory mechanisms. CD46 has two cytoplasmic
tails, Cyt1 and Cyt2, derived from alternative splicing, which are co-expressed in all nucleated human cells. The regulation of
their expression and precise functions in regulating human T cell activation has not been fully elucidated.
Methodology/Principal Findings: Here, we first report the novel role of CD46 in terminating T cell activation. Second, we
demonstrate that its functions as an activator and inhibitor of T cell responses are mediated through the temporal
processing of its cytoplasmic tails. Cyt1 processing is required to turn T cell activation on, while processing of Cyt2 switches
T cell activation off, as demonstrated by proliferation, CD25 expression and cytokine secretion. Both tails require processing
by Presenilin/cSecretase (P/cS) to exert these functions. This was confirmed by expressing wild-type Cyt1 and Cyt2 tails and
uncleavable mutant tails in primary T cells. The role of CD46 tails was also demonstrated with T cells expressing CD19
ectodomain-CD46 C-Terminal Fragment (CTF) fusions, which allowed specific triggering of each tail individually.
Conclusions/Significance: We conclude that CD46 acts as a molecular rheostat to control human T cell activation through
the regulation of processing of its cytoplasmic tails.
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Introduction
Proper functioning of the immune system depends not only on a
rapid, effective activation of immune cells, but also on timely
downregulation of the response. Inadequate termination of these
responses could lead to autoimmunity, chronic inflammation and
cancer. Though the parameters of T cell activation are well
documented, mechanisms that participate in T cell contraction are
less well characterized. A number of mechanisms have been
reported (and recently compiled in a series of reviews [1]). These
include regulation of cell death [2] and autophagy [3], upregula-
tion of negative signaling molecules such as CTLA-4 [4] and PD-1
[5], metabolic amino-acid regulation [6,7], control by T
regulatory (Treg) cells [8] and Treg induction by dendritic cells
[9], among many others. Thus, homeostasis of the immune system
depends on a fine balance between immune cell induction and
deactivation.
CD46 was first identified as a regulator of the complement
cascade [10,11], but has subsequently been shown to link innate
immunity to acquired immunity. Its activation promotes T cell
activation and differentiation. Costimulation of TCR with CD46
leads to increased T cell proliferation [12], and affects T cell
morphology [13] and polarity [14]. Furthermore, CD46 activation
leads to Tr1 Treg differentiation [15]. This was characterized by
secretion of high amounts of IL-10 [15] and granzyme B [16].
Interestingly, a recent report demonstrates that CD46 can in fact
switch T cell differentiation from a Th1 to a Tr1 phenotype,
depending on IL-2 concentrations present in the milieu [17]. This
underlines the importance of the plasticity of CD46 in controlling
T cell activation. We have previously shown that Tr1 differenti-
ation is altered in patients with multiple sclerosis (MS). IL-10
secretion upon CD3/CD46 costimulation was impaired in T cells
from ,50% of patients with MS [18,19]. The lack of Tr1
differentiation in MS was recently confirmed by another study
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[20] and in a primate model of MS [21], and the dysregulation of
CD46 pathways in T cells was recently described in patients with
asthma [22] and with rheumatoid arthritis [17]. The role of CD46
in human diseases highlights its importance in controlling T cell
activation, and further underlines the need to understand its
regulation and the molecular mechanisms responsible for its
functions.
CD46 is a type I membrane protein expressed in all nucleated
human cells. Its isoforms, products of alternative splicing, have
four complement control repeats (CCR) at the N-terminus,
followed by a heavily glycosylated region rich in serine, threonine
and proline, a transmembrane segment, and one of two short
cytoplasmic tails termed Cyt1 and Cyt2 [23]. Both tails can
transmit signals [24,25]. Most cell types co-express Cyt1 and Cyt2
except for brain and kidney cells, which predominantly express
Cyt2 [26], and their function is mostly unknown. As mice do not
express CD46 except for testis, we initially studied their role in
inflammation in a CD46 transgenic mouse model of T cell-
dependent contact hypersensitivity. We reported that CD46-Cyt1
inhibits inflammatory responses, whereas Cyt2 augments inflam-
mation [27]. We also demonstrated that CD3/CD46 coactivated
T cells from MS patients have higher levels of CD46-Cyt2 mRNA
compared to activated T cells from healthy donors [19]. This
suggests that the higher level of CD46-Cyt2 transcript resulting
from CD46 engagement in MS patients may influence their T cell
responses. Recently CD46 was shown to be a substrate for the
presenilin/c-secretase (P/cS). Upon infection by pathogenic
Neisseria, epithelial cell CD46 was sequentially cleaved by MMP
and P/cS [28]. MMP cleavage releases a soluble ectodomain and
a C-Terminal Fragment (CTF) consisting of the transmembrane
region and cytoplasmic tail. P/cS then cleaves the CTF, releasing
the Cyt1 and Cyt2 tails into the cytosol. Whether the Cyt1 and/or
Cyt2 ICDs have biological activity is currently unknown.
Herein, we investigated the regulation of CD46 expression upon
T cell activation and tested the hypothesis that P/cS modulates
the function of CD46-Cyt1 and CD46-Cyt2 on immune function.
We demonstrate a novel function of CD46 in terminating T cell
activation. We first present evidence of CD46 processing in human
primary T cells. We show that CD46 is cleaved by MMP in
CD46-coactivated human T cells. Furthermore, our data illustrate
that Cyt1 and Cyt2 levels fluctuate dynamically during T cell
stimulation. CD28 costimulation results in an increase in Cyt1 and
Cyt2 expression, suggestive of a crosstalk between CD46 and
CD28. However, upon CD46 coactivation, CD46 cytoplasmic
isoforms were temporally downregulated. Cyt1 expression de-
creased transiently, whereas Cyt2 expression increased then
strongly decreased. Addition of P/cS enzymatic complex inhib-
itors impaired CD46 tail downregulation. We demonstrate the
requirement of CD46 CTF processing in immune regulation by
two approaches. First, we expressed uncleavable mutant CD46
Cyt1 and Cyt2 CTF constructs (hereafter called CTF1 and CTF2,
respectively) in primary human T cells. Expression of wild-type
(wt) CTF1 promoted T cell proliferation, CD25 expression and
IL-10 secretion, whereas expression of uncleavable CTF1
(UNCL.F1) abrogated T cell activation, demonstrating that
cleavage of Cyt1 is required for its function. Expression of wt
CTF2 decreased IFNc secretion, while expression of uncleavable
CTF2 (UNCL.F2) enhanced T cell proliferation, increased CD25
expression and IFNc secretion, indicating that Cyt2 cleavage acts
as an inhibitory signal for T cell activation. Second, we expressed
CD19 ectodomain-CD46 CTF fusion proteins in primary T cells.
Triggering of Cyt1 or Cyt2 by CD19 ligation led to similar
conclusions in terms of cytokine production and proliferation.
Taken together, our data indicate that processing of CD46 tails is
required to first promote T cell activation followed by signals
resulting in T cell inhibition, demonstrating the unexpected role of
CD46 in turning off its own activation in a negative feedback loop.
These data suggest that the timely activity of P/cS on the two
CD46 isoforms provides a molecular rheostat for regulating T cell
activation.
Results
CD46 is cleaved by a metalloproteinase upon T cell
activation
We first assessed whether activating primary human T cells via
CD46 could modulate its surface expression. Purified human
CD4+ primary T cells were activated by immobilized anti-CD3,
anti-CD3 and anti-CD28 (anti-CD3/CD28), or anti-CD3 and
anti-CD46 antibodies (CD3/CD46) for 2 days. The presence of
CD46 ectodomain on T cells was monitored by flow cytometry.
CD3 and CD3/CD28 costimulation led to an increase in surface
CD46 levels (Figure 1A). In contrast, CD3/CD46 stimulation
resulted in a loss of surface CD46. Reduced levels of surface CD46
were observed up to 5 days post-activation (Figure 1B).
In order to determine whether MMPs are involved in the
downregulation of surface CD46, we cultured T cells in presence
of GM6001, a broad MMP inhibitor. Activating T cells with
CD3/CD46 in the presence of GM6001 partly restored surface
CD46 levels (Figure 1C). Moreover, using an ectodomain-specific
antibody, we were able to immunoprecipitate CD46 from
supernatants of CD3/CD46 stimulated cells, but not from
supernatants of unstimulated cells, or cells stimulated with CD3
or CD3/CD28 (Figure 1D). The slightly lower molecular weight of
soluble CD46 compared to membrane CD46 is the size predicted
for the ectodomain released by MMP. Furthermore, addition of
GM6001 decreased the levels of soluble CD46 in the supernatants
of CD3/CD46 activated T cells. Hence, T cell activation via
CD46 causes its ectodomain to be released from the membrane,
and MMP cleavage is responsible at least in part for this shedding.
We next determined whether addition of MMP inhibitor could
modulate CD46 function and notably IL-10 production. Addition
of GM6001 slightly increased the proliferation of CD46-activated
T cells. However, it significantly inhibited IL-10 production
(Figure S1). These data suggest that CD46 processing may be
required for IL-10 production by CD46-activated T cells.
P/cS causes fluctuations in the levels of the two CD46
cytoplasmic tails
We next addressed the possibilities of further downstream
processing of CD46 cytoplasmic tails in primary human CD4+ T
cells. CD4+ primary T cells were activated by anti-CD3/CD46
antibodies for ,28–40 hrs (early time point) or 96–120 hrs (late
time point). CD46 tails Cyt1 and Cyt2 were monitored by flow
cytometry using tail-specific monoclonal antibodies [29]. At the
early time point, Cyt1 levels were reduced in stimulated cells
compared to unstimulated cells (p = 0.026), whereas Cyt2 levels
were significantly increased (p= 0.0002; Figure 2A and Figure S2).
At the late time point, Cyt1 levels in stimulated and unstimulated
cells were equivalent, whereas Cyt2 levels were significantly lower
than those in unstimulated cells (Figure 2A and Figure S2).
Stimulating cells with CD3 or CD3/CD28 antibodies, i.e., without
CD46 ligation, slightly increased cytoplasmic Cyt1 at the early
time point, with CD3/CD28 having the most dramatic effect
(p = 0.0001; Figure 2B). Cyt1 levels remained elevated at the late
time point, but only in CD3/CD28 stimulated cells (p = 0.0006).
In contrast, CD3 and CD3/CD28 stimulated cells had increased
Cyt2 levels only at the early time point, with CD3/CD28
CD46 Tail Processing Is a Rheostat for T Cells
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stimulation having again the most dramatic effect (p = 0.0001).
These data demonstrate that T cell costimulation by CD46 but
also by CD28 regulates the levels of expression of CD46
cytoplasmic tails, and suggest a crosstalk between these two
costimulatory molecules.
We next investigated whether P/cS is involved in regulating
Cyt1 and Cyt2 tail levels. CD4+ T cells were activated by
immobilized anti-CD3/CD46 antibodies in the presence of
DAPT, a P/cS pharmacological inhibitor, or of DMSO as a
control, for 2 or 4 days, and Cyt1 and Cyt2 levels were analyzed
by flow cytometry using tail-specific monoclonal antibodies. A
representative experiment with one set of donor cells is presented
in Figure 2C. Both Cyt1 and Cyt2 levels were increased in the
presence of DAPT, compared to cells stimulated in the absence of
DAPT (Figure 2C). An increased expression of Cyt1 was detected
at day 2 while increased expression of Cyt2 was detected at day 4.
Similar results were obtained when the experiment was repeated
with addition of L-685,458, another P/cS inhibitor (Figure S3).
These inhibitors had no effect on the levels of surface CD46 (not
shown). These data suggest that P/cS activity modulates the levels
of Cyt1 and Cyt2 isoforms in T cells, in a time-dependent fashion.
IL-2 has no significant effects on CD46 expression
CD46 costimulation drives Tr1 differentiation in presence of IL-
2 [15,17]. Hence, we assessed whether IL-2 modulates CD46
expression. CD4+ T cells were activated with anti-CD3/CD46
antibodies in presence of increasing doses of IL-2. Expression of
cell surface CD46 and of its cytoplasmic isoforms were monitored
overtime by flow cytometry (Figure 3). No significant effect was
observed for surface CD46 expression (Figure 3A). Although there
was a small increase in Cyt1 and Cyt2 expression in presence of
IL-2, it was not significant (Figure 3B). Hence, IL-2 did not seem
to considerably affect CD46 expression.
The expression of the two CD46 CTFs differently affects T
cell responses
To further investigate the role of P/cS processing of CD46 in T
cell functions, we next expressed the Cyt1 or Cyt2 CTF in primary
T cells. These constructs consist of the membrane-spanning
segment of CD46 and either the Cyt1 or Cyt2 cytosolic tail.
Hereafter, these constructs are named CTF1 (containing the Cyt1
tail) or CTF2 (containing the Cyt2 tail) (Figure 4). We first checked
that primary T cells transfected with empty vector responded
normally to CD46 and CD28 co-stimulation. Indeed, these cells
produced high levels of IL-10 and low levels of IFNc when
activated by CD46 antibodies, and higher levels of IFNc when
activated by CD28 antibodies. As reported, cells activated with
CD28/CD46 produced more IL-10 than those activated by CD28
alone (Figure 5A and [15]). Cells were then transfected with
plasmids encoding CTF1, CTF2 or with empty vector (CVO).
Twenty-four hours post-transfection, the cells were activated with
anti-CD3/CD28 or anti-CD3/CD46, or with anti-CD3/CD28/
CD46, and after 4 days, IL-10 and IFNc secretion was assessed by
flow cytometry. We determined the proportion of IL-10+, IL-
10+IFNc+ and IFNc+ secreting cells after expression of each
construct and calculated the proportion of IL-10+/IL-10+IFNc+
and of IFNc+/IL-10+IFNc+ to detect the potential effects of the
CTFs on specific cytokine production (Figure 5B). Activation of
CTF1-expressing cells by CD3/CD28 and CD3/CD28/CD46
increased the proportion of IL-10-secreting cells in the population
Figure 1. CD46 ectodomain is processed by MMPs upon T cell activation. (A) CD4+ T cells were left unstimulated, or stimulated as indicated
with immobilized anti-CD3, anti-CD3/CD28 or anti-CD3/CD46 for 48 hrs. The expression of CD46 at the cell surface was examined by flow cytometry.
The results obtained for one donor are shown. The normalized MFI for CD46 (D to the isotype control) are plotted for the different donors analyzed
(mean 6 SEM, n= 12). All data were analyzed using the Wilcoxon test, a non-parametric paired t-test that does not assume Gaussian distribution. (B)
CD4+ T cells were activated with immobilized anti-CD3/CD46 antibodies or left unstimulated (US) for several days and CD46 surface expression
monitored daily. (C) CD4+ T cells were activated with immobilized antibodies as indicated in presence of GM6001, a broad metalloproteinase inhibitor
(10 mM), or DMSO as a control. After 2 days, the cell surface expression of CD46 was determined by flow cytometry. The representative plots obtained
for one donor are shown, and the normalized data obtained for the different donors (n = 10) are shown on the right panels. (D) The presence of
sCD46 in the cell culture supernatants of activated T cells, as indicated, was determined after CD46 immunoprecipitation and western-blot analysis.
TCL = Total Cell Lysate, as a control for membrane CD46. Representative of 2 experiments.
doi:10.1371/journal.pone.0016287.g001
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compared to cells transfected by the empty vector (p = 0.008), and
slightly decreased the proportion of IFNc-secreting cells but only
upon CD3/CD28 activation. CTF2 expression led to a significant
decrease in IFNc-secreting cells (p = 0.012) but had no significant
effect on IL-10-secreting cells (Figure 5B,C). CD3/CD46-activat-
ed T cells remained mainly insensitive to CTF expression. This is
likely due to the dominant stimulation of the endogenous CD46.
However, as CTF expression could modulate the response of the
cells coactivated by CD28/CD46, this suggests an effect of the
CTF on the CD28 pathway, independently of the endogenous
CD46, supporting the hypothesis of a crosstalk between CD28 and
CD46.
Next, we transfected primary T cells with mutants of CTF1 and
CTF2 that cannot be cleaved by P/cS (UNCL.F1 or UNCL.F2,
respectively) (Figure 4). A representative experiment from one set of
transfected donor cells upon CD3/CD8/CD46 activation is shown
in Figure 5C. UNCL.F1-expressing cells secreted,50% less IL-10
and slightly less IFNc than CTF1-expressing cells. An increase in
Figure 2. CD46 cytoplasmic tails are regulated by P/cS upon T cell activation. Purified CD4+ T cells were left unstimulated or stimulated as
indicated by immobilized anti-CD3/CD46 (A), anti-CD3 or anti-CD3/CD28 (B), for 28–40 hrs (early time point) and 96–120 hrs (late time point). The
expression of the two cytoplasmic tails of CD46 was determined by intracellular staining (0.1% saponin) using specific Cyt1 or Cyt2 monoclonal
antibodies. The samples were analyzed using the Wilcoxon test, a paired test that does not assume Gaussian variation. The means 6 SEM are shown.
(C) CD4+ T cells were stimulated by immobilized anti-CD3/CD46 antibodies for 2 or 4 days in presence of DAPT (10 mM), a P/cS inhibitor, or of DMSO
as control. The expression of Cyt1 and Cyt2 was then analyzed by flow cytometry. There was an increased expression of Cyt1 at D2 and increased
Cyt2 levels at D4 in presence of DAPT. Representative of four experiments.
doi:10.1371/journal.pone.0016287.g002
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IFNc production was observed for UNCL.F2-expressing cells
compared to CTF2-expressing cells. Although UNCL.F2-express-
ing cells secreted more IL-10 than CTF2-expressing cells, the
proportion of IL-10+/IL-10+IFNc+secreting-cells was unaffected.
The proportion of IL-10+ and IFNc+ only secreting cells upon the
different conditions of stimulation obtained for 7 independent
donors is also represented in Figure 5D. Inhibition of CTF1
cleavage abrogated the increase in IL-10+ cells and had a weaker
effect on IFNc-secretion. Inhibition of CTF2 cleavage enhanced the
percentage of IFNc-secreting cells.
We next assessed T cell activation levels by monitoring CD25
expression and proliferation in primary T cells expressing wild-
type and uncleavable CTFs. Transfected T cells were labeled with
CFSE, then activated with anti-CD3/CD46, anti-CD3/CD28 or
anti-CD3/CD28/CD46 antibodies, and CD25 expression and
proliferation were assessed by flow cytometry. A representative
experiment with one set of transfected donor T cells upon CD3/
CD28 activation is presented in Figure 6. CTF1-expressing cells
had higher levels of CD25 and proliferated more than control
cells. Expression of UNCL.F1 abrogated this effect (Figure 6A).
CTF2-expressing cells proliferated similarly than control cells.
However, expression of UNCL.F2 led to a strong increase in
proliferation rate and CD25 expression, compared to CFT2
expressing cells, as shown by the increased percentage of
CFSEloCD25+ cells (inner gate, Figure 6A). The percentage of
changes in CFSEloCD25+ cells upon expression of the uncleavable
constructs compared to cleavable ones obtained for 7 independent
experiments are also represented in Figure 6B. The % of
CFSEloCD25+ cells obtained for the different experiments are
represented in Figure 6C. UNCL.F1-expressing cells had signif-
icant reduced levels of CFSEloCD25+ cells than CTF1-expresing
cells, while expression of UNCL.F2 led to a significant increase in
CFSEloCD25+ cells. This indicates that processing of the two
isoforms regulated cell activation, albeit antagonistically. CTF1
cleavage was necessary to boost T cell activation, while CTF2
cleavage resulted in T cell inhibition.
Specific triggering of CD46 cytoplasmic tail results in
differential T cell activation profile
We next designed fusion constructs that would allow us to
directly and specifically trigger Cyt1 or Cyt2 without affecting
endogenous CD46. We constructed chimeric molecules consisting
of the extracellular domain of CD19, a B cell marker, fused to
CTF1 or CTF2 (Figure 7A). These constructs contain the MMP
Figure 3. IL-2 has no significant effect on CD46 expression. Purified CD4+ T cells were stimulated by immobilized anti-CD3/CD46 with
increasing concentrations of rhIL-2, as indicated, for various lengths of time. Expression of cell surface CD46 (A) and of intracellular Cyt1 or Cyt2 (B)
was monitored by flow cytometry. The means 6 SEM are shown (n= 5). The samples were analyzed using the Wilcoxon test, a paired test that does
not assume Gaussian variation. A slight increase in expression of CD46 cytoplasmic isoforms was observed but no statistical differences were
obtained.
doi:10.1371/journal.pone.0016287.g003
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cleavage domain, and they were named CD19-Cyt1, or CD19-
Cyt2. These constructs were first characterized for the correct
expression of the chimeric proteins by transfecting them into
HEK293 cells and examining fusion protein expression by flow
cytometry using antibodies to CD19 ectodomain, Cyt1 and Cyt2
(Figure 7B). Approximately 40% of cells transfected with
pcDNA3-CD19-Cyt1 expressed CD19 and high levels of Cyt1
while CD19 and high expression level of Cyt2 was only observed
in pcDNA3-CD19-Cyt2 transfected cells. Expression in primary T
cells also resulted in ,40% expression of CD19 (Figure 7C). We
assessed the functionality of the MMP cleavage site in these
fusions. Transfected T cells expressing fusion constructs were left
unstimulated, or were activated with immobilized anti-CD3/
CD28 antibodies in presence or absence of immobilized anti-
CD19 to specifically trigger the fusion proteins, or activated with
anti-CD3/CD46, or anti-CD3/CD28/CD46 antibodies. Ligation
of CD19 strongly decreased surface levels of CD19 (Figure 7C).
This reduced CD19 staining was not due to the masking of the
epitope by detached (and pre-immobilized) CD19 antibodies, as
the cells did not react with FITC-anti-mouse IgG when harvested
from culture (data not shown). These chimeric constructs therefore
contain a functional MMP cleavage site.
We next determined whether specific activation of CD19-Cyt1 or
CD19-Cyt2 could modulate T cell activation. Because coactivation
by CD3/CD28 elicited a much stronger response than CD3 alone
(not shown), we subsequently studied the effect of CD19 ligation on
CD3/CD28 activation. Primary T cells expressing CD19-Cyt1,
CD19-Cyt2 or empty vector were labeled with CFSE and then
activated by immobilized anti-CD3/CD46, or by anti-CD3/CD28
antibodies in presence or absence of anti-CD19. After four days,
proliferation and CD25 expression were assessed by flow cytometry.
A representative experiment is shown in Figure 8A. Expression of
CD19-Cyt1 resulted in a decrease of proliferation of the cells
compared to cells transfected by the control vector, while CD19-
Cyt2 expression by itself, without its ligation, increased prolifera-
tion. Ligation of CD19 had no significant effect of cells transfected
by the control or expressing CD19-Cyt1. In contrast, a dramatic
inhibition of proliferation was observed when CD19-Cyt2 was
engaged. While no significant difference in CD25 expression was
detected for the control cells and CD19-Cyt1 expressing cells, a
strong decrease in CD25 expression was observed for CD19-Cyt2
expressing cells upon CD19 ligation (Figure 8A and B). These
results therefore supported those observed using the CTF
constructs. Expression of CD19-Cyt1 mainly mimicked UNCL.F1
Figure 4. CTF constructs used in this study. (A) Schematic representation of the proteins encoded by the different CTF plasmids used in this
study. Plasmids encoding the CTF portion of either Cyt1 (CTF1) or Cyt2 (CTF2) as well as mutants rendered uncleavable by the P/cS (UNCL.F1 and
UNCL.F2) are represented. (B) Uncleavable CTF constructs. Left panel: Top diagram shows wt and mutant Cyt1 tail constructs. SP: heterologous signal
peptide; black box: peptide linker; unlabelled white box: short segment of CD46 ectodomain; TM: CD46 transmembrane region; Cyt1 (or Cyt2 for
CTF2 constructs) cytoplasmic tail. Lower diagram shows amino-acid sequence of the wt TM and uncleavable mutant TMs with amino-acid
substitution (boxed residues). The Notch1 TM is shown for comparison. Downward arrow points to predicted P/cS cleavage site for CD46; upward
arrow to known cleavage site for Notch1. The right panel shows the immunoblot of CHO cells expressing wt (CTF) and mutant (CTF VV_GG). Arrow
indicates the 6 kD Cyt1 peptide release by P/cS cleavage. GAPDH= loading control.
doi:10.1371/journal.pone.0016287.g004
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expression while CD19-Cyt2 expression mainly reflects UNCL.F2
expression. However, specific activation of CD19-Cyt2 led to a
striking inhibition of proliferation and CD25 expression, and
indicated that Cyt2 differently modulates T cell activation
depending on its triggering and processing.
We next determined the effect of Cyt1 and Cyt2 specific
triggering on cytokine production. T cells expressing CD19-Cyt1
and CD19-Cyt2 were activated by CD3/CD28 or CD3/CD28/
CD19, and cytokine production determined. The percentage of
change in cytokine production upon CD19 ligation was calculated
for IL-10+, IL-10+IFNc+ and IFNc+ cells. Co-activation of CD19-
Cyt1 cells increased the percentage of cells producing IL-10 only
(p = 0.019; Figure 8C). CD19-Cyt1 had no significant effect on the
proportion of IL-10+IFNc+ cells and on IFNc+ secreting cells. In
contrast, CD19 co-activation of CD19-Cyt2 cells significantly
reduced IFNc production (p = 0.037). Finally, CD19 co-activation
of vector only control cells had no effect on either IL-10 or IFNc
production. These results corroborate the findings from CTF-
expressing cells that altered the proportion of IL-10+ or IFNc+-
only producing cells.
Specific triggering of CD19-Cyt2 results in increased
CTLA-4 expression and dephosphorylation of LAT
In order to determine a possible mechanism for the inhibitory
effect of Cyt2, we analyzed CTLA-4 levels, a potent co-inhibitory
molecule for T cells [30]. As shown in Figure 9A, CTLA-4
expression is induced by activation of primary human T cells, and
notably when CD46 is stimulated. In transfected cells, activation
by CD19 had no effect on CD19-Cyt1 expressing cells and control
cells. However, triggering of CD19-Cyt2 led to a strong increase in
CTLA-4 expression, providing a possible mechanism for Cyt2
inhibitory role. The results obtained for one experiment is shown
in Figure 9B, and the average data obtained for the different
donors represented in Figure 9C.
CTLA-4 engagement decreases T cell activation by transmitting
negative signals. Notably, it induces the dephosphorylation of
Figure 5. Cleavage of CTF-Cyt1 and CTF-Cyt2 differently controls IL-10 and IFNc production. (A) Activation of transfected (with a control
plasmid) primary CD4+ T cells results in normal differentiation. Twenty-four hours post transfection by Amaxa/Lonza with the empty vector control
(CVO), CD4+ T cells were stimulated by immobilized anti-CD3/CD46, anti-CD3/CD28 or anti-CD3/CD28/CD46 monoclonal antibodies for 72 hrs. The
secretions of IL-10 and IFNc were assessed by secretion assays (Miltenyi). CD46 costimulation induces mainly IL-10 production, while CD28
coactivation induces more IFNc. CD28/CD46 coligation also induces Tr1/IL-10 secretion (as described by [15]). (B) CD4+ T cells were transfected with
the control plasmid (CVO) or encoding CTF-Cyt1 (CTF1) or CTF-Cyt2 (CTF2) fragments. Twenty-four hours post transfection, CD4+ T cells were
stimulated by immobilized anti-CD3/CD28, anti-CD3/CD46 or anti-CD3/CD28/CD46 monoclonal antibodies, as indicated. After 3 days, the secretions
of IL-10 and IFNc were assessed by secretion assays (Miltenyi). The proportions of IL-10+/IL-10+IFNc+ and of IFNc+/IL-10+IFNc+ secreting cells for the
multiple experiments performed are represented. The means 6 SEM are shown (n= 10). All data were analyzed using the Wilcoxon test, a non-
parametric paired t-test that does not assume Gaussian distribution. (C) CD4+ T cells were transfected with the plasmids encoding CTF-Cyt1 (CTF1) or
CTF-Cyt2 (CTF2) or with the uncleavable CTF1 or CTF2 (UNCL.F1 and UNCL.F2) before analysis of IL-10 and IFNc production. The data obtained for one
donor is shown upon CD3/CD28/CD46 activation. (D) The proportions of IL-10+/IL-10+IFNc+ and of IFNc+/IL-10+IFNc+ secreting cells for the multiple
experiments performed are represented (n = 7).
doi:10.1371/journal.pone.0016287.g005
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proteins activated by TCR stimulation, such as LAT [31]. CD46
activation of T cells induces LAT phosphorylation [12]. Hence, we
next determined the level of LAT phosphorylation upon activation
of each tail. CD4+ T cells were transfected with the control plasmid
or the plasmids encoding CD19-Cyt1 or CD19-Cyt2 and activated
for 5 min in presence of anti-CD3/CD28 with or without CD19
ligation. The phosphorylation of LAT was analyzed by flow
cytometry. The results obtained for one experiment are shown in
Figure 9D, and the average data obtained for the different donors
represented in Figure 9E. As expected, no difference was observed
for the control cells when CD19 was activated. No significant effect
was observed by the simultaneous triggering of CD19-Cyt1 and
CD3/CD28. In contrast, CD19-Cyt2 costimulation induced a
significant decrease in LAT phosphorylation, supporting the
hypothesis of the role of Cyt2 in terminating T cell activation.
Discussion
The outcome of T cell activation results from a computation of
signals received by the T cells, ensuring first proper activation,
followed by adequate termination of the immune response
initiated [1]. Here, we demonstrate the ability of CD46, a major
costimulatory molecule for human T cell activation [12], to
provide both coactivation and termination signals, through the
regulation of expression of its two cytoplasmic isoforms. We first
demonstrate the regulation of CD46 processing. An MMP-
dependent cleavage of CD46 ectodomain was initially observed
at the cell surface of T cells when CD46 was ligated. The
antibodies used for activation and labeling were different, and
there was a clear effect of MMP inhibitor indicating that an MMP-
dependent cleavage was at least partly involved. We also
investigated whether CD46 activation induced its internalization
by measuring intracellular levels of CD46 after intracellular
staining and acid-stripping of the cells, as reported in [32] (data
not shown). No significant increase in CD46 was detected in these
conditions, suggesting that most CD46 was shed from the surface.
This also correlated with the presence of soluble CD46 in the
culture supernatants of coactivated T cells. Apoptosis of neuronal
and epithelial cells also triggers CD46 MMP-dependent shedding
[33,34], indicating that several biological pathways use this
Figure 6. Cleavage of CTF-Cyt1 and CTF-Cyt2 differently controls T cell proliferation and CD25 expression. CD4+ T cells were
transfected with the plasmid encoding CTF-Cyt1 (CTF1) or CTF-Cyt2 (CTF2), or the uncleavable fragments (UNCL.F1and UNCL.F2). Twenty-four hours
post transfection, CD4+ T cells were labeled with CFSE and stimulated with immobilized antibodies for 4 days. Proliferation and CD25 expression was
determined by flow cytometry. (A) The data obtained upon CD3/CD28 activation for one donor is shown. (B) The percentage of change in
CFSEloCD25+ cells upon expression of the uncleavable constructs compared to the cleavable ones upon the different conditions of stimulation is
represented as an average of several independent experiments with different donors (n = 7). (C) The average % of CFSEloCD25+ cells (inner gate in
(A)) obtained in the different experiments performed is also represented.
doi:10.1371/journal.pone.0016287.g006
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mechanism of regulation. The loss of CD46 expression at the cell
surface was followed by the downregulation of its cytoplasmic
isoforms, although with a strikingly different time-course. Cyt1 was
downregulated first, while Cyt2 downregulation was observed
afterwards. The decrease in Cyt1 and Cyt2 expression could be
partially restored in presence of P/cS inhibitors, in a timely
fashion. This suggests that, upon T cell activation, this enzymatic
complex cleaves at least a part of CD46 cytoplasmic tails. We were
barely able to detect by western-blots these fragments in activated
primary T cells (not shown). This may be due to the short half-life
of these fragments once released in the cytosol and the limit in
sensitivity of our assay with primary T cells. However, we could
detect the decrease in full length CD46 upon its activation (not
shown). Importantly, the processing by P/cS of both CD46
cytoplasmic isoforms has been observed upon binding of the
pathogenic Neisseria bacteria, N. gonorrhoeae and N. meningitidis, to
epithelial cells [28]. Hence, CD46 processing might be a general
pathway initiated by its triggering, producing active ICD that will
transduce signals.
Most importantly, we demonstrate herein the dual role of CD46
in regulating human T cell activation. Ten years ago, it was
discovered that CD46 could act as a costimulatory molecule for
human T cells [12] and few years later that it could drive Tr1
differentiation [15]. Our data now illustrate the role of CD46 in
turning off T cell activation, providing a novel concept in the
regulation of the immune response. This ‘‘yin and yang’’ ability of
CD46 in regulating T cell activation is mediated by the P/cS-
dependent processing of its two cytoplasmic isoforms. Activation of
T cells by CD46 leads to Tr1 differentiation [15]. Our data
indicate that Tr1 differentiation initiated by CD46 activation is
mainly due to Cyt1, as its specific activation using the CD19-
CD46 fusion protein promoted IL-10 secretion, previously
characterized as a marker of CD46-induced Tr1 cell differentia-
tion [15,16]. An increase in Granzyme B, another hallmark of
CD46-induced Tr1 cells [16] was also observed (data not shown).
Importantly, the role of Cyt1 in IL-10 production was corrobo-
rated by the CTF constructs, as expression of CTF1 increased the
proportion of IL-10-secreting cells. It also promoted T cell
proliferation and CD25 expression. The cleavage of CTF1 was
required for these functions, as they were abrogated by expression
of the uncleavable CTF1 mutant. As CD3/CD28 activation
induced a much stronger response than CD3 activation alone, we
mainly studied the effects of CTF on CD3/CD28 or CD46 co-
activated T cells. However, we were able to detect similar effects of
the CTF constructs on CD3-activated T cells when CD3 induced
sufficient activation levels (Figure S4). Expression of uncleavable
Figure 7. CD19-CTF fusion proteins used in this study. (A) Schematic representation of the proteins encoded by the different fusion plasmids
used in this study. Plasmids encoding the CD19 ectodomain fused to either CTF-Cyt1 or CTF-Cyt2 was constructed. (B) Chimeric protein expression in
HEK293 cells. HEK cells were transfected by Fugene with pcDNA3 plasmids (control (C), CD19-Cyt1 (Cyt1) or CD19-Cyt2 (Cyt2)). Twenty-four hours
later, the expression of CD19, Cyt1 and Cyt2 was assessed by flow cytometry using anti-CD19-FITC and monoclonal antibodies specific of each
isoform. (C) CD4+ T cells were transfected with the control pcDNA3 plasmid (C) or encoding the fusion proteins consisting of the extracellular domain
of CD19 and CTF of either Cyt1 or Cyt2 and activated as indicated. Twenty-four hours later, CD19 expression was determined by flow cytometry.
Representative of three experiments.
doi:10.1371/journal.pone.0016287.g007
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CTF1 appears to block the cells in an unactivated state and fewer
cells get activated. Expression of CD19-Cyt1 has the same effects –
there are fewer cells capable of being activated. Hence, the
decrease in proliferation of CD19-Cyt1 expressing cells, without its
ligation, correlates with the results obtained by expressing
UNCL.F1. The increase in proliferation and CD25 expression
was not detected in CD19-activated cells expressing CD19-Cyt1
fusion protein. This may relate to the strength of activation of the
cells, as the effect of CTF1 was only observed in CD3/CD28 co-
activated T cells. The specific engagement of Cyt2 led to strikingly
different effects. Expression of uncleavable CTF2 strongly
promotes T cell activation. Similar results are obtained when
CD19-Cyt2 is expressed. This suggests that Cyt2 can trigger
signaling events independently of extracellular ligation, and
participates in T cell activation at the early time point. Specific
Cyt2 activation, via CD19 ligation, provokes its cleavage as
demonstrated by the loss of CD19 expression upon its engage-
ment, and results in lowered IFNc secretion, as well as
dramatically decreased proliferation and CD25 expression com-
pared to CD3/CD28 activation in absence of CD19. Similarly,
expression of an uncleavable CTF2 resulted in an increased IFNc
production, enhanced proliferation and CD25 levels. Further-
more, specific triggering of Cyt2 could enhance CTLA-4 level, a
potent co-inhibitory molecule for T cells [30], providing a possible
mechanism for Cyt2 inhibitory role. Indeed, we could demonstrate
that specific Cyt2 triggering led to a decrease in LAT
phosphorylation. Interestingly, CD46-activated T cells do not
sustain proliferation over longer activation periods [35]. We have
shown that gated CTLA-4+ cells exhibit a strong inhibition of
proliferation when Cyt2 in engaged (Figure S5). Our data suggest
an involvement of Cyt2 by upregulation of CTLA-4 and
subsequent dephosphorylation. Together, these data and the
Figure 8. Specific triggering of Cyt1 and Cyt2 differently controls T cell activation. (A) CD4+ T cells were transfected with the control
pcDNA3 plasmid (C) or encoding the CD19-CTF1 (Cyt1) or CD19-CTF2 (Cyt2) fusion proteins. Twenty-four hours post transfection, CD4+ T cells were
labeled with CFSE. Labeled cells were then stimulated by immobilized anti-CD3/CD46, anti-CD3/CD28 or anti-CD3/CD28/CD19 monoclonal antibodies
and proliferation as well as CD25 expression were determined by flow cytometry. (B) Proliferating cells were gated on CFSE-low cells and the
expression of CD25 was determined. The black lines represent the staining obtained for CD3/CD28 activated cells, the shaded grey histograms
represent the staining for the cells activated in presence of anti-CD19. Representative of three experiments. (C) Transfected cells were activated by
anti-CD3/CD28 or anti-CD3/CD28/CD19 monoclonal antibodies. After 4 days, the secretions of IL-10 and IFNc were assessed by secretion assays
(Miltenyi). The changes in the percentages of IL-10+, IL-10+IFNc+ and IFNc+ secreting cells induced by CD19 ligation compared to secretion in absence
of CD19 (100%) for the multiple experiments performed are represented (n = 9). Samples were analyzed using the Wilcoxon test.
doi:10.1371/journal.pone.0016287.g008
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results obtained using CTF2 clearly demonstrate that the lack of
cleavage results in increased T cell activation. This illustrates that
CTF2 processing is required to trigger inhibitory signals within
activated T cells, in a negative feedback mechanism.
Importantly, while this manuscript was being written, it was
reported that CD46 activation could switch T cells from a Th1
toward to Tr1 phenotype depending on IL-2 concentrations
present in the milieu [17]. However, in our hands, we did not
observe significant effects of increasing IL-2 concentrations on
CD46 processing. Remarkably though, the authors found that
expression of Cyt1 in Jurkat cells led to increased IL-10 secretion.
Moreover, ligation of CD46 in cd T cells that express more Cyt2
than Cyt1 (at least by PCR) results in a decrease in IFNc
expression. Our data corroborate these findings in primary CD4+
T cells, but they also demonstrate the role of CD46 isoforms in
overall primary human T cell activation, and we provide evidence
of the requirement of their processing in such functions.
Importantly, both studies highlight the importance of the plasticity
of CD46 in controlling T cell activation. While Kemper’s group
shows the ability of CD46 to switch cytokine production
depending on IL-2 concentrations, we demonstrate that within
the Tr1 differentiation conditions, CD46 acts as a rheostat for T
cell activation. We first observed the loss of expression of Cyt1,
while Cyt2 processing occurred later. This supports the notion that
the initial regulation of CD46-Cyt1 induces IL-10 production and
Tr1 differentiation, while the later Cyt2 processing results in
switching off Tr1 cells, in a negative feedback mechanism. We had
previously reported that CD46 cytoplasmic isoforms had differ-
ential roles in inflammation using transgenic mice expressing
either isoform. In an in vivo model of contact hypersensitivity
reaction to DNFB, CD46-Cyt1 had a potent anti-inflammatory
role, while Cyt2 promoted inflammation [27]. Our data in human
cells corroborate the anti-inflammatory role of Cyt1 through
activation and Tr1 differentiation, and the pro-inflammatory role
of Cyt2 may be explained by decreased IFNc production [36,37]
and lack of Tr1 differentiation. Importantly, CD46 is defective in
MS, as CD46-activation of both T cells and dendritic cells leads to
a pro-inflammatory phenotype [19,38]. Whilst CD46 activation
induced Tr1 differentiation and IL-10 secretion in T cells from
healthy donors, IL-10 production was decreased by T cells from
Figure 9. Specific Cyt2 triggering increases CTLA-4 expression and decreases LAT phosphorylation. (A) CTLA-4 expression was
determined by flow cytometry on untransfected primary T cells activated as indicated for 4 days. (B) Twenty-four hours post transfection with
pcDNA3 plasmids (control, CD19-Cyt1 or CD19-Cyt2), CD4+ T cells were stimulated with anti-CD3/CD28 (black plain line) or anti-CD3/CD28/CD19
(shaded grey area) monoclonal antibodies for 5 days. The expression of intracellular CTLA-4 was then assessed by flow cytometry. Red and green lines
represent the staining obtained with the isotype controls for both types of activation. The average normalized CTLA-4 staining obtained for 5
experiments is represented in (C). Transfected cells were activated with anti-CD3/CD28 with or without CD19 and addition of a cross-linker for 5 min
at 37uC. Activated cells were immediately fixed and then permeabilized. The presence of phospho-LAT was detected with an anti-pLAT by flow
cytometry. Data representative of one donor are shown in (D). Red lines represent the staining obtained with the isotype controls. The average
normalized pLAT staining obtained for 4 experiments is represented in (E).
doi:10.1371/journal.pone.0016287.g009
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MS patients [19,20,21,39]. This was associated with an increased
RNA expression of the Cyt2 isoform upon T cell activation [19].
Our data now reinforce the likely role of the abnormal Cyt1/Cyt2
ratio in the lack of Tr1 differentiation in patients with MS.
Overall, our data suggest that CD46, through the temporal
processing of its cytoplasmic tails, acts as a molecular rheostat for
human T cells. We propose that, first, Cyt1 is cleaved which promotes
T cell activation and IL-10 production, and that, later, Cyt2 cleavage
sends a negative feedback message, turning off T cell activation, as
summarized in the model depicted in Figure 10 and based on the data
presented in Figure S6. Further elucidation of the transduction
cascades initiated by CD46 isoforms will be required to fully
understand their role in human T cell activation. The understanding
of the mechanisms regulating their expression will provide a potent
tool for immuno-therapies and will complete our growing knowledge
on T cell activation and contraction in health and disease.
Materials and Methods
Cell purification and activation
PBMC were isolated by Ficoll-Hypaque density gradient
centrifugation (Pharmacia LKB Biotechnology, Piscataway, NJ),
from heparinized venous blood from healthy donors obtained after
informed consent. Ethical approval was obtained from the Lothian
Board Ethics Committee. CD4+ T cells were negatively isolated
using magnetic beads (CD4 isolation kit II, Miltenyi Biotec,
Auburn, CA, purification .90%). T cells were then cultured in
culture wells pre-coated with anti-CD3 (OKT3, 5 mg/ml), anti-
CD28 (CD28.2, 10 mg/ml), anti-CD46 (10 mg/ml) (20.6, kindly
provided by Dr. Chantal Rabourdin-Combe, France), anti-CD19
(AbD Serotec, 10 mg/ml), or irrelevant IgG1 (Invitrogen, 10 mg/
ml). Exogenous IL-2 (10 U/ml) was added to CD3/CD46
stimulated cells as previously described [15]. In some experiments,
the P/cS inhibitors DAPT (N-[N-(3,5-Difluorophenacetyl-L-
alanyl)]-S-phenylglycine t-Butyl Ester) or L-685,458 (Sigma-
Aldrich) were added to the culture.
Cell transfection
CD4+ T cells were negatively isolated (Miltenyi, purification
.90%) and transfected (Amaxa/Lonza), following the manufac-
turer’s instructions (U-14). HEK293 cells were transfected by
Fugene (Roche). Twenty-four hours later, the expression of CD19,
Cyt1 and Cyt2 was assessed by flow cytometry using CD19-PE
(BD Biosciences), or specific monoclonal antibodies against Cyt1
or Cyt2 [29] (in 0.1% saponin).
CTF constructs
The CTF expression constructs were made by subcloning PCR
products amplified from CD46 pSecTag2/Hygro (Invitrogen)
clones for Cyt1 and Cyt2 into pIRESneo (GenBank Accession
no. U89673). PCR products were generated using primers
CTF_IRES_EcoR1_F with IRES_BamHI_R_CTF1 for Cyt1
and CTF_IRES_EcoR1_F and IRES_BamHI_R_CTF2 for
Cyt2. PCR products were digested with EcoR1 and BamH1
prior to cloning into pIRESneo. The predicted P/cS cleavage site
was mutagenized with the VV_GG and VV_GG_rc primers using
the QuikChange Lightning Site-Directed mutagenesis kit (Strata-
gene) according to the manufacturers instructions (Figure 4).
Fusion proteins
The extracellular domain of CD19 was fused to CD46 CTF1 or
CTF2. After total RNA extraction from HeLa and Raji cells,
cDNAs were obtained using specific primers: AA3 for CD19, AA4
for Cyt-1 and AA5 for Cyt-2 (Table 1). The CD19 extracellular
region was amplified by PCR with the primers AA1 and AA2
using PHUSION hot start polymerase (Finnzyme) with the
addition of HindIII and XbaI restriction sites at the 59 and 39
ends, respectively. Cyt1 and Cyt2 transmembrane and intracyto-
plasmic domains were amplified with the pairs of primers AA3,
AA4 and AA3, AA5 respectively. Amplified CD19, Cyt1 and Cyt2
cDNA were cloned in pBluescript II plasmid (Stratagene) and
sequenced. Chimeric molecules containing CD19 extracellular
region fused to the CTF domain of either CD46-Cyt1 or Cyt2
isoform were created by SOE-PCR [40,41] using PHUSION hot
start polymerase. For chimeric CD19-Cyt1, primer AA1 annealed
at the 59 end of CD19; primer AA4 annealed at the 39 end of Cyt1
cDNA. Primers AA6 and AA7 were complementary to each other,
overlapping at the respective fusion point of the two cDNA
molecules. The chimeric cDNA was cloned into pcDNA3 vector
Figure 10. Proposed model of the yin and yang role of CD46 in human T cell activation. Upon CD3/CD46 activation, there is
downregulation of Cyt1 expression and increase in Cyt2 expression at the early time point compared to unstimulated T cells. Cyt1 expression level
then returns to the level of expression observed in unstimulated T cells, while the downregulation of Cyt2 expression occurs at the late time point.
We propose that Cyt1 isoform is first cleaved by P/cS while there is an increase in Cyt2 expression. This results in T cell activation, increased
proliferation and CD25 expression as well as IL-10 secretion. Later on, Cyt2 is processed by the P/cS, which induces a negative feedback mechanism
and results in T cell inhibition, with lowered IFNc secretion, decreased proliferation and CD25 expression and increased CTLA-4 expression.
doi:10.1371/journal.pone.0016287.g010
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(Invitrogen) using the HindIII and XbaI restriction sites introduced
in the cDNA. The chimeric CD19-Cyt2 construct was similarly
generated, using primers AA1, AA5, AA6 and AA7. All constructs
were verified by sequencing.
Proliferation assay
Eighteen hours post transfection, T cells were labeled with
CFSE after extensive washes with cold PBS, for 10 min at 37C.
After quenching the reaction with cold 10%RPMI and further
washes, the cells were seeded in 96-well plates precoated with
immobilized antibodies as indicated. Four days later, the
proliferation and CD25 expression (anti-CD25-APC) was assessed
by flow cytometry.
IFNc and IL-10 secretion assays
Eighteen hours post transfection, T cells were seeded into 48-
well culture plates (2.56105 cells per well) pre-coated with various
antibodies. Four days later, the cells were harvested and the
amounts of IL-10- and IFNc-secreting cells were determined using
the secretion assays from Miltenyi (IL-10-PE; IFNc-APC).
Flow cytometry
The expression level of CD46 ectodomain was assessed by flow
cytometry with anti-CD46-FITC (BD Pharmingen). The expres-
sion level of Cyt1 or Cyt2 was performed by intracellular flow
cytometry staining (with 0.1% saponin) using the specific
monoclonal anti-Cyt1 or Cyt2 antibodies previously generated
[29]. The relative expression to the staining with the isotype
control was calculated by calculating the DMFI (MFI antibody
stained - MFI control antibody).
Detection of phospho-LAT
Transfected cells were activated with the appropriate Abs
(CD3/CD28 with CD19 or irrelevant IgG1) and addition of a
cross-linker for 5 min at 37uC [12]. Activated cells were
immediately fixed (Cytofix, BD Biosciences) and then permeabi-
lized (Perm buffer, BD Biosciences). The presence of phospho-
LAT was detected with an anti-pLAT (pY171; BD Biosciences)
and analyzed by flow cytometry.
Statistical analyses
The groups were analyzed using the Graphpad Prism software.
Data were analyzed using the Wilcoxon test, a non-parametric test
that does not assume Gaussian variation. All p-values are two-tails
and with a 95% confidence interval.
Supporting Information
Figure S1 Addition of the GM6001 metalloproteinase
inhibitor inhibits IL-10 production by CD46-activated T
cells. Purified CD4+ T cells were left unstimulated, or stimulated
by immobilized anti-CD3 or anti-CD3/CD46, as indicated, in
presence of GM6001 or DMSO as control for 4 days. The
proliferation was then assessed by thymidine incorporation, and
the levels of IL-10 and IFNc secreted in the culture supernatants
were analyzed by ELISA.
(TIFF)
Figure S2 Timely downregulation of expression of Cyt1
and Cyt2 upon T cell activation. Purified CD4+ T cells were
left unstimulated, or stimulated by immobilized anti-CD3/CD46,
as indicated, for 28–40 hrs (early time point) and 96–120 hrs (late
time point). The expression of the two cytoplasmic tails of CD46
was determined by intracellular staining (0.1% saponin) using
specific anti-Cyt1 or Cyt2 monoclonal antibodies (blue line), or
isotype control (red line). The data obtained for three different
donors are shown.
(TIFF)
Figure S3 Inhibition of P/cS increases the levels of
Cyt1/Cyt2 expression. CD4+ T cells were stimulated by
immobilized anti-CD3/CD46 antibodies for 2 or 4 days in
presence or absence of L-685,458, a P/cS inhibitor. The
expression of Cyt1 and Cyt2 was then analyzed by flow cytometry.
Addition of L-685,458 increases the levels of Cyt1 and Cyt2.
(TIFF)
Figure S4 CTF expression can also alter the profile of
cytokine produced and the proliferation of CD3-activat-
ed transfected T cells. Twenty-four hours post transfection by
















1Bold letters indicate HindII and XbaI restriction sites. Overlapping sequences for generation of chimeric cDNA are underlined.
doi:10.1371/journal.pone.0016287.t001
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Amaxa/Lonza with the different CTF constructs, CD4+ T cells
were stimulated by immobilized anti-CD3 or anti-CD3/CD28
antibodies. (A) The secretions of IL-10 and IFNc were assessed by
secretion assays (Miltenyi). (B) Proliferation was assessed by flow
cytometry (n = 8). In some experiments, anti-CD3 stimulation was
very weak – hence we mainly studied the effects of expression of
CTF in CD3/CD28 activated T cells. However, in the
experiments where it induced T cell activation, we were then
able to observe a similar effect of the CTF constructs.
(TIFF)
Figure S5 Cyt2 inhibits proliferation of CTLA-4+ cells.
Twenty-four hours post transfection by Amaxa/Lonza with the
different CD19-CD46 fusion proteins, CD4+ T cells were pre-
labeled with CFSE and then stimulated by immobilized anti-
CD3/CD28, anti-CD3/CD28/CD19 or anti-CD3/CD28/CD46
antibodies and CTLA-4 expression was determined after 4 days.
The proliferation of CTLA-4+ gated cells is shown.
(TIFF)
Figure S6 Kinetics of Cyt1 and Cyt2 expression upon
CD46-coactivation. Purified CD4+ T cells were left unstimu-
lated (US), or stimulated by immobilized anti-CD3/CD46 (Stim),
as indicated, for several days. The expression of the two
cytoplasmic tails of CD46 was determined by intracellular staining
using specific anti-Cyt1 or Cyt2 monoclonal antibodies (n = 5).
(TIFF)
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Prostaglandin E2 Affects T Cell Responses through
Modulation of CD46 Expression
Karoline Kickler,* Kathryn Maltby,* Siobhán Ni Choileain,*,† Jillian Stephen,*
Sheila Wright,‡ David A. Hafler,x,{,‖ Henry N. Jabbour,‡ and Anne L. Astier*,†
The ubiquitous protein CD46, a regulator of complement activity, promotes T cell activation and differentiation toward a regulatory
Tr1-like phenotype. The CD46-mediated differentiation pathway is defective in several chronic inflammatory diseases, underlying
the importance of CD46 in controlling T cell function and the need to understand its regulatory mechanisms. Using an RNA
interference-based screening approach in primary T cells, we have identified that two members of the G protein-coupled receptor
kinases were involved in regulating CD46 expression at the surface of activated cells. We have investigated the role of PGE2, which
binds to the E-prostanoid family of G protein-coupled receptors through four subtypes of receptors called EP 1–4, in the
regulation of CD46 expression and function. Conflicting roles of PGE2 in T cell functions have been reported, and the reasons
for these apparent discrepancies are not well understood. We show that addition of PGE2 strongly downregulates CD46 expression
in activated T cells. Moreover, PGE2 differentially affects T cell activation, cytokine production, and phenotype depending on the
activation signals received by the T cells. This was correlated with a distinct pattern of the PGE2 receptors expressed, with EP4
being preferentially induced by CD46 activation. Indeed, addition of an EP4 antagonist could reverse the effects observed on
cytokine production after CD46 costimulation. These data demonstrate a novel role of the PGE2–EP4 axis in CD46 functions, which
might at least partly explain the diverse roles of PGE2 in T cell functions. The Journal of Immunology, 2012, 188: 5303–5310.
CD46 is a ubiquitously expressed type I membrane proteinthat was first identified as a regulator of the complementcascade, preventing autolysis of cells by binding to C3b/
C4b and allowing their cleavage by protease I (1, 2). About 10
years ago, CD46 was shown to link innate immunity to acquired
immunity. Indeed, costimulation of the TCR with CD46 leads to
increased T cell proliferation (3) and affects T cell morphology (4)
and polarity (5). Importantly, CD46 also drives Tr1 differentiation,
characterized by secretion of high amounts of IL-10 (6) and
granzyme B (7). IL-2 is key in CD46-mediated Tr1 differentiation,
acting as a sensor to switch T cells from a Th1 to a Tr1 phenotype
(8). The enzymatic processing of CD46 is a crucial feature of the
CD46-mediated pathway that is involved in regulating T cell
function. CD46 surface expression is strongly downregulated
upon its own triggering, partly due to MMP cleavage of its
ectodomain (9–11). This is followed by g-secretase cleavage of
the two cytoplasmic tails of CD46, which is important to initiate
and terminate T cell responses (11, 12). This again underlines the
importance of the plasticity of CD46 in controlling T cell ho-
meostasis. Moreover, CD46-mediated Tr1 differentiation is altered
in patients with multiple sclerosis (MS), characterized by an im-
paired IL-10 secretion upon CD3/CD46 costimulation (13–16),
and the dysregulation of CD46 pathways in T cells was recently
described in patients with asthma (17) and in a small group of
patients with rheumatoid arthritis (RA) (8). The identification of
a dysfunctional CD46 pathway in chronic inflammatory diseases
highlights its importance in controlling T cell homeostasis and
further underlines the need to understand its regulation and the
molecular mechanisms responsible for its functions.
Using an RNA interference (RNAi)-based approach (18) to
dissect the molecular pathways that regulate CD46 expression on
primary human T cells, we identified two members of the serine/
threonine kinase G protein-coupled receptor kinase (GRK) family
involved in the regulation of CD46 expression. GRKs phosphor-
ylate agonist-activated G protein-coupled receptors (GPCRs) (19,
20), resulting in their binding to b-arrestins and subsequent sig-
naling impairment and internalization, a process known as de-
sensitization (21, 22). There are seven types of GRK referred to
as GRK 1–7, each with different expression profiles (21). Among
them, GRK 2, 3, 5, and 6 are ubiquitously expressed, but are
expressed at particularly high levels in immune cells, and have
been shown to regulate inflammation (23).
In this study, we show that the knockdown of GRK2 and GRK3
strongly decreased CD46 expression and that activation of CD46
increased GRK2/3 expression levels. GRK2/3 have been shown to
regulate PGE2 receptors, among other GPCRs (24). As PGE2 is
a known modulator of T cell functions (25), we assessed the role of
PGE2 in the regulation of CD46 expression and function to dem-
onstrate a role of GRKs in the CD46 pathway. PGE2 notably inhibits
T cell proliferation by downregulating both IL-2 and the IL-2Ra-
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chain (CD25) (26). PGE2 can also markedly reduce production of
Th1-associated cytokines such as IFN-g, causing a switch from a
Th1 to a Th2 cytokine secretion profile in these cells (26, 27).
However, PGE2 has also been shown to promote Th1 differentiation
(28, 29) and to either decrease (30, 31) or promote IL-17 production
(32–35). PGE2 can also induce Foxp3 in naive CD4
+ T cells, with
an increase in regulatory cell function (36). Hence, multiple effects
of PGE2 have been reported, and although the local concentrations
of PGE2 are important to control T cell differentiation (28), the
reasons for these apparent discrepancies are not well understood.
Moreover, there are no studies on any potential effects of PGE2 on
the CD46-mediated pathway. In this study, we first demonstrate that
the addition of PGE2 to T cell cultures strongly decreased CD46
expression in activated T cells. Second, we show that the addition of
PGE2 differentially affected T cell responses depending on the ac-
tivation signals, as responses to CD28 and CD46 costimulation were
different. Whereas T cell proliferation was decreased in all con-
ditions, the IL-10/IFN-g ratio was either increased or decreased
depending on the activation status. Moreover, specific changes in the
phenotype of activated T cells were observed. PGE2 binds to the E-
prostanoid family of GPCRs, through four subtypes of receptors
called EP 1–4 (24). We show that CD46 and CD28 costimulation
led to different patterns of expression of the two PGE2 receptors,
EP2 and EP4, with EP4 being preferentially expressed by CD46
activation. Overall, we demonstrate a novel role of the PGE2–EP4
axis in CD46 functions and how this influences the effects of PGE2
on human T cell activation.
Materials and Methods
Abs and reagents used
The Abs used for activation were anti-CD3 (OKT3; 5 mg/ml), anti-CD28
(CD28.2; 5 mg/ml), and anti-CD46 (20.6; 10 mg/ml), kindly provided by
Dr. Chantal Rabourdin-Combe (INSERM, Lyon, France). PGE2 (100 nM,
unless otherwise stated) was from Sigma. Recombinant human IL-2
(Tecin) was added at 10 U/ml. The selective EP4 antagonist (ONO-AE2-
227; 300 nM) was chemically synthesized by Charnwood Molecular
(Leicester, U.K.). The EP2 antagonist (AH6809; 10 mM) was purchased
from Calbiochem (Nottingham, U.K.). The Abs for flow cytometry were
as follows: anti-CD46–FITC (clone MEM-258; BioLegend), anti-CD25–
allophycocyanin (clone M-A251), anti-CD69–PE (clone FN50), and anti–
CTLA-4–PE (clone BNI3) (BD Pharmingen). Anti-human Foxp3–allo-
phycocyanin (clone PCH101; eBioscience) recognized all Foxp3+ T cells
(37). Anti–p-Tyr STAT3 (pY705)–Pacific blue was purchased from BD
Biosciences. The Abs used for the GRK2/3 Western blot (rabbit) was
purchased from Cell Signaling and used at 1 mg/ml (in 5% milk–TBST),
followed by addition of anti-rabbit IgG–HRP from Promega (1:10,000).
Cell purification and activation
PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation
(Pharmacia LKB Biotechnology, Piscataway, NJ) from heparinized venous
blood from healthy donors obtained after informed consent. Ethical approval
was obtained from the Lothian Board Ethics Committee. CD4+ T cells were
negatively isolated using magnetic beads (purification.90%; CD4 Isolation
Kit II; Miltenyi Biotec, Auburn, CA). T cells (13 106 cells/1 ml/well) were
then cultured in 24-well plates precoated with anti-CD3, anti-CD28, or anti-
CD46, in RPMI 1640 containing 10% FCS. Exogenous IL-2 (10 U/ml) was
added to CD3/CD46 stimulated cells as previously described (6). In some
experiments, PGE2, selective EP2 or EP4 antagonists, and DMSO or ethanol
as vehicle control (similar dilution) were added to the culture.
The RNAi Consortium RNAi library
The complete description of the RNAi Consortium lentiviral RNAi library
used in this study has been reported (38) and already used to infect primary
T cells (18), and it is now commercialized by Sigma-Aldrich. Human
genes are targeted with !5 short hairpin RNAs (shRNAs) expressed under
the control of the U6 Pol III promoter in a lentiviral vector (pLKO.1) that
also confers puromycin resistance. Plasmid DNA purification and lentiviral
production were performed as described [(38) and http://www.broad.mit.
edu/rnai/trc/lib].
T cell stimulation and infection
CD4+ T cells (2 3 105 cells/well) were cultured in 96-well plates precoated
with anti-CD3 (OKT3; 2.5 mg/ml) and anti-CD28 (2D10; 2.5 mg/ml) in
presence of human recombinant IL-2 (Tecin, 20 U/ml; National Cancer
Institute, Frederick, MD) for 24 h before infection. The infection was carried
out by centrifugation for 90 min at 2300 rpm at room temperature in
presence of the viral supernatant and polybrene (8mg/ml). After removal of
the virus, fresh medium was added. Infected cells were then selected by
addition of puromycin (2.5 mg/ml) 48 h postinfection, and the cells were
expanded in IL-2 for 10 d. Cells were then restimulated with anti-CD3/
CD28 Abs in the presence of IL-2. At 24 h post-restimulation, the level
of CD46 expression at the cell surface was determined by flow cytometry.
GRK2/3 detection by Western blot
Purified CD4+ T cells were activated in 48-well plates precoated with anti-
CD3, anti-CD46, or anti-CD28 Abs and cultured for 3 d. Cells were then
lysed with lysis buffer (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl,
pH 8, 5 mM EDTA, 1 mM PMSF, 1 mM iodoacetamide, 10 mM NaF, 0.4
mM Na2VO4). Cell lysates were run on an 8% SDS-PAGE and amounts of
GRK2 and GRK3 detected by Western blot using anti-GRK2 Abs that
cross-react with GRK3 (Cell Signaling). The membranes were then
stripped and reblotted with anti-GAPDH mAb to evaluate protein quan-
tities. Densitometry analyses (with ImageJ) were then performed to cal-
culate the GRK/GAPDH ratio.
Flow cytometry
The expression level of CD46, CD25, and CD69 was assessed by flow
cytometry with anti-CD46–FITC, anti-CD69–PE, and anti-CD25–allo-
phycocyanin. The presence of CTLA-4 (PE) and Foxp3 (allophycocyanin)
was determined after permeabilization of the cells with 0.1% saponin. The
relative expression to the staining with the isotype control was calculated
by calculating the Dmean fluorescence intensity (MFI) (MFI Ab stained 2
MFI control Ab). Samples were run on a BD FACSCalibur. Phosphory-
lation of STAT3 was analyzed with an anti–p-Tyr STAT3–Pacific blue and
run on a BD FACSCalibur LSR Fortessa. All flow cytometry data were
analyzed using FlowJo (Tree Star).
T cell proliferation
Purified T cells (23 105 cells/200 ml/well) were cultured in 96-well plates,
precoated with anti-CD3, anti-CD28, or anti-CD46, in 10% FCS–RPMI
1640 for 72 h before addition of 1 mCi [3H]thymidine (Amersham). Pro-
liferation was determined using a Liquid Scintillation Counter (Wallac).
ELISA
Cytokine production was determined in cell culture supernatants using
ELISA specific for human IL-10 (BD Pharmingen, San Jose, CA) and IFN-g
(Endogen, Cambridge, MA). Recombinant hIL-10 (BD Pharmingen) and
hIFN-g (Endogen) were used as standards.
EP 1–4 PCR
These PCRs were performed as previously described (39). Briefly, RNAs
from activated T cells were extracted using the RNeasy Mini Kit (Qiagen).
RNA samples were reverse-transcribed using VILO (Invitrogen, Paisley,
U.K.) according to the manufacturer’s guidelines. RT-PCR analysis of EP1,
EP2, EP3, and EP4 was carried out using an ABI Prism 7500 (Applied
Biosystems, Warrington, U.K.). Results are expressed relative to a standard
(pooled normal human endometrial tissue cDNA) included in all reactions.
Data are represented as mean 6 SEM.
Statistical analyses
The groups were analyzed using the GraphPad Prism software. Data were
analyzed using the Wilcoxon test. All p values are two-tailed and with
a 95% confidence interval.
Results
An RNAi screen identifies GRKs as novel regulators of CD46
expression in primary human T cells
To gain new insights into the regulation of CD46 expression in
primary human T cells, we carried out an RNAi screen using
a subgenomic library targeting !1000 genes, focused on kinases
and phosphatases, and containing three to five shRNAs per gene,
as previously described (18). Our goal was to identify novel










































regulators of CD46 expression in primary human T cells. The
level of CD46 expression at the cell surface of T cells infected
with lentivirus particles expressing a distinct and unique shRNA
was determined by flow cytometry. Using a statistical Z-score (see
Ref. 18) to quantify the deviation of CD46 levels from the mean of
all measurements within the same plate, we selected shRNAs that
significantly modulated CD46 expression compared with the co-
hort of control wells consisting of cells infected with control
shRNAs (against nonmammalian reporter genes) (Fig. 1A). GRK2
and GRK3, two members of the GRK family, decreased CD46
expression once knocked down (Fig. 1A, circled). Two shRNA
constructs out of four for GRK2 and two out of three for GRK3 led
to a similar phenotype (Fig. 1A). These data were reproduced in
two independent experiments performed with different donors
(Fig. 1B). Representative plots showing normal CD46 expression
compared with expression upon GRK2 and GRK3 knockdowns are
shown in Fig. 1C. Hence, downregulation of GRKs decreased
CD46 expression in activated primary human T cells.
CD46 activation led to enhanced GRK2/3 levels
T cell activation by PHA and anti-CD3 Abs increases GRK ex-
pression and activity (40, 41). Hence, we next assessed whether
CD46 costimulation could modulate GRK2/3 levels. CD4+ T cells
were activated by immobilized anti-CD3, anti-CD3/CD28, or anti-
CD3/CD46 Abs for 3 d. GRK2/3 levels were then assessed by
Western blots using anti-GRK2/3 Abs. T cell activation by CD28
and especially CD46 led to enhanced levels of GRKs (Fig. 1D).
Hence, these data demonstrate a relationship between GRKs and
the CD46 pathway.
PGE2 decreases CD46 surface expression in activated T cells
PGE2 is a known T cell modulator that signals through binding to
the E-prostanoid family of GPCRs (namely EP 1–4). GRK2 regu-
lates expression of the EP4 receptor (24), and we found that EP4
knockdown led to increased CD46 expression (Supplemental Fig. 1),
suggesting a role of PGE2 in controlling CD46 expression. Hence, to
assess whether signaling through GPCR/GRK could modulate CD46
expression, we next investigated the effect of PGE2 on CD46 ex-
pression and function. CD4+ T cells were activated with anti-CD3,
anti-CD3/CD46, or anti-CD3/CD28 Abs in the presence of PGE2 or
DMSO as a vehicle control, and expression of CD46 was monitored
by flow cytometry. Fig. 2A shows the representative data obtained
after 2 d of culture for one donor, and Fig. 2B shows the average data
obtained with the different donors after 2 or 5 d of culture (n = 15).
The percentage changes in CD46 expression upon addition of PGE2
(compared with expression levels in absence of PGE2 as baseline)
were also calculated and are presented in Fig. 2C. As previously
shown, CD46 ligation led to a strong downregulation of its expres-
sion. A slight increase in CD46 surface expression was detected
when CD46 and CD28 were co-ligated, suggesting that there is a
cross-talk between CD28 and CD46 that partially restores CD46
levels (Fig. 2B). The addition of PGE2 led to a slight increase in
CD46 expression in unstimulated T cells after 2 d of culture (Fig. 2B,
2C). In contrast, PGE2 treatment led to decreased CD46 expression
in activated T cells with the stronger reduction (!40%) observed
upon CD46 costimulation. The effect of PGE2 was lost in CD3-
activated T cells at day 5 (Fig. 2B). However, the decrease in CD46
expression was sustained by CD28 and CD46 costimulation, with
again the stronger effect observed upon CD46 ligation. Fig. 2D shows
the dose-dependent effect of PGE2 on CD46 expression. Hence,
PGE2 clearly modulates CD46 expression in activated T cells.
PGE2 differentially affects T cell activation depending on the
costimulation signal
We next assessed the role of PGE2 on T cell activation. CD4
+
T cells were activated with anti-CD3, anti-CD3/CD46, or anti-
CD3/CD28 Abs in the presence or absence of PGE2. First,
T cell proliferation was determined by [3H]thymidine incorpora-
tion (n = 10). As expected, addition of PGE2 significantly de-
creased T cell proliferation in a dose-dependent manner, but the
strongest effect was observed upon CD46 costimulation (Fig. 3A,
3B). Similar effect was observed when proliferation was deter-
mined by CFSE labeling (data not shown). Second, we determined
whether the levels of cytokine produced by activated T cells were
modified by addition of PGE2. We focused on IL-10 and IFN-g as
CD46 has the ability to switch T cells from producing IFN-g to
FIGURE 1. GRKs regulate CD46 expression in primary T cells. (A) An
RNAi screen was performed on primary CD4+ T cells infected by lenti-
virus coding for 5000 different shRNA (1 shRNA construct per well). The
Z-score obtained after knockdown of GRK2 and GRK3 compared with
controls is shown. Infection by two different shRNA constructs targeting
GRK2 and GRK3 led to strong negative Z-scores, corresponding to a de-
crease in CD46 expression (circled). (B) The Z-scores obtained across two
independent experiments with different donors for the multiple shRNAs
targeting GRK2 and GRK3 are shown. The phenotypes observed were
repeatedly due to the same hairpins. (C) CD46 expression measured by
flow cytometry on cells infected with control lentiviruses or shRNA for
GRK2 and GRK3. Arrows point to the constructs inducing CD46 down-
regulation. (D) CD46 activation induces GRK2/3. CD4+ T cells were left
unstimulated (US) or were activated with immobilized anti-CD3, anti-
CD3/CD28, or anti-CD3/CD46 Abs for 3 d. Cell lysates were obtained and
GRK2/3 levels determined by Western blot. Quantification was obtained
after stripping of the membrane and reblotting with GAPDH Abs. The
GRK/GAPDH ratio obtained for four donors is also represented.










































secreting IL-10 (8) and does not induce any Th2 cytokines (6, 42).
Secretion of IL-10 and IFN-g was quantified by ELISA, and we
also calculated the IL-10/IFN-g ratio to bypass the variations due
to the changes in proliferation (n = 15). As previously described,
CD46 activation promotes a Tr1-like phenotype, visualized by an
increase in the IL-10/IFN-g ratio (Fig. 3C). PGE2 drastically de-
creased cytokine production (Fig. 3C). However, PGE2 had dif-
ferent effects on the relative levels of cytokines produced
depending on the activation signals received by the T cells. A
trend toward an increase in IL-10/IFN-g was observed upon CD3
activation alone, reflecting the known effect of PGE2 in the
downregulation of IFN-g. Costimulation with CD28 had no sig-
nificant effect on the IL-10/IFN-g ratio, suggesting that the lower
level of cytokine production was mainly correlated with the lower
proliferation of the cells. In contrast, ligation of CD46 resulted in
a significant decrease in the IL-10/IFN-g ratio in the presence of
PGE2. Moreover, the effects of CD46 were dominant over CD28
as also observed upon CD3/CD28/CD46 co-ligation. Importantly,
similar trends were obtained when naive CD4+ T cells were used
(data not shown). Overall, these data indicate that PGE2 exerts
different effects on cytokine production that mainly depend on the
signals received by T cells.
PGE2 modulates the phenotype of CD46-costimulated T cells
We next determined whether PGE2 was affecting the phenotype of
CD46-costimulated T cells. As PGE2 is known to reduce CD25
expression in CD3-activated T cells (36), we assessed the ex-
pression levels of CD25 as a control. We also determined the
levels of CD69, another activation marker (Fig. 4A). Moreover, as
PGE2 has been reported to induce regulatory T cells (Tregs) (36),
we determined the expression levels of CTLA-4 (Fig. 4A), Foxp3,
and CD46 (Fig. 4B). Fig. 4C represents the average change in
expression upon addition of PGE2 obtained for the different do-
nors (n = 6). A strong decrease in CD25 expression was detected
for all conditions of activation, including CD46-costimulated
T cells. Surprisingly, whereas CD69 expression was strongly de-
creased in the presence of PGE2 upon CD3 and CD28 activation,
its expression was maintained when the cells were costimulated by
CD46. T cell activation in the presence of PGE2 also resulted in
a decrease in CTLA-4 expression, which was slightly restored
upon costimulation. Lastly, PGE2 increased Foxp3 expression in
both CD28 and CD46 costimulated T cells. Notably, the cells
acquiring Foxp3 maintained CD46 expression although CD46
expression in CD46-costimulated T cells was downregulated by
PGE2 (Fig. 4B). These data show that, depending on the activa-
tion signals, PGE2 differentially affects a variety of phenotypic
markers in T cells that are involved in regulating T cell activation
as well as Treg functions.
PGE2 inhibits STAT3 phosphorylation
PGE2 decreased CD46 expression in activated T cells, and it has
been shown to modulate STAT3 signaling (43, 44). As the CD46
FIGURE 2. PGE2 regulates CD46 expression. (A) Purified CD4
+ T cells were left unstimulated (US) or stimulated as indicated by immobilized Abs in
the presence of PGE2 or DMSO as vehicle control. CD46 expression was then monitored by flow cytometry after 2 d (CD46 staining: shaded gray areas;
isotype control: black lines). (B) The expression of CD46 was monitored in T cells cultured for either 2 or 5 d in the presence or absence of PGE2 (n = 15).
(C) The percentage changes in CD46 expression upon addition of PGE2 compared with expression levels in the absence of PGE2 as baseline are repre-
sented. Samples were analyzed using the Wilcoxon test. The means 6 SEM are shown (n = 15 donors). (D) The expression of CD46 was monitored in
T cells cultured for 3 d in the presence of increasing doses of PGE2, as indicated (n = 3).










































promoter includes a STAT3 binding site, and as the direct interac-
tion between STAT3 and CD46 has been previously demonstrated
by chromatin immunoprecipitation (ChIP) assays, mutations of the
STAT3 binding sites in CD46, and by the use of anti-STAT3 oli-
gonucleotides (45, 46), we determined the levels of STAT3 phos-
phorylation in activated T cells. T cells were activated for 24 h in
the presence or absence of PGE2 and STAT3 phosphorylation de-
termined by flow cytometry. An increase in phosphorylation was
observed in all activated T cells, including CD46-costimulated
T cells. Addition of PGE2 decreased STAT3 phosphorylation,
with the strongest effect observed upon CD46 ligation (Fig. 5).
Specific changes in PGE2 receptors are induced by CD46
activation
PGE2 binds to four GPCRs, namely EP1, EP2, EP3, and EP4. We
determined their mRNA expression by quantitative PCR upon
FIGURE 3. PGE2 modulates T cell
activation depending on the activation
signals. Purified CD4+ T cells were
stimulated by immobilized Abs as in-
dicated in the presence or absence of
PGE2. (A) Proliferation was deter-
mined after 4 d by [3H]thymidine in-
corporation (n = 10). (B) The dose
effect of PGE2 on T cell proliferation
of T cells activated by anti-CD3/CD28,
anti-CD3/CD46, or anti-CD3/CD28/
CD46 is shown (n = 3). (C) Cells were
activated as in (A), and the amounts of
IL-10 and IFN-g in the supernatants
were determined by ELISA (n = 15).
The IL-10/IFN-g ratio is also repre-
sented to show specific effects inde-
pendent of the changes in proliferation
induced by PGE2.
FIGURE 4. PGE2 modulates T cell phenotype upon activation. (A) Purified CD4
+ T cells were stimulated with immobilized anti-CD3, anti-CD3/anti-
CD28 (CD3.28), anti-CD3/CD46 (CD3.46), or anti-CD3/CD28/CD46 (CD3.28.46) Abs in the presence (shaded gray histograms) or absence (black line) of
PGE2. After 5 d, the expression of surface CD25 and CD69 and intracellular CTLA-4 was determined by flow cytometry. (B) Expression of Foxp3 and
CD46 was also determined after intracellular staining. (C) The percentage changes in CD25, CTLA-4, CD69, and Foxp3 expression upon addition of PGE2
obtained for the different donors are represented (n = 6).










































T cell activation with anti-CD3, anti-CD3/CD28, and anti-CD3/
CD46 Abs for 48 h (n = 3 different donors, and experiments
performed at different times). As previously reported (33), only
EP2 and EP4 were strongly expressed in T cells. Whereas CD3
and CD28 costimulation induced both EP2 and EP4 expression
(Fig. 6A), CD46 activation only led to an increased EP4 expres-
sion, hence strongly increasing the EP4/EP2 ratio (Fig. 6B).
To understand the role of EP4 in CD46 activation, we added the
selective EP4 antagonist ONO-AE2-227 to T cell culture and
assessed cytokine production. Blocking EP4 led to an increase in
the IL-10/IFN-g ratio, but only when CD46 was ligated, and we
did not observe any effect of the EP2 antagonist AH6809 (Fig.
6C). This further demonstrates the role of the PGE2–EP4 axis in
regulating IL-10 production by CD46-activated T cells.
Discussion
This study reports novel elements in the complex regulation of
primary human T cell activation. Our data show that GRKs and the
PGE2–EP4 axis are involved in the CD46 pathway and that it
modulates CD46 expression and functions. Knocking down GRKs
led to a strong downregulation of CD46 at the surface of activated
T cells. It is known that GRK levels are modulated by T cell
activation (40, 41), and we report in this study that CD46 co-
stimulation increased levels of GRK expression. Notably, de-
creased levels of GRK2 and GRK6 were observed in T cells from
patients with RA (47) and MS (48, 49), and proinflammatory
cytokines and oxygen radicals can decrease GRK2 levels in vitro
(50). Hence, the levels of GRKs are highly modulated during
inflammation, and this suggests the subsequent modulation of
expression of CD46, a key regulator of T cell activation, in in-
flammatory settings. As CD46 is dysfunctional in T cells from
patients with MS and RA, future investigation into the role of
GRKs upon CD46 activation in these patients might highlight
some of the molecular mechanisms of this defective pathway.
GRKs control GPCR signaling by phosphorylating these
receptors, which provokes their internalization and degradation,
a crucial feature of the plasticity of the immune system involved in
the regulation of inflammation (reviewed in Ref. 23). Indeed, al-
most 30% of drugs on the market target GPCR (51, 52). We in-
vestigated the role of PGE2, which signals through four subtypes
of the E-prostanoid subfamily of GPCRs (EP1, EP2, EP3, and
EP1–4) in T cell responses. Although the antiproliferative role of
PGE2 on T cells is well established, the role of PGE2 in T cell
differentiation is much more complex and not well understood,
as it has some complex proinflammatory and immunoregulatory
properties. In this study, we have compared the effects of PGE2 in
CD28 and CD46 costimulated T cells. As previously shown, PGE2
exerted a strong antiproliferative role on all activated T cells.
However, the effect was much stronger in CD46-costimulated
T cells than in CD28-coactivated T cells. Despite the decrease
in proliferation, activated T cells did secrete some significant
levels of IL-10 and IFN-g. In a number of studies, the addition of
PGE2 caused a marked reduction in Th1 cytokines (26, 27),
whereas other studies indicate the role of PGE2 in inducing Th1 or
Th17 differentiation (28, 33). We found that the relative levels of
IL-10 and IFN-g secreted were differentially modulated depend-
ing on the activation signals received by the T cells. Whereas CD3
activation favored an increase in the IL-10/IFN-g ratio, as previ-
ously described, we did not find any significant effects on CD28-
costimulated T cells. However, there was a significant decrease in
the IL-10/IFN-g ratio upon CD46 ligation. PGE2 therefore skews
the usually regulatory cells toward a more inflammatory secretion
profile. PGE2 downregulates both IL-2 and CD25 (26). As IL-2 is
required for CD46-mediated Tr1 differentiation (8), it is likely that
the effect of PGE2 on IL-2 and CD25 expression as well as the
inhibition of CD46 expression contribute to inhibit IL-10 pro-
duction by CD46-activated T cells. Our data also underline that
the actions of PGE2 are largely dependent on the activation of the
T cells, as previously reported on the secretion of IL-3 by T cells
(53). Hence, it becomes clear that PGE2 differentially modulates
T cell responses depending on the environment and signals re-
ceived by the T cells. Our data highlight the role of PGE2 in the
production of IFN-g and IL-10, which are, at least in part, de-
termined by the regulation of expression of CD46.
PGE2 strongly modulates the phenotype of activated T cells. We
show that the addition of PGE2 decreased CD46 expression. This
was observed in all activated T cells, although the effect was much
more pronounced upon CD46 ligation. Of note, we observed a
slight increase in CD46 expression in unactivated T cells. Notably,
PGE2 has been found to upregulate CD55, another regulator of
complement activation molecule, in colon cancer cells (54).
Hence, there is a similar pattern for CD46 in resting T cells.
However, the increased expression of CD55 might also partially
counteract the downregulation of CD46 expression observed in
FIGURE 5. PGE2 inhibits STAT3 phosphorylation. Purified CD4
+
T cells were stimulated by immobilized Abs as indicated in the presence or
absence of PGE2. After 24 h, the level of p-Tyr STAT3 was determined by
flow cytometry (representative of two independent experiments). (STAT3
staining: shaded gray areas; isotype control: black lines.)
FIGURE 6. T cell activation results in expression of different PGE2
receptors depending on the activation signal. Purified CD4+ T cells were
stimulated by immobilized Abs as indicated for 2 d. mRNA was then
prepared and the expression levels of the four PGE2 receptors (EP1–4)
determined. (A) Relative expression of EP2 and EP4 in activated T cells.
The means 6 SEM are shown (n = 3 donors). Samples were analyzed
using the Wilcoxon test. (B) The ratio of EP4/EP2 relative expression has
been plotted. CD46 activation results in an increased EP4/EP2 ratio. (C)
EP4 is involved in the modulation of cytokines produced by CD46-
costimulated T cells. Purified CD4+ T cells were stimulated by immobi-
lized Abs as indicated in the presence of EP2 or EP4 antagonist and
DMSO or ethanol as a control, respectively. The levels of IL-10 and IFN-g
were quantified, and the IL-10/IFN-g ratio is represented. Representative
of three experiments.










































activated cells to protect from complement attack. Importantly, as
CD46 is ubiquitously expressed, it is likely that PGE2 will also
modulate its expression and function in other cell types, such as
dendritic cells, especially as PGE2, like CD46, has been shown to
regulate IL-23 production (35, 55).
It was previously demonstrated that PGE2 decreased CD25
expression and upregulated Foxp3 levels in human T cells (36).
We confirmed these findings and report that similar decreased
CD25 and increased Foxp3 expression are also detected after
CD46 costimulation. Moreover, PGE2 caused a strong reduction
of expression of the coinhibitory molecule CTLA-4 on CD3-
activated cells, but CTLA-4 expression was mostly maintained
upon costimulation. CTLA-4 is expressed at high levels by Tregs
and is involved in their function (56), hence the increase in Foxp3
correlates with CTLA-4 expression. PGE2 also decreased CD69
expression in activated T cells, although not in CD46-costimulated
cells. CD69 is transiently induced after activation but can persist
on leukocyte infiltrates in chronic inflammatory diseases. CD69-
deficient mice developed exacerbated forms of arthritis, allergic
asthma, and other inflammatory settings, and it was proposed that
CD69 could act as a regulator of Th17 differentiation (57). The
fact that PGE2 maintained CD69 in CD46-costimulated T cells
is intriguing and warrants further investigation on this pathway,
notably in chronic inflammatory diseases where the CD46 path-
way is dysfunctional.
The different effects on cytokine production and phenotype
observed in the presence of PGE2 were correlated with distinct
profiles of expression of PGE2 receptors. CD3 and CD28 led to
similar increase in EP2 and EP4, which is consistent with what
had been shown in the mouse (58) and in human T cells (33).
However, CD46 costimulation largely favored EP4 expression,
and addition of an EP4 antagonist increased the IL-10/IFN-g ratio
by CD46-activated T cells, highlighting the specific role of EP4
in CD46 function. Contrasting effects of PGE2 on cytokine pro-
duction have previously been shown to be mediated by specific
receptors. Boniface et al. (33) show that PGE2 can act on CD3/
CD28/CD2-coactivated human T cells to promote IL-17, which is
mainly mediated by EP2, whereas it inhibits IFN-g and IL-10
production mainly through EP4 signaling. Both the EP2 and the
EP4 receptors couple with the Galpha(s) protein, whereas the EP1
and the EP3 receptors are known to couple to Galpha(q) and
Galpha(i), respectively. However, differences in signaling between
EP2 and EP4 have indeed been demonstrated, as for example EP4
but not EP2 leads to ERK phosphorylation via PI3K activation
(59). It is likely that different signaling cascades are involved in
the CD28 and CD46 pathways. The link between CD46 and EP4
is also intriguing as there is a special emphasis on these receptors
in MS. Among PGE2 receptor-deficient mice, only the EP4-
subtype knockout can significantly inhibit experimental autoim-
mune encephalomyelitis (29). Moreover, MS-associated single
nucleotide polymorphisms in EP4 (also called PTEGR4) have
been demonstrated (60). As it is now clearly established that the
CD46 pathway is dysfunctional in MS (13–16), further inves-
tigations should address the question as to whether the CD46–
PGE2–EP4–GRK pathway is dysfunctional in MS.
Hence, we propose a model in which PGE2, secreted at sites
of inflammation and possibly by T cells themselves (61, 62), binds
to EP4, the specific PGE2 receptor induced by CD46 activation.
This initiates a signaling cascade that results in decreasing CD46
expression, which might be, at least in part, through STAT3
inhibition. Further studies using STAT3 ChIP experiments could
confirm the role of PGE2 in the regulation of CD46 transcription
by STAT3. GRKs are also induced by CD46 costimulation and
will then bind to EP4 and terminate response through internali-
zation of the PGE2 receptor. Of note, whereas EP4 couples via
arrestin upon ligand binding, EP2 does not and is resistant to
agonist-induced desensitization (63). Therefore, it seems logical
that CD46 would favor EP4 that can be desensitized to ensure that
proper levels of CD46 expression are restored. When GRKs are
knocked down, the PGE2–EP4 signaling goes on resulting in a
continuous decrease in CD46 expression.
The effects of PGE2 are known to be complex, depending on the
site and timing of release, and the cell on which it acts. Our data
demonstrate the novel role of the PGE2–EP4–GRK axis in CD46
functions and how this influences the effects of PGE2 on cytokine
production and expression of several markers involved in T cell
regulation. The many complex and interlinked actions of PGE2
on lymphocytes and on other immune cells will require further
investigation to decipher fully the complexity of this system.
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